WO2022130384A1 - Controlling ubiquitination of mlkl for treatment of disease - Google Patents
Controlling ubiquitination of mlkl for treatment of disease Download PDFInfo
- Publication number
- WO2022130384A1 WO2022130384A1 PCT/IL2021/051498 IL2021051498W WO2022130384A1 WO 2022130384 A1 WO2022130384 A1 WO 2022130384A1 IL 2021051498 W IL2021051498 W IL 2021051498W WO 2022130384 A1 WO2022130384 A1 WO 2022130384A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- mlkl
- cancer
- ubiquitination
- disease
- Prior art date
Links
- 230000034512 ubiquitination Effects 0.000 title claims abstract description 132
- 238000010798 ubiquitination Methods 0.000 title claims abstract description 131
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 52
- 201000010099 disease Diseases 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title description 47
- 101100237799 Mus musculus Mlkl gene Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 195
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000004472 Lysine Substances 0.000 claims abstract description 53
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 52
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 claims abstract description 38
- 101710083978 Mixed lineage kinase domain-like protein Proteins 0.000 claims abstract description 38
- 244000052769 pathogen Species 0.000 claims abstract description 32
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 32
- 230000037361 pathway Effects 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims description 102
- 206010028980 Neoplasm Diseases 0.000 claims description 62
- 230000000694 effects Effects 0.000 claims description 54
- 201000011510 cancer Diseases 0.000 claims description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 30
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 27
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 22
- -1 Tigatuzumab Chemical compound 0.000 claims description 16
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims description 15
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims description 15
- 230000003828 downregulation Effects 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000005775 apoptotic pathway Effects 0.000 claims description 14
- 238000006384 oligomerization reaction Methods 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 13
- 230000021597 necroptosis Effects 0.000 claims description 12
- 241000186779 Listeria monocytogenes Species 0.000 claims description 10
- 102000001301 EGF receptor Human genes 0.000 claims description 9
- 108060006698 EGF receptor Proteins 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 241000709661 Enterovirus Species 0.000 claims description 6
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 230000003827 upregulation Effects 0.000 claims description 6
- 102100033334 E3 ubiquitin-protein ligase Itchy homolog Human genes 0.000 claims description 5
- 101710118892 E3 ubiquitin-protein ligase Itchy homolog Proteins 0.000 claims description 5
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 5
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 5
- 231100000135 cytotoxicity Toxicity 0.000 claims description 5
- 230000003013 cytotoxicity Effects 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- VLULRUCCHYVXOH-UHFFFAOYSA-N 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound CC1=CC=CC=C1CN1C(=O)C(CN(CC=2C=CC=CC=2)CC2)=C2N2CCN=C21 VLULRUCCHYVXOH-UHFFFAOYSA-N 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 3
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 3
- 241000712431 Influenza A virus Species 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 229940126682 ONC201 Drugs 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 229950000317 dulanermin Drugs 0.000 claims description 3
- 102000044949 human TNFSF10 Human genes 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 229950001869 mapatumumab Drugs 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims description 3
- 229950004742 tigatuzumab Drugs 0.000 claims description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 5
- 108700012411 TNFSF10 Proteins 0.000 claims 5
- 241000004176 Alphacoronavirus Species 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 175
- 108090000623 proteins and genes Proteins 0.000 description 87
- 102000004190 Enzymes Human genes 0.000 description 71
- 108090000790 Enzymes Proteins 0.000 description 71
- 102000004169 proteins and genes Human genes 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 43
- 235000018977 lysine Nutrition 0.000 description 40
- 102000044159 Ubiquitin Human genes 0.000 description 34
- 108090000848 Ubiquitin Proteins 0.000 description 34
- 230000035772 mutation Effects 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 28
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 26
- 239000002679 microRNA Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 102000003390 tumor necrosis factor Human genes 0.000 description 26
- 108091033409 CRISPR Proteins 0.000 description 23
- 210000001163 endosome Anatomy 0.000 description 23
- 230000009368 gene silencing by RNA Effects 0.000 description 23
- 241000186781 Listeria Species 0.000 description 21
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 108091070501 miRNA Proteins 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 108020005004 Guide RNA Proteins 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 102220198512 rs141447598 Human genes 0.000 description 16
- 108020004459 Small interfering RNA Proteins 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 230000026731 phosphorylation Effects 0.000 description 15
- 238000006366 phosphorylation reaction Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000030833 cell death Effects 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 102000053642 Catalytic RNA Human genes 0.000 description 12
- 101710163270 Nuclease Proteins 0.000 description 12
- 230000002222 downregulating effect Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 108090000994 Catalytic RNA Proteins 0.000 description 11
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 11
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 108091092562 ribozyme Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 238000010362 genome editing Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 101150030875 RAB7A gene Proteins 0.000 description 9
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000003712 lysosome Anatomy 0.000 description 9
- 230000001868 lysosomic effect Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 108091027757 Deoxyribozyme Proteins 0.000 description 7
- 101001011662 Mus musculus Mixed lineage kinase domain-like protein Proteins 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 102000053379 human MLKL Human genes 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 238000010459 TALEN Methods 0.000 description 6
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 6
- 241000607447 Yersinia enterocolitica Species 0.000 description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000002132 lysosomal effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000008045 co-localization Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000037433 frameshift Effects 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 4
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 4
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108091028113 Trans-activating crRNA Proteins 0.000 description 4
- 101150063416 add gene Proteins 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 230000005740 tumor formation Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 229940123169 Caspase inhibitor Drugs 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102220550054 Mixed lineage kinase domain-like protein_L58G_mutation Human genes 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000001750 anti-listerial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 229930192649 bafilomycin Natural products 0.000 description 3
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001768 subcellular fraction Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- 108090000644 Angiozyme Proteins 0.000 description 2
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091007065 BIRCs Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 102100031918 E3 ubiquitin-protein ligase NEDD4 Human genes 0.000 description 2
- 102100040341 E3 ubiquitin-protein ligase UBR5 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 2
- 101000636713 Homo sapiens E3 ubiquitin-protein ligase NEDD4 Proteins 0.000 description 2
- 101000671838 Homo sapiens E3 ubiquitin-protein ligase UBR5 Proteins 0.000 description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
- 101000939517 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 2 Proteins 0.000 description 2
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 2
- 229940083346 IAP antagonist Drugs 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 102100025184 Mitogen-activated protein kinase kinase kinase 13 Human genes 0.000 description 2
- 102220550072 Mixed lineage kinase domain-like protein_I76G_mutation Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 108010068086 Polyubiquitin Proteins 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 102220556195 Polyubiquitin-C_K63R_mutation Human genes 0.000 description 2
- 102100023193 Probable E3 ubiquitin-protein ligase MARCHF10 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 101150020913 USP7 gene Proteins 0.000 description 2
- 102100029643 Ubiquitin carboxyl-terminal hydrolase 2 Human genes 0.000 description 2
- 102100021013 Ubiquitin carboxyl-terminal hydrolase 7 Human genes 0.000 description 2
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 2
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 2
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 description 2
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 2
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 2
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000019113 chromatin silencing Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013608 rAAV vector Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000012033 transcriptional gene silencing Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GUDJFFQZIISQJB-UHFFFAOYSA-N 4-cyano-5-(3,5-dichloropyridin-4-yl)sulfanyl-n-(4-methylsulfonylphenyl)thiophene-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC(=O)C(S1)=CC(C#N)=C1SC1=C(Cl)C=NC=C1Cl GUDJFFQZIISQJB-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 101710110983 Abaecin Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 101710107631 Andropin Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 101710114744 Bombinin Proteins 0.000 description 1
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 102000014572 CHFR Human genes 0.000 description 1
- 102000015347 COP1 Human genes 0.000 description 1
- 108060001826 COP1 Proteins 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229940123363 Cathepsin D inhibitor Drugs 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 101150066912 Cbl gene Proteins 0.000 description 1
- 101150023302 Cdc20 gene Proteins 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100026992 Dermcidin Human genes 0.000 description 1
- 108010034929 Dermcidin Proteins 0.000 description 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101710164770 Drosomycin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 1
- 102100032045 E3 ubiquitin-protein ligase AMFR Human genes 0.000 description 1
- 102100027415 E3 ubiquitin-protein ligase Arkadia Human genes 0.000 description 1
- 102100021740 E3 ubiquitin-protein ligase BRE1A Human genes 0.000 description 1
- 102100030428 E3 ubiquitin-protein ligase E3D Human genes 0.000 description 1
- 102100027325 E3 ubiquitin-protein ligase HACE1 Human genes 0.000 description 1
- 102100034677 E3 ubiquitin-protein ligase HECTD1 Human genes 0.000 description 1
- 102100034678 E3 ubiquitin-protein ligase HECTD3 Human genes 0.000 description 1
- 102100034674 E3 ubiquitin-protein ligase HECW1 Human genes 0.000 description 1
- 102100034675 E3 ubiquitin-protein ligase HECW2 Human genes 0.000 description 1
- 102100034745 E3 ubiquitin-protein ligase HERC2 Human genes 0.000 description 1
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 description 1
- 102100030370 E3 ubiquitin-protein ligase Hakai Human genes 0.000 description 1
- 102100022409 E3 ubiquitin-protein ligase LNX Human genes 0.000 description 1
- 102100038616 E3 ubiquitin-protein ligase MARCHF1 Human genes 0.000 description 1
- 101710168829 E3 ubiquitin-protein ligase MARCHF1 Proteins 0.000 description 1
- 102100040930 E3 ubiquitin-protein ligase MARCHF2 Human genes 0.000 description 1
- 101710168717 E3 ubiquitin-protein ligase MARCHF2 Proteins 0.000 description 1
- 102100040931 E3 ubiquitin-protein ligase MARCHF3 Human genes 0.000 description 1
- 101710168719 E3 ubiquitin-protein ligase MARCHF3 Proteins 0.000 description 1
- 102100040933 E3 ubiquitin-protein ligase MARCHF4 Human genes 0.000 description 1
- 101710168718 E3 ubiquitin-protein ligase MARCHF4 Proteins 0.000 description 1
- 102100022183 E3 ubiquitin-protein ligase MIB1 Human genes 0.000 description 1
- 102100022199 E3 ubiquitin-protein ligase MIB2 Human genes 0.000 description 1
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 description 1
- 102100036326 E3 ubiquitin-protein ligase Praja-1 Human genes 0.000 description 1
- 102100036333 E3 ubiquitin-protein ligase Praja-2 Human genes 0.000 description 1
- 102100040278 E3 ubiquitin-protein ligase RNF19A Human genes 0.000 description 1
- 102100031748 E3 ubiquitin-protein ligase SIAH2 Human genes 0.000 description 1
- 102100030796 E3 ubiquitin-protein ligase rififylin Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 1
- 101000776154 Homo sapiens E3 ubiquitin-protein ligase AMFR Proteins 0.000 description 1
- 101000650322 Homo sapiens E3 ubiquitin-protein ligase Arkadia Proteins 0.000 description 1
- 101000896083 Homo sapiens E3 ubiquitin-protein ligase BRE1A Proteins 0.000 description 1
- 101000942970 Homo sapiens E3 ubiquitin-protein ligase CHFR Proteins 0.000 description 1
- 101000772959 Homo sapiens E3 ubiquitin-protein ligase E3D Proteins 0.000 description 1
- 101001009246 Homo sapiens E3 ubiquitin-protein ligase HACE1 Proteins 0.000 description 1
- 101000872880 Homo sapiens E3 ubiquitin-protein ligase HECTD1 Proteins 0.000 description 1
- 101000872865 Homo sapiens E3 ubiquitin-protein ligase HECTD3 Proteins 0.000 description 1
- 101000872869 Homo sapiens E3 ubiquitin-protein ligase HECW1 Proteins 0.000 description 1
- 101000872871 Homo sapiens E3 ubiquitin-protein ligase HECW2 Proteins 0.000 description 1
- 101000872516 Homo sapiens E3 ubiquitin-protein ligase HERC2 Proteins 0.000 description 1
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 description 1
- 101001083405 Homo sapiens E3 ubiquitin-protein ligase Hakai Proteins 0.000 description 1
- 101000997630 Homo sapiens E3 ubiquitin-protein ligase Itchy homolog Proteins 0.000 description 1
- 101000620132 Homo sapiens E3 ubiquitin-protein ligase LNX Proteins 0.000 description 1
- 101000973503 Homo sapiens E3 ubiquitin-protein ligase MIB1 Proteins 0.000 description 1
- 101000973495 Homo sapiens E3 ubiquitin-protein ligase MIB2 Proteins 0.000 description 1
- 101001023703 Homo sapiens E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 description 1
- 101001001813 Homo sapiens E3 ubiquitin-protein ligase Praja-1 Proteins 0.000 description 1
- 101001001821 Homo sapiens E3 ubiquitin-protein ligase Praja-2 Proteins 0.000 description 1
- 101001104280 Homo sapiens E3 ubiquitin-protein ligase RNF19A Proteins 0.000 description 1
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 1
- 101001107071 Homo sapiens E3 ubiquitin-protein ligase RNF8 Proteins 0.000 description 1
- 101000807547 Homo sapiens E3 ubiquitin-protein ligase UBR4 Proteins 0.000 description 1
- 101000703348 Homo sapiens E3 ubiquitin-protein ligase rififylin Proteins 0.000 description 1
- 101000957340 Homo sapiens Multivesicular body subunit 12B Proteins 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 101001035260 Homo sapiens Probable E3 ubiquitin-protein ligase HERC3 Proteins 0.000 description 1
- 101001035259 Homo sapiens Probable E3 ubiquitin-protein ligase HERC4 Proteins 0.000 description 1
- 101000978726 Homo sapiens Probable E3 ubiquitin-protein ligase MARCHF10 Proteins 0.000 description 1
- 101000808592 Homo sapiens Probable ubiquitin carboxyl-terminal hydrolase FAF-X Proteins 0.000 description 1
- 101000832248 Homo sapiens STAM-binding protein Proteins 0.000 description 1
- 101000680666 Homo sapiens Tripartite motif-containing protein 5 Proteins 0.000 description 1
- 101000838411 Homo sapiens Tubulin epsilon chain Proteins 0.000 description 1
- 101000841471 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 15 Proteins 0.000 description 1
- 101000939467 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 28 Proteins 0.000 description 1
- 101000748132 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 30 Proteins 0.000 description 1
- 101000759994 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 47 Proteins 0.000 description 1
- 101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 description 1
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
- 101000772955 Homo sapiens Ubiquitin-protein ligase E3B Proteins 0.000 description 1
- 101000894590 Homo sapiens Uncharacterized protein C20orf85 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 101710200033 Moricin Proteins 0.000 description 1
- 102100038748 Multivesicular body subunit 12B Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100087591 Mus musculus Rictor gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 108091007059 NEDD4 family of E3 HECT ubiquitin ligases Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100039910 Probable E3 ubiquitin-protein ligase HERC3 Human genes 0.000 description 1
- 102100039913 Probable E3 ubiquitin-protein ligase HERC4 Human genes 0.000 description 1
- 101710178193 Probable E3 ubiquitin-protein ligase MARCHF10 Proteins 0.000 description 1
- 102100038603 Probable ubiquitin carboxyl-terminal hydrolase FAF-X Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 description 1
- 102000056817 RNF5 Human genes 0.000 description 1
- 102000004910 RNF8 Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 102100024472 STAM-binding protein Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 101150070607 Siah2 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101000959886 Solanum tuberosum Aspartic protease inhibitor 2 Proteins 0.000 description 1
- 101000959868 Solanum tuberosum Aspartic protease inhibitor 8 Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical group O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102100022405 Tripartite motif-containing protein 5 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100028984 Tubulin epsilon chain Human genes 0.000 description 1
- 102000003442 UBR4 Human genes 0.000 description 1
- 102100029164 Ubiquitin carboxyl-terminal hydrolase 15 Human genes 0.000 description 1
- 102100029821 Ubiquitin carboxyl-terminal hydrolase 28 Human genes 0.000 description 1
- 102100040052 Ubiquitin carboxyl-terminal hydrolase 30 Human genes 0.000 description 1
- 102100025029 Ubiquitin carboxyl-terminal hydrolase 47 Human genes 0.000 description 1
- 102100024250 Ubiquitin carboxyl-terminal hydrolase CYLD Human genes 0.000 description 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 1
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 description 1
- 102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 description 1
- 102100030429 Ubiquitin-protein ligase E3B Human genes 0.000 description 1
- 102100021442 Uncharacterized protein C20orf85 Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- PENDGIOBPJLVBT-HMMOOPTJSA-N abt-773 Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(C)OC\C=C\C=1C=C2C=CC=CC2=NC=1)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O PENDGIOBPJLVBT-HMMOOPTJSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229960001169 brivudine Drugs 0.000 description 1
- 108010025307 buforin II Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000404 calcium aluminium silicate Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 229950010329 cethromycin Drugs 0.000 description 1
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 229960002488 dalbavancin Drugs 0.000 description 1
- 108700009376 dalbavancin Proteins 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 108090000454 dermaseptin Proteins 0.000 description 1
- YFHLIDBAPTWLGU-CTKMSOPVSA-N dermaseptin Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C1=CN=CN1 YFHLIDBAPTWLGU-CTKMSOPVSA-N 0.000 description 1
- 229940049701 dermaseptin Drugs 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960003203 erythromycin estolate Drugs 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 229960004213 erythromycin lactobionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- VNUQOJUAIRBYQO-UHFFFAOYSA-N esculentin Natural products COC1CC(OC2CCC3(C)C4C(O)C(O)C5(C)C(O)(CCC5(O)C4(O)CC=C3C2)C(=O)C)OC(C)C1OC6CC(OC)C(OC7OC(C)C(O)C(OC)C7O)C(C)O6 VNUQOJUAIRBYQO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960000628 fidaxomicin Drugs 0.000 description 1
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960001447 fomivirsen Drugs 0.000 description 1
- XCWFZHPEARLXJI-UHFFFAOYSA-N fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 102000057519 human ITCH Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003606 oligomerizing effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 108091007054 readthrough proteins Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960002771 retapamulin Drugs 0.000 description 1
- STZYTFJPGGDRJD-NHUWBDDWSA-N retapamulin Chemical compound C([C@H]([C@@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CS[C@@H]3C[C@H]4CC[C@H](N4C)C3)C)C[C@]32[C@H]1C(=O)CC3 STZYTFJPGGDRJD-NHUWBDDWSA-N 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 102220226361 rs1064794680 Human genes 0.000 description 1
- 102220080600 rs797046116 Human genes 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229960003865 tazobactam Drugs 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention in some embodiments thereof, relates to method of treating diseases and, more particularly, but not exclusively, to infectious diseases, cancer and inflammatory bowel diseases (IBD) by controlling the level of ubiquitination of mixed lineage kinase-like molecule (MLKL).
- IBD infectious diseases, cancer and inflammatory bowel diseases
- MLKL mixed lineage kinase-like molecule
- cytokines of the tumor necrosis factor (TNF) family induce cell death has led to the identification of a form of programmed cell death called “necroptosis”, in which the mixed lineage kinase-like molecule (MLKL), upon its phosphorylation by the protein kinase RIPK3, triggers lethal rupture of the cellular membrane.
- MLKL mixed lineage kinase-like molecule
- This pathway was later shown also to be activated by a number of other inducers, including other cytokines and different pathogen components employing various proximally signaling proteins to activate RIPK3 (7-7).
- MLKL Prior its phosphorylation, MLKL resides mainly in the cytoplasm, but it can also be found in the nucleus, where it is activated by certain pathogens (9-11). Death mediation by MLKL appears to happen in the cell membrane (72, 13). It was previously reported that some of the activated MLKL molecules also associate with endosomal membranes, where they bind to ESCRT proteins and are then released from the cell within extracellular vehicles (EVs) whose generation they facilitate (14).
- EVs extracellular vehicles
- compositions including oligomers comprising RIPK3 proteins and RIPK1 proteins including, but not limited to, full length RIPK3 homodimers, truncated RIPK3 oligomers and/or full length RIPK3/RIPK1 heterodimers.
- WO2018/033929 teaches agents which regulate MLKL for the treatment of inflammation in general and, more specifically of cancer.
- a method of treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject comprising administering to the subject a therapeutically effective amount of an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL), thereby treating the disease caused by the pathogen.
- MLKL mixed lineage kinase domain-like protein
- a method of treating a cancer sensitive to TRAIL receptor mediated cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically down- regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the cancer.
- an article of manufacture comprising an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) and an antibacterial or antiviral agent.
- MLKL mixed lineage kinase domain-like protein
- an article of manufacture comprising an agent which downregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) and an agent that activates the TRAIL apoptotic pathway and/or TNF alpha.
- MLKL mixed lineage kinase domain-like protein
- an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) for use in treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject.
- MLKL mixed lineage kinase domain-like protein
- a method of treating inflammatory bowel disease (IBD) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically up-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the IBD.
- IBD inflammatory bowel disease
- an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) for use in treating IBD.
- MLKL mixed lineage kinase domain-like protein
- a method of treating a cancer in a subject in need thereof comprising co-administering to the subject a therapeutically effective amount of an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL and TNF alpha, thereby treating the cancer.
- a method of treating a disease associated with an upregulation of activity of EGF receptor in a subject comprising administering to the subject a therapeutically effective amount of an agent that specifically down- regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the disease.
- the disease is selected from the group consisting of non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer and breast cancer.
- the pathogen is a virus.
- the virus is selected from the group consisting of Influenza A virus, Foot and mouth disease virus, Rhinovirus, Adenovirus, Ebolavirus, Kaposi Sarcoma Virus, Simian virus 40, Papillomavirus, Polio virus, Lymphocytic choriomeningitis virus (LCMV), Rhinovirus and Coronavirus.
- the pathogen is a bacteria.
- the bacteria is Listeria monocytogenes.
- the agent enhances the activity and/or amount of a ubiquitin ligase that is capable of ubiquitinating lysine at position 50 of mixed lineage kinase domain-like protein (MLKL).
- MLKL mixed lineage kinase domain-like protein
- the agent is the ubiquitin ligase.
- the agent is a polynucleotide encoding the ubiquitin ligase.
- the ubiquitin ligase is E3 ubiquitin- protein ligase Itchy homolog (ITCH).
- the agent enhances oligomerization of the MLKL.
- the agent activates protein kinase RIPK3.
- the agent is a multivalent agent that binds the MLKL.
- the method further comprises administering to the subject an agent that directly targets the pathogen.
- the agent is a peptide agent that is a substrate for ubiquitination by the E3 ubiquitin-protein ligase.
- the peptide agent comprises at least 10 amino acids of MLKL.
- the agent is a polynucleotide agent that is capable of down-regulation the amount of ITCH in cancer cells of the subject.
- the method further comprises administering to the subject an agent that activates the TRAIL apoptotic pathway.
- the agent that activates the TRAIL apoptotic pathway is selected from the group consisting of Mapatumumab, Contatumumab, TAS266, ONC201, Tigatuzumab, Dulanermin and Circularly permuted TRAIL (CPT).
- the cancer is selected from the group consisting of myeloma, lymphoma, colorectal cancer, NSCLC, liver cancer, triple negative breast cancer, pancreatic cancer, cervical cancer, soft tissue sarcoma, ovarian cancer, glioblastoma.
- the agent enhances the activity and/or amount of a ubiquitin ligase that is capable of ubiquitinating lysine at position 50 of mixed lineage kinase domain-like protein (MLKL).
- MLKL mixed lineage kinase domain-like protein
- the agent is the ubiquitin ligase.
- the agent is a polynucleotide encoding the ubiquitin ligase.
- the ubiquitin ligase is E3 ubiquitin- protein ligase Itchy homolog (ITCH).
- the agent which downregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) is coformulated with the agent that activates the TRAIL apoptotic pathway.
- FIGs. 1A-G Activated MLKL is ubiquitinated at specific lysine residues.
- MLKL ubiquitination in response to TBZ occurs as a consequence of its oligomerization.
- the extents of MLKL ubiquitination (top), aggregation (middle) and phosphorylation (bottom) were determined in MLKL knockout (KO) HT-29 cells expressing constitutively wild-type (WT) MLKL and its indicated mutants.
- D-F Ubiquitination and oligome rization of the indicated mutants of (D, E) human MLKL expressed transiently in MLKL-KO HT-29 cells, and (F) mouse MLKL inducibly expressed in MLKL-KO MEFs, upon treatment with TBZ.
- FIGs. 2A-L Ubiquitinated MLKL associates with endosomal membranes.
- A Assessment of the occurrence of ubiquitinated and phosphorylated MLKL in the indicated subcellular fractions (15 pg protein applied per well).
- PAM plasma membrane associated membrane
- PM plasma membrane
- B-I Immunocytochemical analysis of the effect of the K50R mutation in MLKL on the association of MLKL (B-E) and of both MLKL and ubiquitin (F-I) with early (Rab5 + ) and late (Rab7 + ) endosomes in MLKL-KO HT-29 cells that inducibly express MLKL, observed after 2.5 h of treatment with TBZ.
- B, C and F, G Quantification of the data (-110 cells).
- D, E and H, I Examples of the immunofluorescence images.
- D and E green - MLKL, magenta - Rab5 or 7, white (and arrows) - MLKL+Rab5 or 7.
- H and I green - MLKL, red - Rab5 or7, blue - ubiquitin, magenta - Rab5 or 7 + ubiquitin, cyan - MLKL + ubiquitin, white (and arrows) - Rab5 or 7 + MLKL + ubiquitin.
- Scale bar 10 pm.
- K, L Effect of the K50R mutation in MLKL on (H) the association of MLKL with ESCRT proteins and on (I) MLKL release in EVs from HT-29 cells treated for 2.5 h with TBZ.
- FIGs. 3A-K MLKL ubiquitination is mediated by ITCH.
- ITCH binds to MLKL in 293T cells transiently overexpressing both proteins. Western analysis following the precipitation of MLKL via fused Strep tag.
- ITCH binds inducibly to MLKL in HT-29 cells constitutively expressing wild-type MLKL but not its T357A/S358A or L162G/L165G mutant, and binds constitutively to the MLKL L58G/176G mutant.
- D Western analysis of the binding of the various MLKL mutants to ITCH on transient expression in 293T cells.
- E Diagram showing the deletion mutants used and the location of the WW motifs in ITCH.
- F G. Immunocytochemical evidence for the colocalization of ITCH and activated MLKL in association with endosomes.
- F Quantification of the data (in 75 cells).
- G Immunofluorescence images. White (arrows), co-localization of both MLKL (green) and ITCH (blue) with either Rab5 or Rab 7 (red, upper and lower panels, respectively). Scale bar, 10 pm.
- H. ITCH catalyzes in vitro the ubiquitination of MLKL but not of its K50R mutant.
- FIGs. 4A-L Ubiquitination of MLKL facilitates lysosomal destruction of Lysteria.
- K-L Immunocytochemical analysis of the location of Listeria in early and late endosomes, in lysosomes and in the cytosol, 5 h after infection, and their modulation by TBZ- treatment, in HT-29 cells inducibly expressing wild-type or K50R-mutated MLKL.
- K Ratios of the numbers of Listeria in the indicated compartments (analysis of 130 infected cells).
- L Typical immunofluorescence images.
- FIGs. 5A-F Activated MLKL is ubiquitinated at specific lysine residues.
- A-C Assessment of the ubiquitination and/or phosphorylation of MLKL in (A) wild-type MEFs, in response to TBZ, (B) HT-29 cells in which FADD was knocked out by CRISPR/Cas9, in response to treatment with just TNF and Bv6 (TB), and (C) TBZ-treatment of HT-29 cells in which the endogenous MLKL was knocked out, and either the wild type or the K50R-mutated human MLKL was inducibly re-expressed under control of the GEV16/pF5x UAS system.
- FIGs. 6A-F Ubiquitinated MEKE associates with endosomal membranes.
- A-D Additional examples of the immunofluorescent images whose quantitative analysis is presented in Figure 2.
- A, B Association of MLKL with early (Rab5 + , A) and late (Rab7 + , B) endosomes.
- C, D Association of both MLKL and ubiquitin with early (Rab5 + , C) and late (Rab 7 + , D) endosomes.
- a and B green - MLKL, magenta - Rab5 or 7, white (and arrow) - MLKL + Rab5 or 7.
- C and D green - MLKL, red - Rab5 or 7, blue - ubiquitin, magenta - Rab5 or 7 + ubiquitin, cyan - MLKL + ubiquitin, white (and arrows) - Rab5 or 7 + MLKL + ubiquitin. Scale bar, 10 pm.
- E, F Comparative immunohistochemical analysis of the extent of association of MLKL and ubiquitin with (E) early endosomes and (F) the endoplasmic reticulum in HT-29 cells after 3 h of treatment with TBZ.
- FIGs. 7A-F Functional consequences of MLKL ubiquitination
- A, B Immunoblot analysis of the kinetics of intracellular degradation of (A) EGF and EGFR and of (B) TNF, in TBZ-treated MLKL-KO HT-29 cells that inducibly express wild-type or K50R-mutated MLKL.
- C, D Increase in sensitivity to TBZ-induced cell death in (C) MEFs expressing the K50R, K51R- mutated mouse MLKL and in (D) HT-29 cells expressing the K50R human MLKL mutant. In both cells the endogenous MLKL was knocked out and then the wild-type and the mutant MLKL were expressed inducibly.
- E Quantification of the data (-100 infected cells).
- F Example of the immuno staining: green - Lampl (a lysosomal marker), red - staining of acidification by the LysoTracker reagent, blue - Listeria, yellow - Lampl + LysoTracker, magenta - Listeria + LysoTracker, cyan - Listeria + Lampl, white- Listeria + Lysotracker + Lampl. Scale bar, 10 pm.
- FIG. 8 Diagrammatic presentation of the protocols of infection with Listeria monocytogenes.
- FIG. 9A Spectrum Annotation of Scan #21400 VLGLIKPLEMLQDQGKR (SEQ ID NO: 10)[Trypsin Digested:GG (Ubiquitination Site) on K]R.
- FIG. 9B Spectrum Annotation of Scan #3228 LHHSEAPELHGKIR (SEQ ID NO: 9) [Trypsin DigesteckGG (Ubiquitination Site) on K]IR.
- FIGs. 10A-D illustrate that MLKL ubiquitination facilitates destruction of Y. enterocolitica and E. coli bacteria.
- FIGs. 10A-B Yields of Y. enterocolitica bacteria 5 h after infection of HT-29 cells or their HT- 29 K50R mutant, and 6 h after infection of L929 cells or their K50,51R mutant, and the modulation of these yields obtained by treatment of the HT-29 cells with TBZ and treatment of the L929 cells with TNF.
- FIGs. 10C-D Yields of E. coli 8 h after infection of L929 cells or their K50,51R mutant, and the modulation of these yields obtained by treatment of the L929 cells with TNF.
- the present invention in some embodiments thereof, relates to method of treating diseases and, more particularly, but not exclusively, to infectious diseases, cancer and IBD, by controlling the level of ubiquitination of mixed lineage kinase-like molecule (MLKL).
- MLKL mixed lineage kinase-like molecule
- MLKL Phosphorylation of MLKL by the protein-kinase RIPK3 targets MLKL to the cell membrane, where it triggers necroptotic cell death.
- the present inventors now report that conjugation of polyubiquitin chains (that are at least partly K63 -linked) to distinct lysine residues in the phosphorylated MLKL molecule, is facilitated, at least partly, by the ubiquitin ligase ITCH that binds MLKL via its WW domains, targets MLKL to endosomes. This results in the release of phosphorylated MLKL in extracellular vesicles and decreased cell death. MLKL ubiquitination also enhances endosomal trafficking, which augments translocation of the bacterium Listeria monocytogenes to the lysosomes, leading to growth arrest of the bacteria ( Figures 4A-J). The present inventors have identified the K50 site on MLKL as the major target for ubiquitination, as verified by mass spectrometry.
- the present inventors propose taking advantage of this mechanism for the treatment of additional diseases which are associated with pathogenic agents.
- the present inventors contemplate agents that that up-regulate MLKL ubiquitination at the above mentioned site for the treatment of diseases which are caused by (or associated with) pathogens that enter the cell via phagosomes, which then fuse with the endosomes.
- the present inventors have shown that targeting MLKL to endosomes is dictated by ubiquitination of K50. Since this phenomenon endows cells with resistance to necroptotic death, the present inventors propose that agent that facilitate the ubiquitination of K50 will protect from the pathological consequences of necroptosis and be useful for treating inflammatory bowel disease (IBD) - see for example Sha li et al., World J Clin Cases 2018 November 26; 6(14): 745-752; Shindo et al., Shindo et al., iScience 15, 536-551, May 31, 2019 and Negroni et al., Biomolecules 2020, 10, 1431; doi:10.3390/bioml0101431.
- IBD inflammatory bowel disease
- the present inventors propose that agents that decrease ubiquitination can be applied to facilitate anti-cancer therapy with ligands of the TNF family such as TNF-related apoptosis-inducing ligand (TRAIL).
- ligands of the TNF family such as TNF-related apoptosis-inducing ligand (TRAIL).
- TRAIL TNF-related apoptosis-inducing ligand
- a method of treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject comprising administering to the subject a therapeutically effective amount of an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL), thereby treating the disease caused by the pathogen.
- an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) thereby treating the disease caused by the pathogen.
- a method of treating inflammatory bowel disease (IBD) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically up-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the IBD.
- IBD inflammatory bowel disease
- MLKL refers to the Mixed Lineage Kinase Domain-Like protein, a product of Gene ID: 197259.
- Exemplary MLKL amino acid sequences are set forth in GenBank accession nos. NP_001135969.1 and NP_689862.1.
- the amino acid sequence of MLKL is as set forth in SEQ ID NO: 6.
- the positioning of the ubiquitination i.e. position 50 is according to the amino acid sequence as set forth in SEQ ID NO: 6.
- Ubiquitination takes place by a cascade of enzyme activity (i.e. a plurality of enzymes which work together to bring about the same function - ubiquitination). For example, El activates the Ub; then Ub is transferred to E2 ligase. E2 ligase together with E3 recognize a specific target and ligate the Ub to the target protein. In some cases Ub is transferred directly to E3 ligase.
- the present invention contemplates upregulation of any of the components of the ubiquitination system such that ubiquitination at position 50 of MLKL is enhanced.
- the agent upregulates the activity and or amount of ubiquitinating enzyme that is responsible for adding a ubiquitin moiety at position 50 of MLKL.
- the ubiquitinating enzyme is a human ubiquitinating enzyme.
- Ubiquitin-activating enzymes (Els) have the EC number EC 6.2.1.45, ubiquitin-conjugating enzymes have the EC number EC 2.3.2.23 and ubiquitin ligases have the EC number 2.3.2.27.
- the agent up-regulates the amount and/or activity of an
- Table 1 herein below provides nomenclature and most common synonyms used for E2 ubiquitin conjugating enzymes.
- the E2 nomenclature is in accordance with that used by the Human Genome Organization. Table 1
- the agent upregulates the amount and/or activity of E3 ligase.
- Exemplary E3 ligases contemplated by the present invention include which may be responsible for ubiquitination of MLKL, but are not limited to ITCH, Siah2, Smurf 1, MDM2, BRCA1, PARKIN, UBE3A, TRIM5, NEDD4, UBR5, Huwel, Arkadia, MuRFl, TRAF6, Trim32, UBR4, UBE3B and UBE3D.
- the E3 ligase is E3 ubiquitin-protein ligase Itchy homolog (ITCH).
- Itch is an example of an E3 -ubiquitin ligase that belongs to the Nedd4-like E3 family, and is characterized by a modular organization that includes: an N-terminal protein kinase C-related C2 domain; multiple WW domains; and a C-terminal HECT (homologous to the E6-associated protein carboxyl terminus) Ubiquitin (Ub)-protein ligase domain.
- E3 ligases which may be responsible for ubiquitinating MLKL include AMFR, APC/Cdc20, APC/Cdhl, C6orfl57, Cbl, CBLL1, CHFR, CHIP, DTL (Cdt2), E6-AP, HACE1, HECTD1, ECTD2, HECTD3, HECW1, HECW2, HERC2, HERC3, HERC4, HERC5, HUWE1, HYD, ITCH, LNX1, mahogunin, MARCH-I, MARCH-II, MARCH-III, MARCH-IV, MARCH- VI, MARCH- VII, MARCH- VIII, MARCH-X, MDM2, MEKK1, MIB1, MIB2, MycBP2, NEDD4, NEDD4L, Parkin, PELH, Pirh2, PJA1, PJA2, RFFL, RFWD2, Rictor, RNF5, RNF8, RNF19, RNF190 and RNF20.
- Agents which increase the amount of a ubiquitinating enzyme capable of ubiquitinating MLKL at position 50 include agents which are capable of increasing the transcription (for example a transcription factor known to interact with the 5'untranslated region of the ubiquitinating enzyme) of the ubiquitinating enzyme, the translation of the ubiquitinating enzyme or the stability of the ubiquitinating enzyme.
- the agent which increases the amount of the ubiquitinating enzyme may be a polynucleotide which encodes the ubiquitinating enzyme, the protein itself or an active peptide thereof.
- the ubiquitinating enzyme (e.g. ITCH) (or the polynucleotide which encodes the ubiquitinating enzyme) which is administered to the subject is (or encodes a protein that is) at least 50 % homologous, more preferably at least 60 % homologous, more preferably at least 70 % homologous, more preferably at least 80 % homologous, and most preferably at least 90 % homologous to the polypeptide sequence as set forth in SEQ ID NO:7 as determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters) comprising ubiquitinating enzyme activity.
- the homolog may also refer to a deletion, insertion, or substitution variant, including an amino acid substitution, thereof and biologically active polypeptide fragments thereof.
- Recombinant techniques are typically used to generate the ubiquitinating enzyme (e.g. ITCH) of the present invention. These techniques may be preferred due to the length of the protein and the large amounts required thereof. Such recombinant techniques are described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60- 89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 3:17-311, Coruzzi et al. (1984) EMBO J.
- a polynucleotide encoding the ubiquitinating enzyme is ligated into a nucleic acid expression vector, which comprises the polynucleotide sequence under the transcriptional control of a cis-regulatory sequence (e.g., promoter sequence) suitable for directing constitutive, tissue specific or inducible transcription of the ubiquitinating enzyme in the host cells.
- a cis-regulatory sequence e.g., promoter sequence
- an isolated polynucleotide refers to a single or double stranded nucleic acid sequence which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).
- complementary polynucleotide sequence refers to a sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence can be subsequently amplified in vivo or in vitro using a DNA dependent DNA polymerase.
- genomic polynucleotide sequence refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.
- composite polynucleotide sequence refers to a sequence, which is at least partially complementary and at least partially genomic.
- a composite sequence can include some exonal sequences required to encode the ubiquitinating enzyme, as well as some intronic sequences interposing there between.
- the intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements.
- polynucleotide sequences of the present invention are inserted into expression vectors (i.e., a nucleic acid construct) to enable expression of the recombinant ubiquitinating enzyme.
- the expression vector of the present invention may include additional sequences which render this vector suitable for replication and integration in prokaryotes, eukaryotes, or preferably both (e.g., shuttle vectors).
- Typical cloning vectors contain transcription and translation initiation sequences (e.g., promoters, enhances) and transcription and translation terminators (e.g., polyadenylation signals).
- prokaryotic or eukaryotic cells can be used as host-expression systems to express the ubiquitinating enzymes of the present invention.
- microorganisms such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the ubiquitinating enzyme coding sequence; yeast transformed with recombinant yeast expression vectors containing the ubiquitinating enzyme coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the ubiquitinating enzyme coding sequence.
- virus expression vectors e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV
- the expression construct of the present invention can also include sequences engineered to optimize stability, production, purification, yield or activity of the expressed ubiquitinating enzyme.
- Transformed cells are cultured under effective conditions, which allow for the expression of high amounts of recombinant peptide.
- Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production.
- An effective medium refers to any medium in which a cell is cultured to produce the recombinant ubiquitinating enzyme of the present invention.
- Such a medium typically includes an aqueous solution having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins.
- Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art.
- resultant ubiquitinating enzyme of may either remain within the recombinant cell, secreted into the fermentation medium, secreted into a space between two cellular membranes, such as the periplasmic space in E. coli; or retained on the outer surface of a cell or viral membrane.
- the phrase "recovering the recombinant ubiquitinating enzyme" used herein refers to collecting the whole fermentation medium containing the ubiquitinating enzyme and need not imply additional steps of separation or purification.
- ubiquitinating enzymes can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
- standard protein purification techniques such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
- the expressed coding sequence can be engineered to encode the ubiquitinating enzyme fused to a cleavable moiety.
- a fusion protein can be designed so that the ubiquitinating enzyme can be readily isolated by affinity chromatography; e.g., by immobilization on a column specific for the cleavable moiety.
- the ubiquitinating enzyme can be released from the chromatographic column by treatment with an appropriate enzyme or agent that specifically cleaves the fusion protein at this site [e.g., see Booth et al., Immunol. Lett. 19:65-70 (1988); and Gardella et al., J. Biol. Chem. 265:15854-15859 (1990)].
- the ubiquitinating enzyme of the present invention is preferably retrieved in "substantially pure" form.
- the phrase "substantially pure” refers to a purity that allows for the effective use of the ubiquitinating enzyme in the applications described herein.
- the ubiquitinating enzyme of the present invention can also be synthesized using in vitro expression systems. These methods are well known in the art and the components of the system are commercially available.
- the ubiquitinating enzyme may be administered to the subject in need thereof as polynucleotides where they are expressed in vivo i.e. gene therapy.
- gene therapy refers to the transfer of genetic material (e.g. DNA or RNA) of interest into a host to treat or prevent a genetic or acquired disease or condition or phenotype.
- the genetic material of interest encodes a product (e.g. a protein, polypeptide, peptide, functional RNA, antisense) whose production in vivo is desired.
- the genetic material of interest can encode a hormone, receptor, enzyme, polypeptide or peptide of therapeutic value.
- ex vivo and (2) in vivo gene therapy Two basic approaches to gene therapy have evolved: (1) ex vivo and (2) in vivo gene therapy.
- ex vivo gene therapy cells are removed from a patient, and while being cultured are treated in vitro.
- a functional replacement gene is introduced into the cell via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the host/patient.
- These genetically reimplanted cells have been shown to express the transfected genetic material in situ.
- the cells may be autologous or non- autologous to the subject. Since non-autologous cells are likely to induce an immune reaction when administered to the body several approaches have been developed to reduce the likelihood of rejection of non-autologous cells.
- target cells are not removed from the subject rather the genetic material to be transferred is introduced into the cells of the recipient organism in situ, that is within the recipient. These genetically altered cells have been shown to express the transfected genetic material in situ.
- nucleic acid constructs used to express the ubiquitinating enzyme comprises cell- specific promoter sequence elements.
- Recombinant viral vectors are useful for in vivo expression of the ubiquitinating enzyme since they offer advantages such as lateral infection and targeting specificity.
- Lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny.
- Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
- deubiquitinating enzyme refers to an enzyme that cleaves ubiquitin from proteins.
- the deubiquitinating enzyme is a cysteine protease or a metalloprotease.
- Exemplary deubiquitinating enzymes which may be capable of deubiquitinating ubiquitinated MLKL at position 50 include USP7, USP47, USP2, USP7, USP15, USP9X, USP28, USP30.
- Downregulation of the deubiquitinating enzyme may be effected at the protein or nucleotide level as is further described herein below.
- agents that are contemplated which can serve as therapeutics for diseases caused by pathogenic agents are those that enhance oligomerization of MLKL.
- agents that activate protein kinase RIPK3 are contemplated.
- RIPK3 phosphorylates MLKL and by this triggers its oligomerization.
- agents include, but are not limited to TRAIL, ligands of TLR (Toll-like receptors) such as BCG and Interferon alpha.
- agents capable of oligomerizing MLKL include multivalent agents that bind MLKL (e.g. a chimeric oligomer of the antigen binding portion of anti-MLKL antibody, fused to cellpenetrating moiety - see for example Alewine et al., The Oncologist 2015;20:176-185).
- the agents disclosed herein above may be used to treat a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject. Once the pathogen enters the cell, the pathogen is typically driven into the lysosome.
- the agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) is capable of performing its activity in live cells (i.e. increases the uptake of the pathogen into the lysosome), hence, preventing the release of live pathogen from infected cells in which MLKL is activated.
- the pathogen which is responsible for causing the disease is a bacteria.
- the bacterial pathogen is Listeria monocytogenes.
- the bacterial pathogen is of the genus Yersinia (e.g. Yersinia enterocolitica or Yersinia pestis. It will be appreciated that since Yersinia bacteria has been associated with various diseases such as Crohn’s disease and reactive arthritis, the present inventors contemplate treating these diseases which upregulate ubiquitination of lysine at position 50 of MLKL.
- Yersinia e.g. Yersinia enterocolitica or Yersinia pestis.
- the pathogen is E-coli.
- Additional disease causing bacteria include, but are not limited to Mycobacterium Tuberculosis, Mycobacterium Leprae, Legionella pneumophila, Shigella flexneri and Francisella tularensis, which are also contemplated by the present invention.
- the bacteria is not salmonella typhimurium.
- the pathogen is a parasite, including, but not limited to single-celled protozoans such as the agents of malaria, sleeping sickness, and amoebic dysentery.
- the pathogen which causes the disease is a virus.
- viruses that utilize the endosomal pathway include Influenza A virus, Foot and mouth disease virus, Rhinovirus, Adenovirus, Ebolavirus, Kaposi Sarcoma Virus, Simian virus 40, Papillomavirus, Polio virus, Lymphocytic choriomeningitis virus (LCMV), Rhinovirus and
- the pathogen is an intracellular pathogen. Additional viruses that cause disease are summarized in Table 2, herein below.
- coronaviruses examples include: human coronavirus 229E, human coronavirus OC43, SARS-CoV, HCoV NL63, HKU1, MERS-CoV and SARS-CoV-2.
- the coronavirus is SARS-CoV-2.
- Exemplary viral diseases which may be treated according to embodiments of the present invention are summarized in Table 3, herein below.
- the viral disease is COVID- 19.
- Agents that directly target include antibiotics and antibacterial peptides.
- antibiotic agent refers to a group of chemical substances, isolated from natural sources or derived from antibiotic agents isolated from natural sources, having a capacity to inhibit growth of, or to destroy bacteria, and other microorganisms, used chiefly in treatment of infectious diseases.
- antibiotic agents include, but are not limited to; Amikacin; Amoxicillin; Ampicillin; Azithromycin; Azlocillin; Aztreonam; Aztreonam; Carbenicillin; Cefaclor; Cefepime; Cefetamet; Cefinetazole; Cefixime; Cefonicid; Cefoperazone; Cefotaxime; Cefotetan; Cefoxitin; Cefpodoxime; Cefprozil; Cefsulodin; Ceftazidime; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalexin; Cephalothin; Cethromycin; Chloramphenicol; Cinoxacin; Ciprofloxacin; Clarithromycin; Clindamycin; Cioxacillin; Co- amoxiclavuanate; Dalbavancin; Daptomycin; Dicloxacillin; Doxycycline; Enoxacin; Erythromycin estolate; Erythromycin ethicillin
- Anti-bacterial antibiotic agents include, but are not limited to, aminoglycosides, carbacephems, carbapenems, cephalosporins, cephamycins, fluoroquinolones, glycopeptides, lincosamides, macrolides, monobactams, penicillins, quinolones, sulfonamides, and tetracyclines.
- Antibacterial agents also include antibacterial peptides. Examples include but are not limited to abaecin; andropin; apidaecins; bombinin; brevinins; buforin II; CAP18; cecropins; ceratotoxin; defensins; dermaseptin; dermcidin; drosomycin; esculentins; indolicidin; LL37; magainin; maximum H5; melittin; moricin; prophenin; protegrin; and or tachyplesins.
- the antiviral drug may be selected from the group consisting of remdesivir, an interferon, ribavirin, adefovir, tenofovir, acyclovir, brivudin, cidofovir, fomivirsen, foscarnet, ganciclovir, penciclovir, amantadine, rimantadine and zanamivir.
- the agents which upregulate ubiquitination of MLKL may be formulated together with the antibacterial or antiviral agent (e.g. in a single pharmaceutical composition) or may be provided as separate compositions and packaged together in a single article of manufacture.
- the agents may, if desired, be presented together in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing each of the active ingredients.
- the pack may, for example, comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
- Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.
- agents described herein above may also be used to treat inflammatory bowel disease (IBD) which includes ulcerative colitis and Crohn’s disease.
- IBD inflammatory bowel disease
- MEKE when ubiquitinated in lysine 50, antagonizes TRAIL-induced cell death by enhancing endosomal-trafficking.
- agents that arrest MLKL ubiquitination will, by preventing the MLKL-induced endosomal-trafficking and lysosomal-destruction of anti-cancer ligands like TRAIL, and their receptors, facilitate the anti-cancer effects of these ligands in cancers such as colon cancer, gastric cancer, and pancreatic adenocarcinoma.
- the extent of ubiquitination of MLKL in these cancers may serve as a potential biomarker for the extent of susceptibility to cell death induction by ligands such as TRAIL, when these ligands are applied for tumor therapy.
- a method of treating a cancer sensitive to TRAIL receptor mediated cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the cancer.
- Down-regulating of ubiquitination may be understood as being complete elimination of ubiquitination at position 50 of MLKL or at least a 50 % decrease in the number of molecules undergoing ubiquitination, a 60 % decrease in the number of molecules undergoing ubiquitination ubiquitination, a 70 % decrease in the number of molecules undergoing ubiquitination ubiquitination or higher.
- cancer sensitive to TRAIL receptor mediated cytotoxicity include but are not limited to myeloma, lymphoma, colorectal cancer, NSCLC, liver cancer, triple negative breast cancer, pancreatic cancer, cervical cancer, soft tissue sarcoma, ovarian cancer, glioblastoma. Additional information regarding such cancers can be found in Yuan et al., Cancer Metastasis Rev. 2018 December ; 37(4): 733-748, the contents of which are incorporated herein by reference.
- the present inventors have shown that downregulation of ubiquitination of MLKL at the K50 site leads to a significant decrease in the rate of degradation of receptors and ligands thereof.
- agents that downregulate ubiquitination of MLKL at the K50 site reduce the amount of cell-bound epidermal growth factor (EGF) and tumor necrosis factor (TNF), as well as of the EGF receptor (Figure 7A, B).
- EGF epidermal growth factor
- TNF tumor necrosis factor
- the present inventors propose use of agents that downregulate ubiquitination of MLKL at the K50 site to enhance the therapeutic activity of TNF alpha treatment (e.g. to enhance the effect of TNF alpha in the treatment of cancer using the limb perfusion approach).
- a method of treating cancer comprising co-administering a therapeutically effective amount of an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL and TNF alpha to the subject, thereby treating the cancer.
- Typical cancers that are treated with TNF alpha include bulky melanoma metastases and soft tissue sarcomas. Additional chemotherapeutic agents may be combined with this treatment, according to the particular cancer type and status.
- the chemotherapeutic agent melphalan may be combined with the TNF alpha and the agent that downregulates ubiquitination of MLKL at the K50.
- the present inventors have shown that agents that downregulate ubiquitination of MLKL at the K50 site reduce the amount of cell-bound epidermal growth factor (EGF), the present inventors propose treating diseases associated with an upregulation of activity of EGF receptor by administering agents that specifically down-regulate ubiquitination of lysine at position 50 of MLKL.
- EGF cell-bound epidermal growth factor
- diseases which are associated with an up-regulation of activity of EGF receptors include non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer and breast cancer.
- Agents that are capable of specifically down-regulating ubiquitination of lysine at position 50 of MLKL include those that decrease the activity and/or amount of ubiquitin enzymes capable of same.
- the agent may be a polynucleotide agent which hybridizes with the ubiquitinating enzyme, a neutralizing antibody or a small molecule antagonist.
- Down-regulation at the nucleic acid level is typically effected using a nucleic acid agent, having a nucleic acid backbone, DNA, RNA, mimetics thereof or a combination of same.
- the nucleic acid agent may be encoded from a DNA molecule or provided to the cell per se.
- RNA silencing refers to a group of regulatory mechanisms [e.g. RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), quelling, co- suppression, and translational repression] mediated by RNA molecules which result in the inhibition or "silencing" of the expression of a corresponding protein-coding gene.
- RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.
- RNA silencing agent refers to an RNA which is capable of specifically inhibiting or “silencing" the expression of a target gene.
- the RNA silencing agent is capable of preventing complete processing (e.g, the full translation and/or expression) of an mRNA molecule through a post-transcriptional silencing mechanism.
- RNA silencing agents include non-coding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated.
- Exemplary RNA silencing agents include dsRNAs such as siRNAs, miRNAs and shRNAs.
- the RNA silencing agent is capable of inducing RNA interference.
- the RNA silencing agent is capable of mediating translational repression.
- the RNA silencing agent is specific to the target RNA (e.g., ubiquitin kinase) and does not cross inhibit or silence other targets or a splice variant which exhibits 99% or less global homology to the target gene, e.g., less than 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% global homology to the target gene; as determined by PCR, Western blot, Immunohistochemistry and/or flow cytometry.
- target RNA e.g., ubiquitin kinase
- RNA interference refers to the process of sequence- specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs).
- RNA silencing agents that can be used according to specific embodiments of the present invention.
- DsRNA, siRNA and shRNA - The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer.
- Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs).
- Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes.
- the RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single- stranded RNAhaving sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex.
- RISC RNA-induced silencing complex
- siRNA refers to small inhibitory RNA duplexes (generally between 18-30 base pairs) that induce the RNA interference (RNAi) pathway.
- RNAi RNA interference
- siRNAs are chemically synthesized as 21mers with a central 19 bp duplex region and symmetric 2-base 3'-overhangs on the termini, although it has been recently described that chemically synthesized RNA duplexes of 25-30 base length can have as much as a 100-fold increase in potency compared with 21mers at the same location.
- RNA silencing agent of some embodiments of the invention may also be a short hairpin RNA (shRNA).
- RNA agent refers to an RNA agent having a stem- loop structure, comprising a first and second region of complementary sequence, the degree of complementarity and orientation of the regions being sufficient such that base pairing occurs between the regions, the first and second regions being joined by a loop region, the loop resulting from a lack of base pairing between nucleotides (or nucleotide analogs) within the loop region.
- the number of nucleotides in the loop is a number between and including 3 to 23, or 5 to 15, or 7 to 13, or 4 to 9, or 9 to 11. Some of the nucleotides in the loop can be involved in base-pair interactions with other nucleotides in the loop.
- RNA silencing agent of some embodiments of the invention need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non-nucleotides. miRNA and miRNA mimics - According to another embodiment the RNA silencing agent may be a miRNA.
- miRNA refers to a collection of non-coding single-stranded RNA molecules of about 19-28 nucleotides in length, which regulate gene expression. miRNAs are found in a wide range of organisms (viruses. fwdarw.humans) and have been shown to play a role in development, homeostasis, and disease etiology.
- miRNA mimic refers to synthetic non-coding RNAs that are capable of entering the RNAi pathway and regulating gene expression. miRNA mimics imitate the function of endogenous miRNAs and can be designed as mature, double stranded molecules or mimic precursors (e.g., or pre-miRNAs). miRNA mimics can be comprised of modified or unmodified RNA, DNA, RNA-DNA hybrids, or alternative nucleic acid chemistries (e.g., LNAs or 2'-O,4'-C-ethylene-bridged nucleic acids (ENA)).
- nucleic acid chemistries e.g., LNAs or 2'-O,4'-C-ethylene-bridged nucleic acids (ENA)
- the length of the duplex region can vary between 13-33, 18-24 or 21-23 nucleotides.
- the miRNA may also comprise a total of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides.
- the sequence of the miRNA may be the first 13-33 nucleotides of the pre-miRNA.
- the sequence of the miRNA may also be the last 13-33 nucleotides of the pre-miRNA.
- Preparation of miRNAs mimics can be effected by any method known in the art such as chemical synthesis or recombinant methods.
- contacting cells with a miRNA may be effected by transfecting the cells with e.g. the mature double stranded miRNA, the pre-miRNA or the pri-miRNA.
- the pre-miRNA sequence may comprise from 45-90, 60-80 or 60-70 nucleotides.
- the pri-miRNA sequence may comprise from 45-30,000, 50-25,000, 100-20,000, 1,000- 1,500 or 80-100 nucleotides.
- Antisense - Antisense is a single stranded RNA designed to prevent or inhibit expression of a gene by specifically hybridizing to its mRNA. Downregulation of a ubiquitinating enzyme can be effected using an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding the ubiquitinating enzyme.
- Nucleic acid agents can also operate at the DNA level as summarized infra.
- Downregulation of agents such as ubiquitinating enzymes can also be achieved by inactivating the gene (e.g., MLKL, RIPK3 or RIPK1) via introducing targeted mutations involving loss-of function alterations (e.g. point mutations, deletions and insertions) in the gene structure.
- inactivating the gene e.g., MLKL, RIPK3 or RIPK1
- targeted mutations involving loss-of function alterations e.g. point mutations, deletions and insertions
- loss-of-function alterations refers to any mutation in the DNA sequence of a gene (e.g., ubiquitinating enzyme) which results in downregulation of the expression level and/or activity of the expressed product, i.e., the mRNA transcript and/or the translated protein.
- a gene e.g., ubiquitinating enzyme
- Non-limiting examples of such loss-of-function alterations include a missense mutation, i.e., a mutation which changes an amino acid residue in the protein with another amino acid residue and thereby abolishes the enzymatic activity of the protein; a nonsense mutation, i.e., a mutation which introduces a stop codon in a protein, e.g., an early stop codon which results in a shorter protein devoid of the enzymatic activity; a frame-shift mutation, i.e., a mutation, usually, deletion or insertion of nucleic acid(s) which changes the reading frame of the protein, and may result in an early termination by introducing a stop codon into a reading frame (e.g., a truncated protein, devoid of the enzymatic activity), or in a longer amino acid sequence (e.g., a readthrough protein) which affects the secondary or tertiary structure of the protein and results in a non-functional protein, devoid of the enzymatic activity
- Genome Editing using engineered endonucleases - this approach refers to a reverse genetics method using artificially engineered nucleases to cut and create specific double- stranded breaks at a desired location(s) in the genome, which are then repaired by cellular endogenous processes such as, homology directed repair (HDR) and non-homologous end-joining (NFfEJ).
- HDR homology directed repair
- NFfEJ non-homologous end-joining
- HDR utilizes a homologous sequence as a template for regenerating the missing DNA sequence at the break point.
- a DNA repair template containing the desired sequence must be present during HDR.
- Genome editing cannot be performed using traditional restriction endonucleases since most restriction enzymes recognize a few base pairs on the DNA as their target and the probability is very high that the recognized base pair combination will be found in many locations across the genome resulting in multiple cuts not limited to a desired location.
- restriction enzymes recognize a few base pairs on the DNA as their target and the probability is very high that the recognized base pair combination will be found in many locations across the genome resulting in multiple cuts not limited to a desired location.
- ZFNs Zinc finger nucleases
- TALENs transcription-activator like effector nucleases
- CRISPR/Cas system CRISPR/Cas system.
- Meganucleases are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif. The four families of meganucleases are widely separated from one another with respect to conserved structural elements and, consequently, DNA recognition sequence specificity and catalytic activity. Meganucleases are found commonly in microbial species and have the unique property of having very long recognition sequences (>14bp) thus making them naturally very specific for cutting at a desired location.
- meganucleases can be designed using the methods described in e.g., Certo, MT et al.
- ZFNs and TALENs Two distinct classes of engineered nucleases, zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), have both proven to be effective at producing targeted double-stranded breaks (Christian et al., 2010; Kim et al., 1996; Li et al., 2011; Mahfouz et al., 2011; Miller et al., 2010).
- CRISPR-Cas system Many bacteria and archaea contain endogenous RNA-based adaptive immune systems that can degrade nucleic acids of invading phages and plasmids. These systems consist of clustered regularly interspaced short palindromic repeat (CRISPR) genes that produce RNA components and CRISPR associated (Cas) genes that encode protein components.
- CRISPR RNAs crRNAs
- crRNAs contain short stretches of homology to specific viruses and plasmids and act as guides to direct Cas nucleases to degrade the complementary nucleic acids of the corresponding pathogen.
- RNA/protein complex RNA/protein complex and together are sufficient for sequence- specific nuclease activity: the Cas9 nuclease, a crRNA containing 20 base pairs of homology to the target sequence, and a trans-activating crRNA (tracrRNA) (Jinek et al. Science (2012) 337: 816-821.). It was further demonstrated that a synthetic chimeric guide RNA (gRNA) composed of a fusion between crRNA and tracrRNA could direct Cas9 to cleave DNA targets that are complementary to the crRNA in vitro.
- gRNA synthetic chimeric guide RNA
- transient expression of Cas9 in conjunction with synthetic gRNAs can be used to produce targeted double- stranded brakes in a variety of different species (Cho et al., 2013; Cong et al., 2013; DiCarlo et al., 2013; Hwang et al., 2013a, b; Jinek et al., 2013; Mali et al., 2013).
- the CRIPSR/Cas system for genome editing contains two distinct components: a gRNA and an endonuclease e.g. Cas9.
- the gRNA is typically a 20 nucleotide sequence encoding a combination of the target homologous sequence (crRNA) and the endogenous bacterial RNA that links the crRNA to the Cas9 nuclease (tracrRNA) in a single chimeric transcript.
- the gRNA/Cas9 complex is recruited to the target sequence by the base-pairing between the gRNA sequence and the complement genomic DNA.
- the genomic target sequence must also contain the correct Protospacer Adjacent Motif (PAM) sequence immediately following the target sequence.
- PAM Protospacer Adjacent Motif
- the binding of the gRNA/Cas9 complex localizes the Cas9 to the genomic target sequence so that the Cas9 can cut both strands of the DNA causing a double-strand break.
- the double-stranded brakes produced by CRISPR/Cas can undergo homologous recombination or NHEJ.
- the Cas9 nuclease has two functional domains: RuvC and HNH, each cutting a different DNA strand. When both of these domains are active, the Cas9 causes double strand breaks in the genomic DNA.
- a significant advantage of CRISPR/Cas is that the high efficiency of this system coupled with the ability to easily create synthetic gRNAs enables multiple genes to be targeted simultaneously. In addition, the majority of cells carrying the mutation present biallelic mutations in the targeted genes.
- nickases Modified versions of the Cas9 enzyme containing a single inactive catalytic domain, either RuvC- or HNH-, are called ‘nickases’. With only one active nuclease domain, the Cas9 nickase cuts only one strand of the target DNA, creating a single-strand break or 'nick'. A single-strand break, or nick, is normally quickly repaired through the HDR pathway, using the intact complementary DNA strand as the template. However, two proximal, opposite strand nicks introduced by a Cas9 nickase are treated as a double-strand break, in what is often referred to as a 'double nick' CRISPR system.
- a double-nick can be repaired by either NHEJ or HDR depending on the desired effect on the gene target.
- using the Cas9 nickase to create a double-nick by designing two gRNAs with target sequences in close proximity and on opposite strands of the genomic DNA would decrease off- target effect as either gRNA alone will result in nicks that will not change the genomic DNA.
- dCas9 Modified versions of the Cas9 enzyme containing two inactive catalytic domains
- dCas9 can be utilized as a platform for DNA transcriptional regulators to activate or repress gene expression by fusing the inactive enzyme to known regulatory domains.
- the binding of dCas9 alone to a target sequence in genomic DNA can interfere with gene transcription.
- both gRNA and Cas9 should be expressed in a target cell.
- the insertion vector can contain both cassettes on a single plasmid or the cassettes are expressed from two separate plasmids.
- CRISPR plasmids are commercially available such as the px33O plasmid from Addgene.
- Genome editing using recombinant adeno-associated virus (rAAV) platform is based on rAAV vectors which enable insertion, deletion or substitution of DNA sequences in the genomes of live mammalian cells.
- the rAAV genome is a single-stranded deoxyribonucleic acid (ssDNA) molecule, either positive- or negative-sensed, which is about 4.7 kb long. These single-stranded DNA viral vectors have high transduction rates and have a unique property of stimulating endogenous homologous recombination in the absence of double-strand DNA breaks in the genome.
- ssDNA deoxyribonucleic acid
- rAAV genome editing has the advantage in that it targets a single allele and does not result in any off- target genomic alterations.
- rAAV genome editing technology is commercially available, for example, the rAAV GENESISTM system from HorizonTM (Cambridge, UK).
- Methods for qualifying efficacy and detecting sequence alteration include, but not limited to, DNA sequencing, electrophoresis, an enzyme-based mismatch detection assay and a hybridization assay such as PCR, RT-PCR, RNase protection, in-situ hybridization, primer extension, Southern blot, Northern Blot and dot blot analysis.
- Sequence alterations in a specific gene can also be determined at the protein level using e.g. chromatography, electrophoretic methods, immunodetection assays such as ELISA and western blot analysis and immunohistochemistry.
- Ribozyme molecule capable of specifically cleaving an mRNA transcript encoding the ubiquitinating enzyme.
- Ribozymes are being increasingly used for the sequence- specific inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., Curr Opin Biotechnol. 9:486- 96 (1998)].
- the possibility of designing ribozymes to cleave any specific target RNA has rendered them valuable tools in both basic research and therapeutic applications.
- ribozymes have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders [Welch et al., Clin Diagn Virol. 10:163- 71 (1998)]. Most notably, several ribozyme gene therapy protocols for HIV patients are already in Phase 1 trials. More recently, ribozymes have been used for transgenic animal research, gene target validation and pathway elucidation. Several ribozymes are in various stages of clinical trials. ANGIOZYME was the first chemically synthesized ribozyme to be studied in human clinical trials.
- ANGIOZYME specifically inhibits formation of the VEGF-r (Vascular Endothelial Growth Factor receptor), a key component in the angiogenesis pathway.
- Ribozyme Pharmaceuticals, Inc. as well as other firms have demonstrated the importance of antiangiogenesis therapeutics in animal models.
- HEPTAZYME a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was found effective in decreasing Hepatitis C viral RNA in cell culture assays (Ribozyme Pharmaceuticals, Incorporated - WEB home page).
- DNAzyme molecule capable of specifically cleaving an mRNA transcript or DNA sequence of ubiquitinating enzyme.
- DNAzymes are single- stranded polynucleotides which are capable of cleaving both single and double stranded target sequences (Breaker, R.R. and Joyce, G. Chemistry and Biology 1995;2:655; Santoro, S.W. & Joyce, G.F. Proc. Natl, Acad. Sci. USA 1997;943:4262)
- a general model (the "10-23" model) for the DNAzyme has been proposed.
- DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each.
- This type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions (Santoro, S.W. & Joyce, G.F. Proc. Natl, Acad. Sci. USA 199; for rev of DNAzymes see Khachigian, LM [Curr Opin Mol Ther 4:119-21 (2002)].
- an agent capable of downregulating a ubiquitinating enzyme is an antibody or antibody fragment capable of specifically binding ubiquitinating enzyme.
- the antibody specifically binds at least one epitope of the ubiquitinating enzyme.
- epitope refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.
- Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
- an antibody or antibody fragment capable of specifically binding MLKL, RIPK3 or RIPK1 is typically an intracellular antibody.
- intracellular antibodies also known as “intrabodies”. These are essentially single chain antibodies to which intracellular localization signals have been added (e.g., ER, mitochondrial, nuclear, cytoplasmic). This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, TIBTECH vol. 13: 306-310). Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors and to inhibit a protein function within a cell (See, for example, Richardson et al., 1995, Proc. Natl. Acad. Sci.
- the cDNA encoding the antibody light and heavy chains specific for the target protein of interest are isolated, typically from a hybridoma that secretes a monoclonal antibody specific for the marker.
- Hybridomas secreting anti-marker monoclonal antibodies, or recombinant monoclonal antibodies can be prepared using methods known in the art.
- a monoclonal antibody specific for the marker protein is identified (e.g., either a hybridoma-derived monoclonal antibody or a recombinant antibody from a combinatorial library)
- DNAs encoding the light and heavy chains of the monoclonal antibody are isolated by standard molecular biology techniques.
- light and heavy chain cDNAs can be obtained, for example, by PCR amplification or cDNA library screening.
- cDNA encoding the light and heavy chains can be recovered from the display package (e.g., phage) isolated during the library screening process and the nucleotide sequences of antibody light and heavy chain genes are determined.
- display package e.g., phage
- nucleotide sequences of antibody light and heavy chain genes are determined.
- many such sequences are disclosed in Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 and in the "Vbase" human germline sequence database.
- an intracellular antibody expression vector can encode an intracellular antibody in one of several different forms. For example, in one embodiment, the vector encodes full-length antibody light and heavy chains such that a full-length antibody is expressed intracellularly. In another embodiment, the vector encodes a full-length light chain but only the VH/CH1 region of the heavy chain such that a Fab fragment is expressed intracellularly.
- the vector encodes a single chain antibody (scFv) wherein the variable regions of the light and heavy chains are linked by a flexible peptide linker [e.g., (Gly4Ser)3 and expressed as a single chain molecule.
- a flexible peptide linker e.g., (Gly4Ser)3
- the expression vector encoding the intracellular antibody is introduced into the cell by standard transfection methods, as discussed hereinbefore.
- antibodies may be tested for activity, for example via ELISA.
- aptamer refers to double stranded or single stranded RNA molecule that binds to specific molecular target, such as a protein.
- Various methods are known in the art which can be used to design protein specific aptamers. The skilled artisan can employ SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for efficient selection as described in Stoltenburg R, Reinemann C, and Strehlitz B (Biomolecular engineering (2007) 24(4):381-403).
- Another way of downregulating ubiquitination at position 50 of MLKL is by upregulating a deubiquitinating enzyme capable of deubiquitinating ubiquitinated MLKL.
- Still another way of downregulating ubiquitination at position 50 of MLKL is by administration of a peptide agent that is a substrate for ubiquitination by the E3 ubiquitin-protein ligase.
- a peptide agent that is a substrate for ubiquitination by the E3 ubiquitin-protein ligase.
- peptide agents derived from MLKL which comprise the ubiquitination site at position 50 are contemplated.
- the peptide agents typically comprise at least 5, 6, 7, 8, 9, 10, 15, 20 or more amino acids of MLKL.
- the peptide comprises between 5- 50, 5-40, 5-30, 5-20 amino acids of MLKL.
- the peptide may be attached to a cell penetrating moiety.
- penetrating agent refers to an agent which enhances translocation of an attached polypeptide across a cell membrane.
- the penetrating agent is a peptide and is attached to the C or N terminus of the peptide (either directly or non-directly) via a peptide bond.
- cell penetrating peptides typically have an amino acid composition containing either a high relative abundance of positively charged amino acids such as lysine or arginine, or have sequences that contain an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids.
- the peptides of the present invention are attached to the cell penetrating peptides via a linking moiety.
- the agents which down-regulate ubiquitination of lysine at position 50 of MLKL may be provided to the subject for the treatment of the cancers specified herein with agents that activates the TRAIL apop to tic pathway.
- agents which activate the TRAIL apoptotic pathway include Mapatumumab, Contatumumab, TAS266, ONC201, Tigatuzumab, Dulanermin and Circularly permuted TRAIL (CPT).
- the agents which activate the TRAIL apoptotic pathway may be co-formulated with the agents which down-regulate ubiquitination of lysine at position 50, or may be provided as separate compositions to the subject.
- each agent included in the combination can be formulated separately for use in combination.
- the drugs are said to be used "in combination" when, in a recipient of both drugs, the effect of one drug enhances or at least influences the effect of the other drug.
- the two agents in the combination cooperate to provide an effect on target cells that is greater than the effect of either drug alone.
- This benefit manifests as a statistically significant improvement in a given parameter of target cell fitness or vitality.
- the improvement resulting from treatment with the drug combination can manifest as an effect that is at least additive and desirably synergistic, relative to results obtained when only a single agent is used.
- each drug in the combination can be formulated as it would be for monotherapy, in terms of dosage size and form and regimen.
- the synergy resulting from their combined use may permit the use of somewhat reduced dosage sizes or frequencies, as would be revealed in an appropriately controlled clinical trial.
- the agent which down-regulates ubiquitination of lysine at position 50 of MLKL and the agent which activates the TRAIL apoptotic pathway are administered concomitantly.
- the agent which activates the TRAIL apoptotic pathway and the agent which down-regulates ubiquitination of lysine at position 50 of MLK are administered sequentially, wherein the first agent is used, for example, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, a week, a month or more after the second agent.
- the first agent is used, for example, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, a week, a month or more after the second agent.
- the agent which activates the TRAIL apoptotic pathway and the agent which down-regulates ubiquitination of lysine at position 50 of MLK are administered sequentially, wherein the second agent is used, for example, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, a week, a month or more after the first agent.
- the agents of the present invention may be provided per se or as part of a pharmaceutical composition. which also includes a physiologically acceptable carrier.
- a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.
- a "pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
- the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
- active ingredient refers to the downregulating agents, ligands or population of exosomes accountable for the biological effect.
- physiologically acceptable carrier and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
- An adjuvant is included under these phrases.
- excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, inrtaperitoneal, intranasal, or intraocular injections.
- neurosurgical strategies e.g., intracerebral injection or intracerebroventricular infusion
- molecular manipulation of the agent e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB
- pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers)
- the transitory disruption of the integrity of the BBB by hyperosmotic disruption resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide).
- each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
- tissue refers to part of an organism consisting of cells designed to perform a function or functions. Examples include, but are not limited to, brain tissue, retina, skin tissue, hepatic tissue, pancreatic tissue, bone, cartilage, connective tissue, blood tissue, muscle tissue, cardiac tissue brain tissue, vascular tissue, renal tissue, pulmonary tissue, gonadal tissue, hematopoietic tissue.
- compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer.
- physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient.
- Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the active ingredients for use according to some embodiments of the invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative.
- the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
- a suitable vehicle e.g., sterile, pyrogen-free water based solution
- compositions of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
- compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (e.g. downregulating agents, ligands or population of exosomes) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., a disease associated with activation of a necroptosis activation pathway, necroptosis or inflammation) or prolong the survival of the subject being treated.
- active ingredients e.g. downregulating agents, ligands or population of exosomes
- a disorder e.g., a disease associated with activation of a necroptosis activation pathway, necroptosis or inflammation
- the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays.
- a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
- Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals.
- the data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
- the dosage may vary depending upon the dosage form employed and the route of administration utilized.
- the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l).
- a transgenic mouse model for cancer such as the erb model (Shah N., et al., 1999, Cancer Lett. 146: 15-2; Weistein EL, et al., 2000, Mol. Med. 6: 4-16) or MTV/myc model (Stewart TA et al., 1984, Cell, 38: 627-637), the c-myc model (Leder A., et al., 1986, Cell, 45:485-495), v-Ha-ras or c-neu model (Elson A and Leder P, 1995, J. Biol. Chem. 270: 26116-22) can be used to test the ability of agents that down-regulate ubiquitination of lysine at position 50 of MLKL to suppress tumor growth in vivo.
- mice administered with cancerous cell lines - can be injected with human or animal (e.g., mouse) cancerous cells such as those derived from breast cancer, ovarian cancer, prosate cancer or thyroid cancer, and following the formation of cancerous tumors the mice can be subjected to intra-tumor and/or systemic administration of an agent capable of down-regulating ubiquitination of lysine at position 50 of MLKL.
- human or animal e.g., mouse cancerous cells
- an agent capable of down-regulating ubiquitination of lysine at position 50 of MLKL e.g., human or animal (e.g., mouse) cancerous cells such as those derived from breast cancer, ovarian cancer, prosate cancer or thyroid cancer
- Human ovarian cancer cell lines - SK0V3 (ATCC No. HTB-77), OVCAR-3 HTB-161), OVCAR-4, OVCAR-5, OVCAR-8 and IGROV1;
- Mouse lung carcinoma LL/2 (LLC1) cells (Lewis lung carcinoma) - These cells are derived from a mouse bearing a tumor resulting from an implantation of primary Lewis lung carcinoma. The cells are tumorigenic in C57BL mice, express H-2b antigen and are widely used as a model for metastasis and for studying the mechanisms of cancer chemotherapeutic agents (Bertram JS, et al., 1980, Cancer Lett. 11: 63-73; Sharma S, et al. 1999, J. Immunol. 163: 5020- 5028).
- Mouse B16-F10 cells (Melanoma) - The cells are derived from mouse (C57BL/6J) bearing melanoma (Briles EB, et al., 1978, J. Natl. Cancer Inst. 60: 1217-1222).
- Tumor formation in animal models by administration of cancerous cells - Athymic nu/nu mice can be purchased from the Jackson Laboratory (Bar Harbor, ME). Tumors can be formed by subcutaneous (s.c.) injection of cancerous cells (e.g., 2 x 10 6 cells in 100 pl of PBS per mouse). Tumors are then allowed to grow in vivo for several days (e.g., 6-14 days) until they reach a detectable size of about 0.5 cm in diameter.
- injection of cancerous cells to an animal model can be at the organ from which the cell line is derived (e.g., mammary tissue for breast cancer, ovary for ovarian cancer) or can be injected at an irrelevant tissue such as the rear leg of the mouse.
- the organ from which the cell line is derived e.g., mammary tissue for breast cancer, ovary for ovarian cancer
- an irrelevant tissue such as the rear leg of the mouse.
- the inhibitor is administered to the animal model bearing the tumor either locally at the site of tumor or systemically, by intravenous injection of infusion, via, e.g., the tail vein.
- the time of administration may vary from immediately following injection of the cancerous cell line (e.g., by systemic administration) or at predetermined time periods following the appearance of the solid tumor (e.g., to the site of tumor formation, every 3 days for 3-10 times as described in Ugen KE et al., Cancer Gene Ther. 2006 Jun 9; [Epub ahead of print]).
- Tumor sizes are measured two to three times a week. Tumor volumes are calculated using the length and width of the tumor (in millimeters). The effect of MLKL ubiquitination inhibitor treatment can be evaluated by comparing the tumor volume using statistical analyses such as Student’s t test. In addition, histological analyses can be performed using markers typical for each type of cancer.
- the agent capable of down-regulating MLKL ubiquitination at position 40 is administered to the individual in need thereof, e.g., the animal model bearing the tumor, either locally or systemically, and the effect of the agent on tumor growth is detected using methods known in the art.
- Models for testing agents that up-regulate ubiquitination of lysine at position 50 of MLKL for treatment of IBD include dextran sulfate sodium-induced colitis, Oxazolone-induced colitis, acetic acid-induced colitis and salmonella-induced colitis.
- Transgenic and gene knockout animal models of ulcerative colitis include IL-7 Tg mice and TCRa KO mice.
- Dosage amount and interval may be adjusted individually to provide the active ingredient at a sufficient amount to induce or suppress the biological effect (minimal effective concentration, MEC).
- MEC minimum effective concentration
- the MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
- dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
- compositions to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
- compositions, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
- a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range.
- the phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
- method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- treating includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
- the subject of the present invention typically refers to a mammalian subject - e.g. a human subject.
- the present inventors further propose that uncovering the position on which MLKL is ubiquitilated, paves the way for a novel screening assay which can be used to identify agents that are capable of treating diseases associated with a necroptosis pathway.
- diseases include, but are not limited to a renal disease, a pulmonary disease, a hepatic disease, cancer, infectious disease, neurodegenerative disease, inflammatory bowel disease, ischemic reperfusion, psoriasis and a cardiovascular disease.
- Further diseases are described in Choi et al., doi.org/10.1172/jci.insight.128834, the contents of which are incorporated herein by reference.
- a method of identifying an agent capable of treating a disease associated with activation of a necroptosis pathway comprising:
- the method may be carried out in a cell mixture or a cell-free mixture, comprising MLKL and the necessary components for ubiquitination.
- Ubiquitination may be observed by any means suitable for detection of protein ubiquitination - such as mass spectroscopy and additional methods described in the Examples section herein below.
- An exemplary method for detecting ubiquitination is disclosed in US Patent Application No. 2019-0185902, the contents of which are incorporated herein by reference.
- the agent can be proposed as a candidate for treating a particular disease.
- the agent causes at least a 10 %, 20 %, 30 %, 40 %, 50 % or greater increase/decrease in the amount of ubiquitination of MLKL compared to a control assay which is carried out in the absence of the agent.
- agent is a suitable agent for treating the disease - both in vitro and in vivo, for example using animal models for the disease.
- Cell culture Cells of the human HT-29 colorectal adenocarcinoma line were grown in McCoy’s 5A medium. Normal mouse embryonic fibroblasts (MEFs) and embryonic fibroblasts of MLKL-knockout mice were immortalized by expression of the SV40 large T antigen. MEFs and human embryonic kidney (HEK293T) cells were cultured in Dulbecco’s modified Eagle’s medium. The cell-growth media were supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 pg/ml streptomycin.
- FBS fetal bovine serum
- penicillin 100 U/ml penicillin
- streptomycin 100 fetal bovine serum
- MLKL was knocked out in vitro using the MLKL CRISPR/Cas9 KO plasmid (Santa Cruz, sc-401248) that was transfected with Lipofectamine 3000.
- FADD was knocked out by lentiviral infection with two gRNA sequences (5’-GTTCCTATGCCTCGGGCGCGT (SEQ ID NO: 1) and 5’- ACGCGCCCGAGGCATAGGAAC (SEQ ID NO: 2)) in the pX459 plasmid (Addgene, 62988).
- SMARTpool ON-TARGETplus human ITCH siRNA(L-007196-00- 0050, Dharmacon) was transiently tranfected into HT-29 cells, and the cells were further incubated for 3 days.
- transfected MLKL and its various mutants were fused C-terminally to a double strep tag (WSHPQFEK- GGGSGGGSGGGS-WSHPQFEK - SEQ ID NO: 3).
- the human MLKL L357A/S358A, L58G/I76G and L162G/165G mutants were expressed constitutively in MLKL knocked-down cells as previously described (Yoon, 2016 #4038).
- the GEV16/pF5x UAS system (30) was used to inducibly express, in MLKL knockout cells, the various human and mouse MLKL mutants in which lysine residues were replaced with arginine (and, as controls, the wild-type proteins) and human MLKL fused C-terminally to green fluorescent protein (GFP).
- GFP green fluorescent protein
- this system was also used for the expression of ITCH and the ITCH C83OA mutant that were fused C-terminally to a myc tag (EQKLISEEDL (SEQ ID NO: 4)). Unless otherwise indicated, induction by treatment with 4HT (1 pM) was carried out for 6 h.
- Bafilomycin Al 11038-500
- pepstatin A 9000469-10
- Cayman Chemical and MG132 (M7449), chloroquine (C6628), and 4-hydroxytamoxifen (H6278) were from Sigma- Aldrich.
- Human EGF from ProSpec was biotinylated using an EZ-Link Sulfo-NHS- biotin kit from Thermo Fisher Scientific (21326).
- TNF was from YbdY Biotech, and the bivalent IAP (inhibitor of apoptosis protein) antagonist BV6 and the caspase inhibitor z-VAD-fmk were both from WuXi App Tec.
- Strep-Tactin Sepharose 50% suspension (2-1201-010) and Strep-Tactin elution buffer (2-1042-025 ) were from IBA Lifesciences.
- Agarose-coupled TUBE1 (UM401) was from LifeSensors.
- Brij O10 polyoxyethylene (10) oleyl ether, P6136) was from Sigma-Aldrich.
- the Lipofectamine 3000 transfection reagent (L3000015) was from ThermoFisher, and the JetPEI transfection reagent (101-10N) was from Polyplus-transfection. LysoTracker IM Red DND-99 (L7528) was from ThermoFisher.
- the cDNAs encoding wild-type HA-tagged ubiquitin (17608) were from Addgene.
- Antibodies The following antibodies were applied for Western blot analysis: anti-mouse MLKL (Sabl302339), Anti-HA (H6908), anti p-actin (A5441), anti-Flag M2 (13026) and anti- MVB12B (HPA043683) from Sigma; anti-human MLKL (ab 184718), anti-human phospho- MLKL (abl87091), and anti-Rab7 (ab 137029) from Abeam; anti-TSGlOl (612696), anti-ITCH (611199), anti-EEAl (610456) and anti-phosphotyrosine (61000) from BD Biosciences; anti-LDH (sc-27230), anti-STIM-1 (sc- 166840) and anti-TOM20 (sc- 17764) from Santa Cruz Biotechnology; anti-ubiquitin (VU-1) from LifeSensors; anti-myc tag (05-724) from Millipore; anti-EGFR (6F1) from Enzo
- Alexa Fluor 647-conjugated anti-mouse IgG (715-605- 150) was used and Cy3-conjugated anti-rabbit IgG (111-165-144) from Jackson ImmunoResearch, anti-Lampl -Alexa Fluor 647 (NBP2-25183AF647, Novus Biologicals) and Alexa Fluor 405- conjugated anti-mouse IgG (abl75660) from Abeam.
- Alexa Fluor 405- conjugated anti-mouse IgG abl75660
- Proteins were immunoprecipitated as described (14). To estimate the extent of oligomerization of MLKL, cells were extracted with 1% NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40) including protease and phosphatase inhibitors (1 mM PMSF, 40 mM beta-glycerophosphate, 50 mM NaF and 1 mM sodium vanadate), and this was followed by solubilization in Laemmli SDS PAGE buffer devoid of reducing agent, as described (12). In Western analyses where some nonspecific bands could be seen, specific bands are indicated by arrows.
- HT-29 cells constitutively expressing MLKL that was fused C-terminally to the double Strep-tag (31) were used.
- Interactions of ESCRT proteins with MLKL were assessed following extraction of the cells in a buffer containing 1% Brij, as described (14). Immunoblotting was done as described (9).
- MLKL was eluted by biotin after its precipitation by Strep-Tactin magnetic beads.
- Cytological and immunocytological analyses For immunocytological analyses, cells were fixed with 4% paraformaldehyde for 15 min at room temperature in phosphate buffered saline (PBS), permeabilized with ice-cold methanol for 10 min at -20°C, and blocked with MAXblock Blocking Medium (Active Motif, 15252) overnight at 4°C. The cells were then incubated with the indicated antibodies for 1 h at room temperature, and then with fluorescent dye-conjugated secondary antibodies for 2 h at 4°C in MAXbind Staining Medium (Active Motif, 15253).
- PBS phosphate buffered saline
- Images were acquired with an Olympus IX 81 confocal microscope (Olympus Imaging) using the UPLS APO 60 x /1.35 NA oil objective, and were processed using the FluoView FV 1000 (Olympus Imaging) and ImageJ (NIH) software. Colocalization was determined manually using unsaturated single Z-stack images, by measuring the overlap of signals between channels with constant threshold values. Data are presented as means (%) ⁇ standard deviations (S.D.) in approximately equal numbers of images acquired in at least 3 independent experiments; P values were calculated using a two-tailed Student’s t-test.
- Extracellular vesicles generated by TBZ-treated HT- 29 cells were collected 3 h after TBZ application and were isolated as previously described (14).
- MLKL ubiquitination Samples of 6 million HT-29 cells and 2 million MEFs, seeded 1 day prior to the experiment, were treated with 1 pM 4HT for 12 h to induce expression of wild-type or mutant MLKL.
- Ubiquitinated MLKL was isolated from cell extracts using TUBE 1 -agarose (LifeSensors) according to the manufacturer’s protocol, except that the extraction buffer also contained protease and phosphatase inhibitors (1 mM PMSF, 40 mM betaglycerophosphate, 50 mM NaF, and 1 mM sodium vanadate).
- wild-type and mutant HA-tagged ubiquitins were first expressed constitutively by lentiviral infection in cells inducibly expressing MLKL fused to Strep-tag. Following further growth of the cells for 12 h and, when indicated, stimulation by TBZ, the cells were lysed by boiling in a buffer containing 1% sodium dodecyl sulfate (SDS), 20 mM Tris-HCl (pH 7.5), 5 mM EDTA, and 1 mM dithiothreitol (DTT).
- SDS sodium dodecyl sulfate
- DTT dithiothreitol
- MLKL was affinity-purified using Strep-Tactin beads, and conjugation of the tagged ubiquitin chains to it was assessed by western blotting using anti-HA antibody.
- MLKL affinity-purified by Strep-Tactin beads or — as controls — synthetic K63-linked and K48-linked tetra-ubiquitin chains (UM-K630 and UM- K480, R&D Systems) were incubated with the indicated recombinant deubiquitinases (USP2(E- 506), 200 nM; Otubainl(E-522B), 1 qM; AMSH(E549), 1 qM; CYLD(E-556), 20 nM), for 1 h at 37°C in a reaction buffer containing 50 mM Tris pH 7.5, 5 mM MgCh, 25 mM KC1 and 1 mM DTT. All enzymes and recombinant proteins were from R&D Systems.
- Listeria monocytogenes infection and quantification HT-29 cells and MEFs were seeded 2 days before infection and incubated, prior to infection, for 10 h in BIOGRO-2 serum-free medium (Biological Industries) without antibiotics.
- Listeria monocytogenes strain 10403S, kindly provided by Dr. Steffen Jung
- MOI multiplicity of infection
- MEFs MEFs at a MOI of 5
- the cells were then rinsed with PBS, incubated with 100 pg/ml gentamycin for 10 min and then with fresh growth medium containing 5 pg/ml of gentamicin. Subsequent treatments of the cells were as described in Figure 8.
- the infected cells were rinsed twice with PBS and then lysed in 0.2% Triton X-100 in PBS (1 ml per 2.5-cm well). After serial dilutions the lysates were spread on Brain Hear Infusion (BHI) agar plates (BD diagnostic, 211065). Values presented in the figures are means ⁇ S.D. of colony forming units (CFU); P values were calculated using a two-tailed Student’s t-test.
- BHI Brain Hear Infusion
- MLKL was recently shown to suppress the growth of Listeria monocytogenes 18).
- Listeria enters cells by co-opting receptor-uptake mechanisms.
- the extent to which the Listeria cells are then destroyed in the lysosomes, or keep replicating in the cytoplasm or in membrane encased niches, is subject to modulation by antagonistic mechanisms elaborated by this pathogen and its host cells (e.g. (7 -22)). It was therefore decided to examine whether the ubiquitination-dependent association of MLKL with endosomes contributes to its effect on these bacteria.
- MLKL was found to have an inhibitory effect on Listeria replication, and that this was enhanced by treatment with TBZ.
- this anti-Listerial effect seemed to be exerted as a result of MLKL oligomerization ( Figure 4D). It was observed significantly earlier than any sign of cell death ( Figure 4E) and, unlike the cytotoxic effect, was abolished by mutation of the ubiquitination sites in MLKL ( Figure 4A-C). It was also eliminated by knockdown of ITCH ( Figure 4F).
- MLKL affects Listerial growth both constitutively and in a way that is enhanced upon phosphorylation and ubiquitination of MLKL. They further suggest that the anti-Listerial effect induced upon phosphorylation and ubiquitination of MLKL depends on lysosome functioning, whereas the constitutive anti-Listerial effect of MLKL does not. In exploring the nature of the effect of MLKL on lysosomal function, it was found that stimulation of MLKL phosphorylation has no effect on the relative amounts of acidified lysosomes ( Figures 7E, F).
- MLKL tagged C-terminally with the Strep-tag
- Strep-Tactin beads from 4 x 10 8 human HT-29 cells that had been treated for 3 hours with TBZ- TNF (1000 units/ml) plus the bivalent IAP antagonist BV6 (1 pM) and the caspase inhibitor z-VAD-fmk (20 pM) or, as control, from the same number of untreated HT-29 cells.
- the purified proteins were digested by trypsin. Following trypsinization Ubiquitinated peptides were isolated using the PTMScan Ubiquitin Remnant Motif (K-e-GG) Kit (Cell Signaling). The isolated peptides were then analyzed by liquid chromatography tandem mass spectrometry (MS/MS).
- the peptides having the sequence as set forth in SEQ ID NO: 10 (both the oxidized (row 3) and non-oxidized form (row 4) was found to be ubiquitinated in lysine 50. Both show high ubiquitination after TBZ treatment and no ubiquitination prior to the treatment. Oxidation probably occurred during the manipulation of the samples for the mass spec analysis).
- the peptide listed having the sequence as set forth in SEQ ID NO: 8 was on the border of detection.
- SEQ ID NO: 9 was ubiquitinated in lysine 331. Unlike lysine 50, lysine 331 is not evolutionary conserved and its ubiquitination was only partially dependent on TBZ treatment.
- MLKL ubiquitination also facilitates destruction of some other intracellular bacteria
- the Gram-negative bacterium Yersinia enterocolitica enters cells by co-opting receptor- uptake mechanisms, and its replication within the infected cells is subject to modulation by antagonistic effects exerted both by the bacteria and by cellular defense mechanisms.
- the yields of these bacteria in infected HT-29 and L929 cells it was found that, as with Listeria, in cells that express WT MLKL the yield of Y.
- enterocolitica was effectively decreased by their treatment with TBZ and TNF, respectively, whereas in HT-29 cells expressing the K50R MLKL mutant and in L929 cells expressing the K50,51R MLKL mutant, these treatments had no effect on their bacterial yields ( Figures 10A, B).
Abstract
An agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) is disclosed for use in treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject. Use of the agent for additional diseases is also disclosed.
Description
CONTROLLING UBIQUITINATION OF MLKL FOR TREATMENT OF DISEASE
RELATED APPLICATIONS
This application claims the benefit of priority of Israeli Patent Application No. 279559 filed 17 December, 2020, the contents of which are incorporated herein by reference in their entirety.
SEQUENCE LISTING STATEMENT
The ASCII file, entitled 90063SequenceListing.txt, created on 13 December, 2021, comprising 15,150 bytes, submitted concurrently with the filing of this application is incorporated herein by reference.
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to method of treating diseases and, more particularly, but not exclusively, to infectious diseases, cancer and inflammatory bowel diseases (IBD) by controlling the level of ubiquitination of mixed lineage kinase-like molecule (MLKL).
Exploration of the mechanisms by which cytokines of the tumor necrosis factor (TNF) family induce cell death has led to the identification of a form of programmed cell death called “necroptosis”, in which the mixed lineage kinase-like molecule (MLKL), upon its phosphorylation by the protein kinase RIPK3, triggers lethal rupture of the cellular membrane. This pathway was later shown also to be activated by a number of other inducers, including other cytokines and different pathogen components employing various proximally signaling proteins to activate RIPK3 (7-7).
Phosphorylation of MLKL by RIPK3 triggers in this pseudokinase a conformational change that results in its oligomerization, and also results in the exposure of clusters of charged residues at its N-terminus within a domain consisting of a four a-helical bundle (4HB). The exact mechanism of death mediation by MLKL is still not clear, except that the death seems to be inflicted by binding of the exposed charged residue clusters in MLKL to certain membrane lipids (S).
Prior its phosphorylation, MLKL resides mainly in the cytoplasm, but it can also be found in the nucleus, where it is activated by certain pathogens (9-11). Death mediation by MLKL appears to happen in the cell membrane (72, 13). It was previously reported that some of the activated MLKL molecules also associate with endosomal membranes, where they bind to ESCRT proteins and are then released from the cell within extracellular vehicles (EVs) whose generation they facilitate (14).
U.S. Patent Application No. 2016/0160189 provides methods and compositions for inducing necroptosis in target cells, including cancer cells. Specifically, according to U.S. 2016/0160189 necroptosis is induced using compositions including oligomers comprising RIPK3 proteins and RIPK1 proteins including, but not limited to, full length RIPK3 homodimers, truncated RIPK3 oligomers and/or full length RIPK3/RIPK1 heterodimers.
WO2018/033929 teaches agents which regulate MLKL for the treatment of inflammation in general and, more specifically of cancer.
Park et al., Cell Death and Disease (2020) 11:744 teaches that agents capable of downregulation MLKL can be used to treat cancer.
SUMMARY OF THE INVENTION
According to an aspect of the present invention, there is provided a method of treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL), thereby treating the disease caused by the pathogen.
According to an aspect of the present invention, there is provided a method of treating a cancer sensitive to TRAIL receptor mediated cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically down- regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the cancer.
According to an aspect of the present invention, there is provided an article of manufacture comprising an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) and an antibacterial or antiviral agent.
According to an aspect of the present invention, there is provided an article of manufacture comprising an agent which downregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) and an agent that activates the TRAIL apoptotic pathway and/or TNF alpha.
According to an aspect of the present invention, there is provided an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) for use in treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject.
According to an aspect of the present invention, there is provided a method of treating inflammatory bowel disease (IBD) in a subject in need thereof comprising administering to the
subject a therapeutically effective amount of an agent that specifically up-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the IBD.
According to an aspect of the present invention, there is provided an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) for use in treating IBD.
According to an aspect of the present invention, there is provided method of treating a cancer in a subject in need thereof comprising co-administering to the subject a therapeutically effective amount of an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL and TNF alpha, thereby treating the cancer.
According to an aspect of the present invention, there is provided a method of treating a disease associated with an upregulation of activity of EGF receptor in a subject comprising administering to the subject a therapeutically effective amount of an agent that specifically down- regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the disease.
According to embodiments of the present invention, the disease is selected from the group consisting of non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer and breast cancer.
According to embodiments of the present invention, the pathogen is a virus.
According to embodiments of the present invention, the virus is selected from the group consisting of Influenza A virus, Foot and mouth disease virus, Rhinovirus, Adenovirus, Ebolavirus, Kaposi Sarcoma Virus, Simian virus 40, Papillomavirus, Polio virus, Lymphocytic choriomeningitis virus (LCMV), Rhinovirus and Coronavirus.
According to embodiments of the present invention, the pathogen is a bacteria.
According to embodiments of the present invention, the bacteria is Listeria monocytogenes.
According to embodiments of the present invention, the agent enhances the activity and/or amount of a ubiquitin ligase that is capable of ubiquitinating lysine at position 50 of mixed lineage kinase domain-like protein (MLKL).
According to embodiments of the present invention, the agent is the ubiquitin ligase.
According to embodiments of the present invention, the agent is a polynucleotide encoding the ubiquitin ligase.
According to embodiments of the present invention, the ubiquitin ligase is E3 ubiquitin- protein ligase Itchy homolog (ITCH).
According to embodiments of the present invention, the agent enhances oligomerization of the MLKL.
According to embodiments of the present invention, the agent activates protein kinase RIPK3.
According to embodiments of the present invention, the agent is a multivalent agent that binds the MLKL.
According to embodiments of the present invention, the method further comprises administering to the subject an agent that directly targets the pathogen.
According to embodiments of the present invention, the agent is a peptide agent that is a substrate for ubiquitination by the E3 ubiquitin-protein ligase.
According to embodiments of the present invention, the peptide agent comprises at least 10 amino acids of MLKL.
According to embodiments of the present invention, the agent is a polynucleotide agent that is capable of down-regulation the amount of ITCH in cancer cells of the subject.
According to embodiments of the present invention, the method further comprises administering to the subject an agent that activates the TRAIL apoptotic pathway.
According to embodiments of the present invention, the agent that activates the TRAIL apoptotic pathway is selected from the group consisting of Mapatumumab, Contatumumab, TAS266, ONC201, Tigatuzumab, Dulanermin and Circularly permuted TRAIL (CPT).
According to embodiments of the present invention, the cancer is selected from the group consisting of myeloma, lymphoma, colorectal cancer, NSCLC, liver cancer, triple negative breast cancer, pancreatic cancer, cervical cancer, soft tissue sarcoma, ovarian cancer, glioblastoma.
According to embodiments of the present invention, the agent enhances the activity and/or amount of a ubiquitin ligase that is capable of ubiquitinating lysine at position 50 of mixed lineage kinase domain-like protein (MLKL).
According to embodiments of the present invention, the agent is the ubiquitin ligase.
According to embodiments of the present invention, the agent is a polynucleotide encoding the ubiquitin ligase.
According to embodiments of the present invention, the ubiquitin ligase is E3 ubiquitin- protein ligase Itchy homolog (ITCH).
According to embodiments of the present invention, the agent which downregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) is coformulated with the agent that activates the TRAIL apoptotic pathway.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
FIGs. 1A-G. Activated MLKL is ubiquitinated at specific lysine residues.
A. Time-dependent ubiquitination and phosphorylation of MLKL in human HT-29 cells in response to treatment with TBZ (TNF, 1000 units/ml; the bivalent IAP antagonist BV6, 1 pM; and the caspase inhibitor z-VAD-fmk, 20 pM).
B. MLKL ubiquitination in response to TBZ occurs as a consequence of its oligomerization. The extents of MLKL ubiquitination (top), aggregation (middle) and phosphorylation (bottom) were determined in MLKL knockout (KO) HT-29 cells expressing constitutively wild-type (WT) MLKL and its indicated mutants.
C. Accumulation of ubiquitinated MLKL in response to TBZ is not enhanced by treatment with MG132 (10 pM) or bafilomycin Al (Baf Al, 0.1 pM).
D-F. Ubiquitination and oligome rization of the indicated mutants of (D, E) human MLKL expressed transiently in MLKL-KO HT-29 cells, and (F) mouse MLKL inducibly expressed in MLKL-KO MEFs, upon treatment with TBZ.
G. Ribbon diagram of the 4HB domain in mouse MLKL. The site of ubiquitination of MLKL (green) and the clusters of residues that appear to be crucially involved in the mediation of cell death (red and orange (29)) are indicated.
FIGs. 2A-L. Ubiquitinated MLKL associates with endosomal membranes.
A. Assessment of the occurrence of ubiquitinated and phosphorylated MLKL in the indicated subcellular fractions (15 pg protein applied per well). (PAM, plasma membrane associated membrane; PM, plasma membrane).
B-I. Immunocytochemical analysis of the effect of the K50R mutation in MLKL on the association of MLKL (B-E) and of both MLKL and ubiquitin (F-I) with early (Rab5+) and late (Rab7+) endosomes in MLKL-KO HT-29 cells that inducibly express MLKL, observed after 2.5 h of treatment with TBZ. B, C and F, G: Quantification of the data (-110 cells). (D, E) and (H, I): Examples of the immunofluorescence images. In D and E, green - MLKL, magenta - Rab5 or 7, white (and arrows) - MLKL+Rab5 or 7. In H and I, green - MLKL, red - Rab5 or7, blue - ubiquitin, magenta - Rab5 or 7 + ubiquitin, cyan - MLKL + ubiquitin, white (and arrows) - Rab5 or 7 + MLKL + ubiquitin. Scale bar, 10 pm.
J. Comparison of the amounts of MLKL and of ubiquitinated MLKL in 60 pg of proteins of the total cellular lysate and of EVs released from HT-29 cells in 3 h of treatment with TBZ.
K, L. Effect of the K50R mutation in MLKL on (H) the association of MLKL with ESCRT proteins and on (I) MLKL release in EVs from HT-29 cells treated for 2.5 h with TBZ.
FIGs. 3A-K MLKL ubiquitination is mediated by ITCH.
A. Comparison of the amounts of ITCH in 15 pg of proteins of the total cellular lysate and of EVs released from HT-29 cells in 3 h of treatment with TBZ.
B. ITCH binds to MLKL in 293T cells transiently overexpressing both proteins. Western analysis following the precipitation of MLKL via fused Strep tag.
C. In response to TBZ, ITCH binds inducibly to MLKL in HT-29 cells constitutively expressing wild-type MLKL but not its T357A/S358A or L162G/L165G mutant, and binds constitutively to the MLKL L58G/176G mutant.
D. E. Deletion analysis of ITCH for identification of the region in ITCH to which MLKL binds. (D) Western analysis of the binding of the various MLKL mutants to ITCH on transient expression in 293T cells. (E) Diagram showing the deletion mutants used and the location of the WW motifs in ITCH.
F, G. Immunocytochemical evidence for the colocalization of ITCH and activated MLKL in association with endosomes. (F) Quantification of the data (in 75 cells). (G) Immunofluorescence images. White (arrows), co-localization of both MLKL (green) and ITCH (blue) with either Rab5 or Rab 7 (red, upper and lower panels, respectively). Scale bar, 10 pm.
H. ITCH catalyzes in vitro the ubiquitination of MLKL but not of its K50R mutant.
I. Enhancement, by inducible expression of ITCH, of TBZ- induced ubiquitination of MLKL but not of its K50R mutant that are inducibly expressed in MLKL KO HT-29 cells.
J. Enhancement of TBZ-induced association of MLKL with ESCRT proteins by transient expression of ITCH, and inhibition of this association by its enzymatically inactive mutant.
K. Decrease, by ITCH knockdown, in TBZ-induced ubiquitination of MLKL.
FIGs. 4A-L. Ubiquitination of MLKL facilitates lysosomal destruction of Lysteria.
A. Amounts of viable Listeria in MLKL- KO MEFs inducibly expressing either wild-type mouse MLKL or its K50R, K51R mutant, 4 h after infection, and the effect of TBZ treatment for the last 1 h on the Listerial yields.
B, C. Comparison of the amounts of viable Listeria, 5 h (B) and 24 h (C) after infection, as well as of the effects of TBZ treatment for 2 h at the end of the infection period, in MLKL-KO HT-29 cells and in the KO cells inducibly expressing either wild-type MLKL or its K50R mutant.
D. Effects of various MLKL mutants expressed constitutively in MLKL-KO HT-29 cells and of treatment for 2 h with TBZ at the end of the infection period on the amounts of viable Listeria in the cells 5 h after infection.
E. Comparison of the effects of TBZ treatment for 2 h or 4 h after infection with Listeria on Listerial yield and on the extent of cell death, in wild-type and in MLKL-KO HT-29 cells.
F. Effect of ITCH knockdown on the amount of viable Listeria in HT-29 cells 5 h after infection, and on its modulation by TBZ treatment for 2 h at the end of the infection period.
G-J. Effects of chloroquine (CQ, 25 pM) and pepstatin A (PepA, 10 pg/ml) applied throughout the periods of Listeria infection of HT-29 cells as in B and C.
K-L. Immunocytochemical analysis of the location of Listeria in early and late endosomes, in lysosomes and in the cytosol, 5 h after infection, and their modulation by TBZ- treatment, in HT-29 cells inducibly expressing wild-type or K50R-mutated MLKL. (K) Ratios of the numbers of Listeria in the indicated compartments (analysis of 130 infected cells). (L) Typical immunofluorescence images. Blue-Listeria, green - MLKL, red - Rab7, magenta - Lampl, (a lysosomal marker), yellow - MLKL + Rab7, white - MLKL + Rab7 + Lampl, white arrows - Listeria in MLKL + Rab7 + Lampl.
FIGs. 5A-F. Activated MLKL is ubiquitinated at specific lysine residues.
A-C. Assessment of the ubiquitination and/or phosphorylation of MLKL in (A) wild-type MEFs, in response to TBZ, (B) HT-29 cells in which FADD was knocked out by CRISPR/Cas9, in response to treatment with just TNF and Bv6 (TB), and (C) TBZ-treatment of HT-29 cells in which the endogenous MLKL was knocked out, and either the wild type or the K50R-mutated human MLKL was inducibly re-expressed under control of the GEV16/pF5x UAS system.
D. Conjugation of wild-type- and K63R-mutated HA-tagged ubiquitin to MLKL in HT-29 cells.
E. Comparison of the in-vitro effects of the indicated deubiquitinases on HA-tagged polyubiquitin chains that were conjugated to MLKL in HT-29 cells treated with TBZ for 3 h.
F. Effects of these deubiquitinases on synthetic K63-linked and K48-linked tetra-ubiquitin chains.
FIGs. 6A-F. Ubiquitinated MEKE associates with endosomal membranes.
A-D. Additional examples of the immunofluorescent images whose quantitative analysis is presented in Figure 2. A, B: Association of MLKL with early (Rab5+, A) and late (Rab7+, B) endosomes. C, D: Association of both MLKL and ubiquitin with early (Rab5+, C) and late (Rab 7+, D) endosomes. In A and B: green - MLKL, magenta - Rab5 or 7, white (and arrow) - MLKL + Rab5 or 7. In C and D: green - MLKL, red - Rab5 or 7, blue - ubiquitin, magenta - Rab5 or 7 + ubiquitin, cyan - MLKL + ubiquitin, white (and arrows) - Rab5 or 7 + MLKL + ubiquitin. Scale bar, 10 pm.
E, F. Comparative immunohistochemical analysis of the extent of association of MLKL and ubiquitin with (E) early endosomes and (F) the endoplasmic reticulum in HT-29 cells after 3 h of treatment with TBZ. Green - MLKL, red - early endosomes (in E) or endoplasmic reticulum (in F), blue - ubiquitin, cyan - MLKL + ubiquitin, magenta - early endosomes (in E) or endoplasmic reticulum (in F) + ubiquitin, yellow - MLKL + early endosomes (in E) or endoplasmic reticulum (in F), white (and arrows) - MLKL + early endosomes + ubiquitin.
FIGs. 7A-F. Functional consequences of MLKL ubiquitination
A, B. Immunoblot analysis of the kinetics of intracellular degradation of (A) EGF and EGFR and of (B) TNF, in TBZ-treated MLKL-KO HT-29 cells that inducibly express wild-type or K50R-mutated MLKL.
C, D. Increase in sensitivity to TBZ-induced cell death in (C) MEFs expressing the K50R, K51R- mutated mouse MLKL and in (D) HT-29 cells expressing the K50R human MLKL mutant. In both cells the endogenous MLKL was knocked out and then the wild-type and the mutant MLKL were expressed inducibly.
E, F. Immunocytochemical analysis of the extent of acidification of the lysosomes that contain Listeria in control and TBZ-treated HT-29 cells. (E) Quantification of the data (-100 infected cells). (F) Example of the immuno staining: green - Lampl (a lysosomal marker), red - staining of acidification by the LysoTracker reagent, blue - Listeria, yellow - Lampl + LysoTracker, magenta - Listeria + LysoTracker, cyan - Listeria + Lampl, white- Listeria + Lysotracker + Lampl. Scale bar, 10 pm.
FIG. 8 Diagrammatic presentation of the protocols of infection with Listeria monocytogenes.
FIG. 9A: Spectrum Annotation of Scan #21400 VLGLIKPLEMLQDQGKR (SEQ ID NO: 10)[Trypsin Digested:GG (Ubiquitination Site) on K]R.
FIG. 9B: Spectrum Annotation of Scan #3228 LHHSEAPELHGKIR (SEQ ID NO: 9) [Trypsin DigesteckGG (Ubiquitination Site) on K]IR.
FIGs. 10A-D illustrate that MLKL ubiquitination facilitates destruction of Y. enterocolitica and E. coli bacteria.
FIGs. 10A-B. Yields of Y. enterocolitica bacteria 5 h after infection of HT-29 cells or their HT- 29 K50R mutant, and 6 h after infection of L929 cells or their K50,51R mutant, and the modulation of these yields obtained by treatment of the HT-29 cells with TBZ and treatment of the L929 cells with TNF.
FIGs. 10C-D. Yields of E. coli 8 h after infection of L929 cells or their K50,51R mutant, and the modulation of these yields obtained by treatment of the L929 cells with TNF.
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
The present invention, in some embodiments thereof, relates to method of treating diseases and, more particularly, but not exclusively, to infectious diseases, cancer and IBD, by controlling the level of ubiquitination of mixed lineage kinase-like molecule (MLKL).
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Phosphorylation of MLKL by the protein-kinase RIPK3 targets MLKL to the cell membrane, where it triggers necroptotic cell death.
The present inventors now report that conjugation of polyubiquitin chains (that are at least partly K63 -linked) to distinct lysine residues in the phosphorylated MLKL molecule, is facilitated, at least partly, by the ubiquitin ligase ITCH that binds MLKL via its WW domains, targets MLKL to endosomes. This results in the release of phosphorylated MLKL in extracellular vesicles and decreased cell death. MLKL ubiquitination also enhances endosomal trafficking, which augments translocation of the bacterium Listeria monocytogenes to the lysosomes, leading to growth arrest of the bacteria (Figures 4A-J). The present inventors have identified the K50 site on MLKL as the major target for ubiquitination, as verified by mass spectrometry.
The present inventors propose taking advantage of this mechanism for the treatment of additional diseases which are associated with pathogenic agents. Thus, the present inventors contemplate agents that that up-regulate MLKL ubiquitination at the above mentioned site for the
treatment of diseases which are caused by (or associated with) pathogens that enter the cell via phagosomes, which then fuse with the endosomes.
The present inventors have shown that targeting MLKL to endosomes is dictated by ubiquitination of K50. Since this phenomenon endows cells with resistance to necroptotic death, the present inventors propose that agent that facilitate the ubiquitination of K50 will protect from the pathological consequences of necroptosis and be useful for treating inflammatory bowel disease (IBD) - see for example Sha li et al., World J Clin Cases 2018 November 26; 6(14): 745-752; Shindo et al., Shindo et al., iScience 15, 536-551, May 31, 2019 and Negroni et al., Biomolecules 2020, 10, 1431; doi:10.3390/bioml0101431.
In addition, since downregulation of ubiquitination of MLKL at the K50 site leads to a significant decrease in the rate of degradation of cell-bound epidermal growth factor (EGF) and tumor necrosis factor (TNF), as well as of the EGF receptor (Figure 7A, B), the present inventors propose that agents that decrease ubiquitination can be applied to facilitate anti-cancer therapy with ligands of the TNF family such as TNF-related apoptosis-inducing ligand (TRAIL). The impediments in the degradation of anti-cancer ligands and receptors prompted by blockage of MLKL ubiquitination-mediated trafficking provoke cells vulnerable to TRAIL-mediated cell death.
Thus, according to a first aspect of the present invention, there is provided a method of treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL), thereby treating the disease caused by the pathogen.
According to another aspect of the present invention there is provided a method of treating inflammatory bowel disease (IBD) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically up-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the IBD.
The term “MLKL” refers to the Mixed Lineage Kinase Domain-Like protein, a product of Gene ID: 197259. Exemplary MLKL amino acid sequences are set forth in GenBank accession nos. NP_001135969.1 and NP_689862.1.
In one embodiment, the amino acid sequence of MLKL is as set forth in SEQ ID NO: 6. According to a particular embodiment, the positioning of the ubiquitination (i.e. position 50) is according to the amino acid sequence as set forth in SEQ ID NO: 6.
Ubiquitination takes place by a cascade of enzyme activity (i.e. a plurality of enzymes which work together to bring about the same function - ubiquitination). For example, El activates the Ub;
then Ub is transferred to E2 ligase. E2 ligase together with E3 recognize a specific target and ligate the Ub to the target protein. In some cases Ub is transferred directly to E3 ligase.
The present invention contemplates upregulation of any of the components of the ubiquitination system such that ubiquitination at position 50 of MLKL is enhanced. In one embodiment, the agent upregulates the activity and or amount of ubiquitinating enzyme that is responsible for adding a ubiquitin moiety at position 50 of MLKL.
In one embodiment, the ubiquitinating enzyme is a human ubiquitinating enzyme.
Ubiquitin-activating enzymes (Els) have the EC number EC 6.2.1.45, ubiquitin-conjugating enzymes have the EC number EC 2.3.2.23 and ubiquitin ligases have the EC number 2.3.2.27. According to a specific embodiment, the agent up-regulates the amount and/or activity of an
E2 ligase.
Table 1, herein below provides nomenclature and most common synonyms used for E2 ubiquitin conjugating enzymes. The E2 nomenclature is in accordance with that used by the Human Genome Organization. Table 1
In one embodiment, the agent upregulates the amount and/or activity of E3 ligase.
Exemplary E3 ligases contemplated by the present invention include which may be responsible for ubiquitination of MLKL, but are not limited to ITCH, Siah2, Smurf 1, MDM2, BRCA1, PARKIN, UBE3A, TRIM5, NEDD4, UBR5, Huwel, Arkadia, MuRFl, TRAF6, Trim32, UBR4, UBE3B and UBE3D.
In a specific embodiment, the E3 ligase is E3 ubiquitin-protein ligase Itchy homolog (ITCH).
Itch is an example of an E3 -ubiquitin ligase that belongs to the Nedd4-like E3 family, and is characterized by a modular organization that includes: an N-terminal protein kinase C-related C2 domain; multiple WW domains; and a C-terminal HECT (homologous to the E6-associated protein carboxyl terminus) Ubiquitin (Ub)-protein ligase domain.
Human Itch is described by Perry W L, Hustad C M, Swing D A, O'Sullivan T N, Jenkins N A, Copeland N G. Nat Genet. 1998 18:143-6 and the sequences deposited under GenBank Accession numbers NM_031483 (nucleotide) (gi27477108) and NP_113671 (protein) (gi:27477109).
Other additional E3 ligases which may be responsible for ubiquitinating MLKL include AMFR, APC/Cdc20, APC/Cdhl, C6orfl57, Cbl, CBLL1, CHFR, CHIP, DTL (Cdt2), E6-AP, HACE1, HECTD1, ECTD2, HECTD3, HECW1, HECW2, HERC2, HERC3, HERC4, HERC5, HUWE1, HYD, ITCH, LNX1, mahogunin, MARCH-I, MARCH-II, MARCH-III, MARCH-IV, MARCH- VI, MARCH- VII, MARCH- VIII, MARCH-X, MDM2, MEKK1, MIB1, MIB2, MycBP2, NEDD4, NEDD4L, Parkin, PELH, Pirh2, PJA1, PJA2, RFFL, RFWD2, Rictor, RNF5, RNF8, RNF19, RNF190 and RNF20.
Agents which increase the amount of a ubiquitinating enzyme capable of ubiquitinating MLKL at position 50 (such as ITCH) include agents which are capable of increasing the transcription (for example a transcription factor known to interact with the 5'untranslated region of the ubiquitinating enzyme) of the ubiquitinating enzyme, the translation of the ubiquitinating enzyme or the stability of the ubiquitinating enzyme. Additionally, the agent which increases the
amount of the ubiquitinating enzyme, may be a polynucleotide which encodes the ubiquitinating enzyme, the protein itself or an active peptide thereof.
In one embodiment, the ubiquitinating enzyme (e.g. ITCH) (or the polynucleotide which encodes the ubiquitinating enzyme) which is administered to the subject is (or encodes a protein that is) at least 50 % homologous, more preferably at least 60 % homologous, more preferably at least 70 % homologous, more preferably at least 80 % homologous, and most preferably at least 90 % homologous to the polypeptide sequence as set forth in SEQ ID NO:7 as determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters) comprising ubiquitinating enzyme activity. The homolog may also refer to a deletion, insertion, or substitution variant, including an amino acid substitution, thereof and biologically active polypeptide fragments thereof.
Recombinant techniques are typically used to generate the ubiquitinating enzyme (e.g. ITCH) of the present invention. These techniques may be preferred due to the length of the protein and the large amounts required thereof. Such recombinant techniques are described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60- 89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.
To produce an expression vector for the expression of the ubiquitinating enzyme (e.g. ITCH) of the present invention, a polynucleotide encoding the ubiquitinating enzyme is ligated into a nucleic acid expression vector, which comprises the polynucleotide sequence under the transcriptional control of a cis-regulatory sequence (e.g., promoter sequence) suitable for directing constitutive, tissue specific or inducible transcription of the ubiquitinating enzyme in the host cells.
The phrase “an isolated polynucleotide” refers to a single or double stranded nucleic acid sequence which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).
As used herein the phrase "complementary polynucleotide sequence" refers to a sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence can be subsequently amplified in vivo or in vitro using a DNA dependent DNA polymerase.
As used herein the phrase "genomic polynucleotide sequence" refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.
As used herein the phrase "composite polynucleotide sequence" refers to a sequence, which is at least partially complementary and at least partially genomic. A composite sequence can include some exonal sequences required to encode the ubiquitinating enzyme, as well as some intronic sequences interposing there between. The intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements.
As mentioned hereinabove, polynucleotide sequences of the present invention are inserted into expression vectors (i.e., a nucleic acid construct) to enable expression of the recombinant ubiquitinating enzyme. The expression vector of the present invention may include additional sequences which render this vector suitable for replication and integration in prokaryotes, eukaryotes, or preferably both (e.g., shuttle vectors). Typical cloning vectors contain transcription and translation initiation sequences (e.g., promoters, enhances) and transcription and translation terminators (e.g., polyadenylation signals).
A variety of prokaryotic or eukaryotic cells can be used as host-expression systems to express the ubiquitinating enzymes of the present invention. These include, but are not limited to, microorganisms, such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the ubiquitinating enzyme coding sequence; yeast transformed with recombinant yeast expression vectors containing the ubiquitinating enzyme coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the ubiquitinating enzyme coding sequence.
Other than containing the necessary elements for the transcription and translation of the inserted coding sequence (encoding the ubiquitinating enzyme), the expression construct of the present invention can also include sequences engineered to optimize stability, production, purification, yield or activity of the expressed ubiquitinating enzyme.
Various methods can be used to introduce the expression vector of the present invention into the host cell system. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al.,
Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et al. [Biotechniques 4 (6): 504-512, 1986] and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, see U.S. Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection methods.
Transformed cells are cultured under effective conditions, which allow for the expression of high amounts of recombinant peptide. Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An effective medium refers to any medium in which a cell is cultured to produce the recombinant ubiquitinating enzyme of the present invention. Such a medium typically includes an aqueous solution having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art.
Depending on the vector and host system used for production, resultant ubiquitinating enzyme of may either remain within the recombinant cell, secreted into the fermentation medium, secreted into a space between two cellular membranes, such as the periplasmic space in E. coli; or retained on the outer surface of a cell or viral membrane.
Following a predetermined time in culture, recovery of the recombinant ubiquitinating enzyme is effected.
The phrase "recovering the recombinant ubiquitinating enzyme" used herein refers to collecting the whole fermentation medium containing the ubiquitinating enzyme and need not imply additional steps of separation or purification.
Thus, ubiquitinating enzymes can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
To facilitate recovery, the expressed coding sequence can be engineered to encode the ubiquitinating enzyme fused to a cleavable moiety. Such a fusion protein can be designed so that the ubiquitinating enzyme can be readily isolated by affinity chromatography; e.g., by
immobilization on a column specific for the cleavable moiety. Where a cleavage site is engineered between the ubiquitinating enzyme and the cleavable moiety, the ubiquitinating enzyme can be released from the chromatographic column by treatment with an appropriate enzyme or agent that specifically cleaves the fusion protein at this site [e.g., see Booth et al., Immunol. Lett. 19:65-70 (1988); and Gardella et al., J. Biol. Chem. 265:15854-15859 (1990)].
The ubiquitinating enzyme of the present invention is preferably retrieved in "substantially pure" form.
As used herein, the phrase "substantially pure" refers to a purity that allows for the effective use of the ubiquitinating enzyme in the applications described herein.
In addition to being synthesizable in host cells, the ubiquitinating enzyme of the present invention can also be synthesized using in vitro expression systems. These methods are well known in the art and the components of the system are commercially available.
As mentioned, the ubiquitinating enzyme may be administered to the subject in need thereof as polynucleotides where they are expressed in vivo i.e. gene therapy.
The phrase "gene therapy" as used herein refers to the transfer of genetic material (e.g. DNA or RNA) of interest into a host to treat or prevent a genetic or acquired disease or condition or phenotype. The genetic material of interest encodes a product (e.g. a protein, polypeptide, peptide, functional RNA, antisense) whose production in vivo is desired. For example, the genetic material of interest can encode a hormone, receptor, enzyme, polypeptide or peptide of therapeutic value. For review see, in general, the text "Gene Therapy" (Advanced in Pharmacology 40, Academic Press, 1997).
Two basic approaches to gene therapy have evolved: (1) ex vivo and (2) in vivo gene therapy. In ex vivo gene therapy cells are removed from a patient, and while being cultured are treated in vitro. Generally, a functional replacement gene is introduced into the cell via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the host/patient. These genetically reimplanted cells have been shown to express the transfected genetic material in situ. The cells may be autologous or non- autologous to the subject. Since non-autologous cells are likely to induce an immune reaction when administered to the body several approaches have been developed to reduce the likelihood of rejection of non-autologous cells. These include either suppressing the recipient immune system or encapsulating the non- autologous cells in immunoisolating, semipermeable membranes before transplantation.
In in vivo gene therapy, target cells are not removed from the subject rather the genetic material to be transferred is introduced into the cells of the recipient organism in situ, that is within the recipient. These genetically altered cells have been shown to express the transfected genetic material in situ.
To confer specificity, preferably the nucleic acid constructs used to express the ubiquitinating enzyme comprises cell- specific promoter sequence elements.
Recombinant viral vectors are useful for in vivo expression of the ubiquitinating enzyme since they offer advantages such as lateral infection and targeting specificity. Lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny. Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
It will be appreciated that as well as (or instead of) upregulating expression/activity of a ubiquitnating enzyme capable of ubiquitinating MLKL at position 50, the present inventors also contemplate downregulating a deubiquitinating enzyme that is capable of deubiquitinating ubiquitinated MLKL at position 50.
The term “deubiquitinating” enzyme refers to an enzyme that cleaves ubiquitin from proteins.
According to a specific embodiment, the deubiquitinating enzyme is a cysteine protease or a metalloprotease.
Exemplary deubiquitinating enzymes which may be capable of deubiquitinating ubiquitinated MLKL at position 50 include USP7, USP47, USP2, USP7, USP15, USP9X, USP28, USP30.
Downregulation of the deubiquitinating enzyme may be effected at the protein or nucleotide level as is further described herein below.
Since the present inventors have shown that mere oligomerization of MLKL suffices to dictate its ubiquitination, additional agents that are contemplated which can serve as therapeutics for diseases caused by pathogenic agents (e.g. infectious diseases and IBD) are those that enhance oligomerization of MLKL. For example agents that activate protein kinase RIPK3 are contemplated. RIPK3 phosphorylates MLKL and by this triggers its oligomerization. Examples
of such agents include, but are not limited to TRAIL, ligands of TLR (Toll-like receptors) such as BCG and Interferon alpha.
Other agents capable of oligomerizing MLKL include multivalent agents that bind MLKL (e.g. a chimeric oligomer of the antigen binding portion of anti-MLKL antibody, fused to cellpenetrating moiety - see for example Alewine et al., The Oncologist 2015;20:176-185).
As mentioned, the agents disclosed herein above (i.e. those which upregulates ubiquitination of lysine at position 50 of MLKL) may be used to treat a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject. Once the pathogen enters the cell, the pathogen is typically driven into the lysosome.
Advantageously, the agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL), is capable of performing its activity in live cells (i.e. increases the uptake of the pathogen into the lysosome), hence, preventing the release of live pathogen from infected cells in which MLKL is activated.
In one embodiment, the pathogen which is responsible for causing the disease is a bacteria.
In some embodiments, the bacterial pathogen is Listeria monocytogenes.
In other embodiments, the bacterial pathogen is of the genus Yersinia (e.g. Yersinia enterocolitica or Yersinia pestis. It will be appreciated that since Yersinia bacteria has been associated with various diseases such as Crohn’s disease and reactive arthritis, the present inventors contemplate treating these diseases which upregulate ubiquitination of lysine at position 50 of MLKL.
In some embodiments, the pathogen is E-coli.
Additional disease causing bacteria include, but are not limited to Mycobacterium Tuberculosis, Mycobacterium Leprae, Legionella pneumophila, Shigella flexneri and Francisella tularensis, which are also contemplated by the present invention.
According to a particular embodiment, the bacteria is not salmonella typhimurium.
According to another embodiment, the pathogen is a parasite, including, but not limited to single-celled protozoans such as the agents of malaria, sleeping sickness, and amoebic dysentery.
According to another embodiment, the pathogen which causes the disease is a virus.
Examples of viruses that utilize the endosomal pathway include Influenza A virus, Foot and mouth disease virus, Rhinovirus, Adenovirus, Ebolavirus, Kaposi Sarcoma Virus, Simian virus 40, Papillomavirus, Polio virus, Lymphocytic choriomeningitis virus (LCMV), Rhinovirus and
Coronavirus.
In some embodiments, the pathogen is an intracellular pathogen.
Additional viruses that cause disease are summarized in Table 2, herein below.
Examples of coronaviruses include: human coronavirus 229E, human coronavirus OC43, SARS-CoV, HCoV NL63, HKU1, MERS-CoV and SARS-CoV-2.
According to a particular embodiment, the coronavirus is SARS-CoV-2. Exemplary viral diseases which may be treated according to embodiments of the present invention are summarized in Table 3, herein below.
According to a specific embodiment, the viral disease is COVID- 19.
The present inventor contemplates administering agents that directly target the pathogen in combination with the agents described herein above. Agents that directly target (e.g. bind specifically) bacteria include antibiotics and antibacterial peptides.
As used herein, the term "antibiotic agent" refers to a group of chemical substances, isolated from natural sources or derived from antibiotic agents isolated from natural sources, having a capacity to inhibit growth of, or to destroy bacteria, and other microorganisms, used chiefly in treatment of infectious diseases. Examples of antibiotic agents include, but are not limited to; Amikacin; Amoxicillin; Ampicillin; Azithromycin; Azlocillin; Aztreonam; Aztreonam; Carbenicillin; Cefaclor; Cefepime; Cefetamet; Cefinetazole; Cefixime; Cefonicid; Cefoperazone; Cefotaxime; Cefotetan; Cefoxitin; Cefpodoxime; Cefprozil; Cefsulodin; Ceftazidime; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalexin; Cephalothin; Cethromycin; Chloramphenicol; Cinoxacin; Ciprofloxacin; Clarithromycin; Clindamycin; Cioxacillin; Co- amoxiclavuanate; Dalbavancin; Daptomycin; Dicloxacillin; Doxycycline; Enoxacin; Erythromycin estolate; Erythromycin ethyl succinate; Erythromycin glucoheptonate; Erythromycin lactobionate; Erythromycin stearate; Erythromycin; Fidaxomicin; Fleroxacin; Gentamicin; Imipenem; Kanamycin; Lomefloxacin; Loracarbef; Methicillin; Metronidazole;
Mezlocillin; Minocycline; Mupirocin; Nafcillin; Nalidixic acid; Netilmicin; Nitrofurantoin; Norfloxacin; Ofloxacin; Oxacillin; Penicillin G; Piperacillin; Retapamulin; Rifaxamin, Rifampin; Roxithromycin; Streptomycin; Sulfamethoxazole; Teicoplanin; Tetracycline; Ticarcillin; Tigecycline; Tobramycin; Trimethoprim; Vancomycin; combinations of Piperacillin and Tazobactam; and their various salts, acids, bases, and other derivatives. Anti-bacterial antibiotic agents include, but are not limited to, aminoglycosides, carbacephems, carbapenems, cephalosporins, cephamycins, fluoroquinolones, glycopeptides, lincosamides, macrolides, monobactams, penicillins, quinolones, sulfonamides, and tetracyclines.
Antibacterial agents also include antibacterial peptides. Examples include but are not limited to abaecin; andropin; apidaecins; bombinin; brevinins; buforin II; CAP18; cecropins; ceratotoxin; defensins; dermaseptin; dermcidin; drosomycin; esculentins; indolicidin; LL37; magainin; maximum H5; melittin; moricin; prophenin; protegrin; and or tachyplesins.
The antiviral drug may be selected from the group consisting of remdesivir, an interferon, ribavirin, adefovir, tenofovir, acyclovir, brivudin, cidofovir, fomivirsen, foscarnet, ganciclovir, penciclovir, amantadine, rimantadine and zanamivir.
The agents which upregulate ubiquitination of MLKL may be formulated together with the antibacterial or antiviral agent (e.g. in a single pharmaceutical composition) or may be provided as separate compositions and packaged together in a single article of manufacture.
The agents may, if desired, be presented together in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing each of the active ingredients. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.
As mentioned, the agents described herein above may also be used to treat inflammatory bowel disease (IBD) which includes ulcerative colitis and Crohn’s disease.
MEKE, when ubiquitinated in lysine 50, antagonizes TRAIL-induced cell death by
enhancing endosomal-trafficking. Conversely, agents that arrest MLKL ubiquitination will, by preventing the MLKL-induced endosomal-trafficking and lysosomal-destruction of anti-cancer ligands like TRAIL, and their receptors, facilitate the anti-cancer effects of these ligands in cancers such as colon cancer, gastric cancer, and pancreatic adenocarcinoma. Moreover, the extent of ubiquitination of MLKL in these cancers may serve as a potential biomarker for the extent of susceptibility to cell death induction by ligands such as TRAIL, when these ligands are applied for tumor therapy.
Thus, according to another aspect of the present invention there is provided a method of treating a cancer sensitive to TRAIL receptor mediated cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the cancer.
Down-regulating of ubiquitination may be understood as being complete elimination of ubiquitination at position 50 of MLKL or at least a 50 % decrease in the number of molecules undergoing ubiquitination, a 60 % decrease in the number of molecules undergoing ubiquitination ubiquitination, a 70 % decrease in the number of molecules undergoing ubiquitination ubiquitination or higher.
Examples of cancer sensitive to TRAIL receptor mediated cytotoxicity include but are not limited to myeloma, lymphoma, colorectal cancer, NSCLC, liver cancer, triple negative breast cancer, pancreatic cancer, cervical cancer, soft tissue sarcoma, ovarian cancer, glioblastoma. Additional information regarding such cancers can be found in Yuan et al., Cancer Metastasis Rev. 2018 December ; 37(4): 733-748, the contents of which are incorporated herein by reference.
As mentioned, the present inventors have shown that downregulation of ubiquitination of MLKL at the K50 site leads to a significant decrease in the rate of degradation of receptors and ligands thereof. For example, the present inventors have shown that agents that downregulate ubiquitination of MLKL at the K50 site reduce the amount of cell-bound epidermal growth factor (EGF) and tumor necrosis factor (TNF), as well as of the EGF receptor (Figure 7A, B).
Thus, the present inventors propose use of agents that downregulate ubiquitination of MLKL at the K50 site to enhance the therapeutic activity of TNF alpha treatment (e.g. to enhance the effect of TNF alpha in the treatment of cancer using the limb perfusion approach). Thus, according to still another aspect of the present invention there is provided a method of treating cancer comprising co-administering a therapeutically effective amount of an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL and TNF alpha to the subject,
thereby treating the cancer.
Typical cancers that are treated with TNF alpha include bulky melanoma metastases and soft tissue sarcomas. Additional chemotherapeutic agents may be combined with this treatment, according to the particular cancer type and status. For example, the chemotherapeutic agent melphalan may be combined with the TNF alpha and the agent that downregulates ubiquitination of MLKL at the K50.
Since the present inventors have shown that agents that downregulate ubiquitination of MLKL at the K50 site reduce the amount of cell-bound epidermal growth factor (EGF), the present inventors propose treating diseases associated with an upregulation of activity of EGF receptor by administering agents that specifically down-regulate ubiquitination of lysine at position 50 of MLKL.
Particular examples of diseases which are associated with an up-regulation of activity of EGF receptors include non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer and breast cancer.
Agents that are capable of specifically down-regulating ubiquitination of lysine at position 50 of MLKL include those that decrease the activity and/or amount of ubiquitin enzymes capable of same. The agent may be a polynucleotide agent which hybridizes with the ubiquitinating enzyme, a neutralizing antibody or a small molecule antagonist.
Down-regulation at the nucleic acid level
Down-regulation at the nucleic acid level is typically effected using a nucleic acid agent, having a nucleic acid backbone, DNA, RNA, mimetics thereof or a combination of same. The nucleic acid agent may be encoded from a DNA molecule or provided to the cell per se.
Thus, downregulation of a ubiquitinating enzyme can be achieved by RNA silencing. As used herein, the phrase "RNA silencing" refers to a group of regulatory mechanisms [e.g. RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), quelling, co- suppression, and translational repression] mediated by RNA molecules which result in the inhibition or "silencing" of the expression of a corresponding protein-coding gene. RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.
As used herein, the term "RNA silencing agent" refers to an RNA which is capable of specifically inhibiting or "silencing" the expression of a target gene. In certain embodiments, the RNA silencing agent is capable of preventing complete processing (e.g, the full translation and/or expression) of an mRNA molecule through a post-transcriptional silencing mechanism. RNA
silencing agents include non-coding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated. Exemplary RNA silencing agents include dsRNAs such as siRNAs, miRNAs and shRNAs.
In one embodiment, the RNA silencing agent is capable of inducing RNA interference.
In another embodiment, the RNA silencing agent is capable of mediating translational repression.
According to an embodiment of the invention, the RNA silencing agent is specific to the target RNA (e.g., ubiquitin kinase) and does not cross inhibit or silence other targets or a splice variant which exhibits 99% or less global homology to the target gene, e.g., less than 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% global homology to the target gene; as determined by PCR, Western blot, Immunohistochemistry and/or flow cytometry.
RNA interference refers to the process of sequence- specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs).
Following is a detailed description on RNA silencing agents that can be used according to specific embodiments of the present invention.
DsRNA, siRNA and shRNA - The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs). Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes. The RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single- stranded RNAhaving sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex.
The term "siRNA" refers to small inhibitory RNA duplexes (generally between 18-30 base pairs) that induce the RNA interference (RNAi) pathway. Typically, siRNAs are chemically synthesized as 21mers with a central 19 bp duplex region and symmetric 2-base 3'-overhangs on the termini, although it has been recently described that chemically synthesized RNA duplexes of 25-30 base length can have as much as a 100-fold increase in potency compared with 21mers at the same location. The observed increased potency obtained using longer RNAs in triggering RNAi is suggested to result from providing Dicer with a substrate (27mer) instead of a product
(21mer) and that this improves the rate or efficiency of entry of the siRNA duplex into RISC.
It has been found that position of the 3'-overhang influences potency of an siRNA and asymmetric duplexes having a 3 '-overhang on the antisense strand are generally more potent than those with the 3'-overhang on the sense strand (Rose et al., 2005). This can be attributed to asymmetrical strand loading into RISC, as the opposite efficacy patterns are observed when targeting the antisense transcript.
The strands of a double- stranded interfering RNA (e.g., an siRNA) may be connected to form a hairpin or stem-loop structure (e.g., an shRNA). Thus, as mentioned, the RNA silencing agent of some embodiments of the invention may also be a short hairpin RNA (shRNA).
The term "shRNA", as used herein, refers to an RNA agent having a stem- loop structure, comprising a first and second region of complementary sequence, the degree of complementarity and orientation of the regions being sufficient such that base pairing occurs between the regions, the first and second regions being joined by a loop region, the loop resulting from a lack of base pairing between nucleotides (or nucleotide analogs) within the loop region. The number of nucleotides in the loop is a number between and including 3 to 23, or 5 to 15, or 7 to 13, or 4 to 9, or 9 to 11. Some of the nucleotides in the loop can be involved in base-pair interactions with other nucleotides in the loop.
It will be appreciated that, and as mentioned hereinabove, the RNA silencing agent of some embodiments of the invention need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non-nucleotides. miRNA and miRNA mimics - According to another embodiment the RNA silencing agent may be a miRNA.
The term "microRNA", "miRNA", and "miR" are synonymous and refer to a collection of non-coding single-stranded RNA molecules of about 19-28 nucleotides in length, which regulate gene expression. miRNAs are found in a wide range of organisms (viruses. fwdarw.humans) and have been shown to play a role in development, homeostasis, and disease etiology.
The term "microRNA mimic" or “miRNA mimic” refers to synthetic non-coding RNAs that are capable of entering the RNAi pathway and regulating gene expression. miRNA mimics imitate the function of endogenous miRNAs and can be designed as mature, double stranded molecules or mimic precursors (e.g., or pre-miRNAs). miRNA mimics can be comprised of modified or unmodified RNA, DNA, RNA-DNA hybrids, or alternative nucleic acid chemistries (e.g., LNAs or 2'-O,4'-C-ethylene-bridged nucleic acids (ENA)). For mature, double stranded miRNA mimics, the length of the duplex region can vary between 13-33, 18-24 or 21-23
nucleotides. The miRNA may also comprise a total of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides. The sequence of the miRNA may be the first 13-33 nucleotides of the pre-miRNA. The sequence of the miRNA may also be the last 13-33 nucleotides of the pre-miRNA.
Preparation of miRNAs mimics can be effected by any method known in the art such as chemical synthesis or recombinant methods.
It will be appreciated from the description provided herein above that contacting cells with a miRNA may be effected by transfecting the cells with e.g. the mature double stranded miRNA, the pre-miRNA or the pri-miRNA.
The pre-miRNA sequence may comprise from 45-90, 60-80 or 60-70 nucleotides.
The pri-miRNA sequence may comprise from 45-30,000, 50-25,000, 100-20,000, 1,000- 1,500 or 80-100 nucleotides.
Antisense - Antisense is a single stranded RNA designed to prevent or inhibit expression of a gene by specifically hybridizing to its mRNA. Downregulation of a ubiquitinating enzyme can be effected using an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding the ubiquitinating enzyme.
Nucleic acid agents can also operate at the DNA level as summarized infra.
Downregulation of agents such as ubiquitinating enzymes can also be achieved by inactivating the gene (e.g., MLKL, RIPK3 or RIPK1) via introducing targeted mutations involving loss-of function alterations (e.g. point mutations, deletions and insertions) in the gene structure.
As used herein, the phrase “loss-of-function alterations” refers to any mutation in the DNA sequence of a gene (e.g., ubiquitinating enzyme) which results in downregulation of the expression level and/or activity of the expressed product, i.e., the mRNA transcript and/or the translated protein. Non-limiting examples of such loss-of-function alterations include a missense mutation, i.e., a mutation which changes an amino acid residue in the protein with another amino acid residue and thereby abolishes the enzymatic activity of the protein; a nonsense mutation, i.e., a mutation which introduces a stop codon in a protein, e.g., an early stop codon which results in a shorter protein devoid of the enzymatic activity; a frame-shift mutation, i.e., a mutation, usually, deletion or insertion of nucleic acid(s) which changes the reading frame of the protein, and may result in an early termination by introducing a stop codon into a reading frame (e.g., a truncated protein, devoid of the enzymatic activity), or in a longer amino acid sequence (e.g., a readthrough protein) which affects the secondary or tertiary structure of the protein and results in a non-functional protein, devoid of the enzymatic activity of the non-mutated polypeptide; a readthrough mutation
due to a frame-shift mutation or a modified stop codon mutation (z.e., when the stop codon is mutated into an amino acid codon), with an abolished enzymatic activity; a promoter mutation, z.e., a mutation in a promoter sequence, usually 5' to the transcription start site of a gene, which results in down-regulation of a specific gene product; a regulatory mutation, z.e., a mutation in a region upstream or downstream, or within a gene, which affects the expression of the gene product; a deletion mutation, z.e., a mutation which deletes coding nucleic acids in a gene sequence and which may result in a frame-shift mutation or an in-frame mutation (within the coding sequence, deletion of one or more amino acid codons); an insertion mutation, z.e., a mutation which inserts coding or non-coding nucleic acids into a gene sequence, and which may result in a frame- shift mutation or an in-frame insertion of one or more amino acid codons; an inversion, z.e., a mutation which results in an inverted coding or non-coding sequence; a splice mutation z.e., a mutation which results in abnormal splicing or poor splicing; and a duplication mutation, z.e., a mutation which results in a duplicated coding or non-coding sequence, which can be in-frame or can cause a frame- shift.
Methods of introducing nucleic acid alterations to a gene of interest are well known in the art [see for example Menke D. Genesis (2013) 51: - 618; Capecchi, Science (1989) 244:1288- 1292; Santiago et al. Proc Natl Acad Sci USA (2008) 105:5809-5814; International Patent Application Nos. WO 2014085593, WO 2009071334 and WO 2011146121; US Patent Nos. 8771945, 8586526, 6774279 and UP Patent Application Publication Nos. 20030232410, 20050026157, US20060014264; the contents of which are incorporated by reference in their entireties] and include targeted homologous recombination, site specific recombinases, PB transposases and genome editing by engineered nucleases. Agents for introducing nucleic acid alterations to a gene of interest can be designed publically available sources or obtained commercially from Transposagen, Addgene and Sangamo Biosciences.
Following is a description of various exemplary methods used to introduce nucleic acid alterations to a gene of interest and agents for implementing same that can be used according to specific embodiments of the present invention.
Genome Editing using engineered endonucleases - this approach refers to a reverse genetics method using artificially engineered nucleases to cut and create specific double- stranded breaks at a desired location(s) in the genome, which are then repaired by cellular endogenous processes such as, homology directed repair (HDR) and non-homologous end-joining (NFfEJ). NFfEJ directly joins the DNA ends in a double- stranded break, while HDR utilizes a homologous sequence as a template for regenerating the missing DNA sequence at the break point. In order to
introduce specific nucleotide modifications to the genomic DNA, a DNA repair template containing the desired sequence must be present during HDR. Genome editing cannot be performed using traditional restriction endonucleases since most restriction enzymes recognize a few base pairs on the DNA as their target and the probability is very high that the recognized base pair combination will be found in many locations across the genome resulting in multiple cuts not limited to a desired location. To overcome this challenge and create site-specific single- or doublestranded breaks, several distinct classes of nucleases have been discovered and bioengineered to date. These include the meganucleases, Zinc finger nucleases (ZFNs), transcription-activator like effector nucleases (TALENs) and CRISPR/Cas system.
Meganucleases - Meganucleases are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif. The four families of meganucleases are widely separated from one another with respect to conserved structural elements and, consequently, DNA recognition sequence specificity and catalytic activity. Meganucleases are found commonly in microbial species and have the unique property of having very long recognition sequences (>14bp) thus making them naturally very specific for cutting at a desired location. This can be exploited to make site-specific double-stranded breaks in genome editing. One of skill in the art can use these naturally occurring meganucleases, however the number of such naturally occurring meganucleases is limited. To overcome this challenge, mutagenesis and high throughput screening methods have been used to create meganuclease variants that recognize unique sequences. For example, various meganucleases have been fused to create hybrid enzymes that recognize a new sequence. Alternatively, DNA interacting amino acids of the meganuclease can be altered to design sequence specific meganucleases (see e.g., US Patent 8,021,867). Meganucleases can be designed using the methods described in e.g., Certo, MT et al. Nature Methods (2012) 9:073-975; U.S. Patent Nos. 8,304,222; 8,021,867; 8, 119,381; 8, 124,369; 8, 129,134; 8,133,697; 8,143,015; 8,143,016; 8, 148,098; or 8, 163,514, the contents of each are incorporated herein by reference in their entirety. Alternatively, meganucleases with site specific cutting characteristics can be obtained using commercially available technologies e.g., Precision Biosciences' Directed Nuclease Editor™ genome editing technology.
ZFNs and TALENs - Two distinct classes of engineered nucleases, zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), have both proven to be
effective at producing targeted double-stranded breaks (Christian et al., 2010; Kim et al., 1996; Li et al., 2011; Mahfouz et al., 2011; Miller et al., 2010).
CRISPR-Cas system - Many bacteria and archaea contain endogenous RNA-based adaptive immune systems that can degrade nucleic acids of invading phages and plasmids. These systems consist of clustered regularly interspaced short palindromic repeat (CRISPR) genes that produce RNA components and CRISPR associated (Cas) genes that encode protein components. The CRISPR RNAs (crRNAs) contain short stretches of homology to specific viruses and plasmids and act as guides to direct Cas nucleases to degrade the complementary nucleic acids of the corresponding pathogen. Studies of the type II CRISPR/Cas system of Streptococcus pyogenes have shown that three components form an RNA/protein complex and together are sufficient for sequence- specific nuclease activity: the Cas9 nuclease, a crRNA containing 20 base pairs of homology to the target sequence, and a trans-activating crRNA (tracrRNA) (Jinek et al. Science (2012) 337: 816-821.). It was further demonstrated that a synthetic chimeric guide RNA (gRNA) composed of a fusion between crRNA and tracrRNA could direct Cas9 to cleave DNA targets that are complementary to the crRNA in vitro. It was also demonstrated that transient expression of Cas9 in conjunction with synthetic gRNAs can be used to produce targeted double- stranded brakes in a variety of different species (Cho et al., 2013; Cong et al., 2013; DiCarlo et al., 2013; Hwang et al., 2013a, b; Jinek et al., 2013; Mali et al., 2013).
The CRIPSR/Cas system for genome editing contains two distinct components: a gRNA and an endonuclease e.g. Cas9.
The gRNA is typically a 20 nucleotide sequence encoding a combination of the target homologous sequence (crRNA) and the endogenous bacterial RNA that links the crRNA to the Cas9 nuclease (tracrRNA) in a single chimeric transcript. The gRNA/Cas9 complex is recruited to the target sequence by the base-pairing between the gRNA sequence and the complement genomic DNA. For successful binding of Cas9, the genomic target sequence must also contain the correct Protospacer Adjacent Motif (PAM) sequence immediately following the target sequence. The binding of the gRNA/Cas9 complex localizes the Cas9 to the genomic target sequence so that the Cas9 can cut both strands of the DNA causing a double-strand break. Just as with ZFNs and TALENs, the double-stranded brakes produced by CRISPR/Cas can undergo homologous recombination or NHEJ.
The Cas9 nuclease has two functional domains: RuvC and HNH, each cutting a different DNA strand. When both of these domains are active, the Cas9 causes double strand breaks in the genomic DNA.
A significant advantage of CRISPR/Cas is that the high efficiency of this system coupled with the ability to easily create synthetic gRNAs enables multiple genes to be targeted simultaneously. In addition, the majority of cells carrying the mutation present biallelic mutations in the targeted genes.
However, apparent flexibility in the base-pairing interactions between the gRNA sequence and the genomic DNA target sequence allows imperfect matches to the target sequence to be cut by Cas9.
Modified versions of the Cas9 enzyme containing a single inactive catalytic domain, either RuvC- or HNH-, are called ‘nickases’. With only one active nuclease domain, the Cas9 nickase cuts only one strand of the target DNA, creating a single-strand break or 'nick'. A single-strand break, or nick, is normally quickly repaired through the HDR pathway, using the intact complementary DNA strand as the template. However, two proximal, opposite strand nicks introduced by a Cas9 nickase are treated as a double-strand break, in what is often referred to as a 'double nick' CRISPR system. A double-nick can be repaired by either NHEJ or HDR depending on the desired effect on the gene target. Thus, if specificity and reduced off-target effects are crucial, using the Cas9 nickase to create a double-nick by designing two gRNAs with target sequences in close proximity and on opposite strands of the genomic DNA would decrease off- target effect as either gRNA alone will result in nicks that will not change the genomic DNA.
Modified versions of the Cas9 enzyme containing two inactive catalytic domains (dead Cas9, or dCas9) have no nuclease activity while still able to bind to DNA based on gRNA specificity. The dCas9 can be utilized as a platform for DNA transcriptional regulators to activate or repress gene expression by fusing the inactive enzyme to known regulatory domains. For example, the binding of dCas9 alone to a target sequence in genomic DNA can interfere with gene transcription.
There are a number of publically available tools available to help choose and/or design target sequences as well as lists of bioinformatically determined unique gRNAs for different genes in different species such as the Feng Zhang lab's Target Finder, the Michael Boutros lab's Target Finder (E-CRISP), the RGEN Tools: Cas-OFFinder, the CasFinder: Flexible algorithm for identifying specific Cas9 targets in genomes and the CRISPR Optimal Target Finder.
In order to use the CRISPR system, both gRNA and Cas9 should be expressed in a target cell. The insertion vector can contain both cassettes on a single plasmid or the cassettes are expressed from two separate plasmids. CRISPR plasmids are commercially available such as the px33O plasmid from Addgene.
Genome editing using recombinant adeno-associated virus (rAAV) platform - this genomeediting platform is based on rAAV vectors which enable insertion, deletion or substitution of DNA sequences in the genomes of live mammalian cells. The rAAV genome is a single-stranded deoxyribonucleic acid (ssDNA) molecule, either positive- or negative-sensed, which is about 4.7 kb long. These single-stranded DNA viral vectors have high transduction rates and have a unique property of stimulating endogenous homologous recombination in the absence of double-strand DNA breaks in the genome. One of skill in the art can design a rAAV vector to target a desired genomic locus and perform both gross and/or subtle endogenous gene alterations in a cell. rAAV genome editing has the advantage in that it targets a single allele and does not result in any off- target genomic alterations. rAAV genome editing technology is commercially available, for example, the rAAV GENESIS™ system from Horizon™ (Cambridge, UK).
Methods for qualifying efficacy and detecting sequence alteration are well known in the art and include, but not limited to, DNA sequencing, electrophoresis, an enzyme-based mismatch detection assay and a hybridization assay such as PCR, RT-PCR, RNase protection, in-situ hybridization, primer extension, Southern blot, Northern Blot and dot blot analysis.
Sequence alterations in a specific gene can also be determined at the protein level using e.g. chromatography, electrophoretic methods, immunodetection assays such as ELISA and western blot analysis and immunohistochemistry.
Ribozymes
Another agent capable of downregulating ubiquitinating enzyme is a ribozyme molecule capable of specifically cleaving an mRNA transcript encoding the ubiquitinating enzyme. Ribozymes are being increasingly used for the sequence- specific inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., Curr Opin Biotechnol. 9:486- 96 (1998)]. The possibility of designing ribozymes to cleave any specific target RNAhas rendered them valuable tools in both basic research and therapeutic applications. In the therapeutics area, ribozymes have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders [Welch et al., Clin Diagn Virol. 10:163- 71 (1998)]. Most notably, several ribozyme gene therapy protocols for HIV patients are already in Phase 1 trials. More recently, ribozymes have been used for transgenic animal research, gene target validation and pathway elucidation. Several ribozymes are in various stages of clinical trials. ANGIOZYME was the first chemically synthesized ribozyme to be studied in human clinical trials. ANGIOZYME specifically inhibits formation of the VEGF-r (Vascular Endothelial Growth Factor receptor), a key component in the angiogenesis pathway. Ribozyme
Pharmaceuticals, Inc., as well as other firms have demonstrated the importance of antiangiogenesis therapeutics in animal models. HEPTAZYME, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was found effective in decreasing Hepatitis C viral RNA in cell culture assays (Ribozyme Pharmaceuticals, Incorporated - WEB home page).
DNAzymes
Another agent capable of downregulating ubiquitinating enzyme is a DNAzyme molecule capable of specifically cleaving an mRNA transcript or DNA sequence of ubiquitinating enzyme. DNAzymes are single- stranded polynucleotides which are capable of cleaving both single and double stranded target sequences (Breaker, R.R. and Joyce, G. Chemistry and Biology 1995;2:655; Santoro, S.W. & Joyce, G.F. Proc. Natl, Acad. Sci. USA 1997;943:4262) A general model (the "10-23" model) for the DNAzyme has been proposed. "10-23” DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. This type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions (Santoro, S.W. & Joyce, G.F. Proc. Natl, Acad. Sci. USA 199; for rev of DNAzymes see Khachigian, LM [Curr Opin Mol Ther 4:119-21 (2002)].
Down-regulation at the polypeptide level
One example, of an agent capable of downregulating a ubiquitinating enzyme is an antibody or antibody fragment capable of specifically binding ubiquitinating enzyme. Preferably, the antibody specifically binds at least one epitope of the ubiquitinating enzyme. As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
As the ubiquitinating enzyme is typically localized intracellularly, an antibody or antibody fragment capable of specifically binding MLKL, RIPK3 or RIPK1 is typically an intracellular antibody.
It will be appreciated that targeting of a particular compartment within the cell can be achieved using intracellular antibodies (also known as “intrabodies”). These are essentially single chain antibodies to which intracellular localization signals have been added (e.g., ER, mitochondrial, nuclear, cytoplasmic). This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, TIBTECH vol. 13: 306-310). Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors and to inhibit a protein function within a cell (See, for example, Richardson et al., 1995, Proc. Natl. Acad.
Sci. USA92: 3137-3141; Deshane et al., 1994, Gene Then 1: 332-337; Marasco et al., 1998 Human Gene Ther 9: 1627-42; Shaheen et al., 1996 J. Virol. 70: 3392-400; Werge, T. M. et al., 1990, FEBS Letters 274:193-198; Carlson, J.R. 1993 Proc. Natl. Acad. Sci. USA 90:7427-7428; Biocca, S. et al., 1994, Bio/Technology 12: 396-399; Chen, S-Y. et al., 1994, Human Gene Therapy 5:595-601; Duan, Let al., 1994, Proc. Natl. Acad. Sci. USA 91:5075-5079; Chen, S-Y. et al., 1994, Proc. Natl. Acad. Sci. USA 91:5932-5936; Beerli, R.R. et al., 1994, J. Biol. Chem. 269:23931-23936; Mhashilkar, A.M. et al., 1995, EMBO J. 14:1542-1551; PCT Publication No. WO 94/02610 by Marasco et al.; and PCT Publication No. WO 95/03832 by Duan et al.).
To prepare an intracellular antibody expression vector, the cDNA encoding the antibody light and heavy chains specific for the target protein of interest are isolated, typically from a hybridoma that secretes a monoclonal antibody specific for the marker. Hybridomas secreting anti-marker monoclonal antibodies, or recombinant monoclonal antibodies, can be prepared using methods known in the art. Once a monoclonal antibody specific for the marker protein is identified (e.g., either a hybridoma-derived monoclonal antibody or a recombinant antibody from a combinatorial library), DNAs encoding the light and heavy chains of the monoclonal antibody are isolated by standard molecular biology techniques. For hybridoma derived antibodies, light and heavy chain cDNAs can be obtained, for example, by PCR amplification or cDNA library screening. For recombinant antibodies, such as from a phage display library, cDNA encoding the light and heavy chains can be recovered from the display package (e.g., phage) isolated during the library screening process and the nucleotide sequences of antibody light and heavy chain genes are determined. For example, many such sequences are disclosed in Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 and in the "Vbase" human germline sequence database. Once obtained, the antibody light and heavy chain sequences are cloned into a recombinant expression vector using standard methods.
For cytoplasmic expression of the light and heavy chains, the nucleotide sequences encoding the hydrophobic leaders of the light and heavy chains are removed. An intracellular antibody expression vector can encode an intracellular antibody in one of several different forms. For example, in one embodiment, the vector encodes full-length antibody light and heavy chains such that a full-length antibody is expressed intracellularly. In another embodiment, the vector encodes a full-length light chain but only the VH/CH1 region of the heavy chain such that a Fab fragment is expressed intracellularly. In another embodiment, the vector encodes a single chain antibody (scFv) wherein the variable regions of the light and heavy chains are linked by a flexible
peptide linker [e.g., (Gly4Ser)3 and expressed as a single chain molecule. To inhibit marker activity in a cell, the expression vector encoding the intracellular antibody is introduced into the cell by standard transfection methods, as discussed hereinbefore.
Once antibodies are obtained, they may be tested for activity, for example via ELISA.
Another agent which can be used along with some embodiments of the invention to downregulate the ubiquitinating enzyme is an aptamer. As used herein, the term “aptamer” refers to double stranded or single stranded RNA molecule that binds to specific molecular target, such as a protein. Various methods are known in the art which can be used to design protein specific aptamers. The skilled artisan can employ SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for efficient selection as described in Stoltenburg R, Reinemann C, and Strehlitz B (Biomolecular engineering (2007) 24(4):381-403).
Another way of downregulating ubiquitination at position 50 of MLKL is by upregulating a deubiquitinating enzyme capable of deubiquitinating ubiquitinated MLKL.
Methods of upregulating expression of proteins (including deubiquitinating enzymes) are provided herein above (with respect to ubiquitinating enzymes).
Still another way of downregulating ubiquitination at position 50 of MLKL is by administration of a peptide agent that is a substrate for ubiquitination by the E3 ubiquitin-protein ligase. Thus, for example peptide agents derived from MLKL which comprise the ubiquitination site at position 50 are contemplated. The peptide agents typically comprise at least 5, 6, 7, 8, 9, 10, 15, 20 or more amino acids of MLKL. In one embodiment, the peptide comprises between 5- 50, 5-40, 5-30, 5-20 amino acids of MLKL. The peptide may be attached to a cell penetrating moiety.
As used herein the phrase "penetrating agent" refers to an agent which enhances translocation of an attached polypeptide across a cell membrane.
According to one embodiment, the penetrating agent is a peptide and is attached to the C or N terminus of the peptide (either directly or non-directly) via a peptide bond.
Typically, cell penetrating peptides have an amino acid composition containing either a high relative abundance of positively charged amino acids such as lysine or arginine, or have sequences that contain an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids.
According to a particular embodiment, the peptides of the present invention are attached to the cell penetrating peptides via a linking moiety.
The agents which down-regulate ubiquitination of lysine at position 50 of MLKL may be provided to the subject for the treatment of the cancers specified herein with agents that activates the TRAIL apop to tic pathway.
Examples of agents which activate the TRAIL apoptotic pathway include Mapatumumab, Contatumumab, TAS266, ONC201, Tigatuzumab, Dulanermin and Circularly permuted TRAIL (CPT).
Additional agents known to activate the TRAIL apoptotic pathway are provided in Yuan et al., Cancer Metastasis Rev. 2018 December ; 37(4): 733-748, the contents of which are incorporated herein by reference.
The agents which activate the TRAIL apoptotic pathway may be co-formulated with the agents which down-regulate ubiquitination of lysine at position 50, or may be provided as separate compositions to the subject.
Thus, each agent included in the combination can be formulated separately for use in combination. The drugs are said to be used "in combination" when, in a recipient of both drugs, the effect of one drug enhances or at least influences the effect of the other drug.
The two agents in the combination cooperate to provide an effect on target cells that is greater than the effect of either drug alone. This benefit manifests as a statistically significant improvement in a given parameter of target cell fitness or vitality. In embodiments, the improvement resulting from treatment with the drug combination can manifest as an effect that is at least additive and desirably synergistic, relative to results obtained when only a single agent is used.
In use, each drug in the combination can be formulated as it would be for monotherapy, in terms of dosage size and form and regimen. In this regard, the synergy resulting from their combined use may permit the use of somewhat reduced dosage sizes or frequencies, as would be revealed in an appropriately controlled clinical trial.
According to one embodiment, the agent which down-regulates ubiquitination of lysine at position 50 of MLKL and the agent which activates the TRAIL apoptotic pathway are administered concomitantly.
According to another embodiment, the agent which activates the TRAIL apoptotic pathway and the agent which down-regulates ubiquitination of lysine at position 50 of MLK are administered sequentially, wherein the first agent is used, for example, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, a week, a month or more after the second agent. Such a determination is well within the capacity of one of skill in the art. In another embodiment, the agent
which activates the TRAIL apoptotic pathway and the agent which down-regulates ubiquitination of lysine at position 50 of MLK are administered sequentially, wherein the second agent is used, for example, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, a week, a month or more after the first agent.
The agents of the present invention may be provided per se or as part of a pharmaceutical composition. which also includes a physiologically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.
As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
Herein the term "active ingredient" refers to the downregulating agents, ligands or population of exosomes accountable for the biological effect.
Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.
Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
Techniques for formulation and administration of drugs may be found in “Remington’s Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, inrtaperitoneal, intranasal, or intraocular injections.
Conventional approaches for drug delivery to the central nervous system (CNS) include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport
peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide). However, each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.
The term “tissue” refers to part of an organism consisting of cells designed to perform a function or functions. Examples include, but are not limited to, brain tissue, retina, skin tissue, hepatic tissue, pancreatic tissue, bone, cartilage, connective tissue, blood tissue, muscle tissue, cardiac tissue brain tissue, vascular tissue, renal tissue, pulmonary tissue, gonadal tissue, hematopoietic tissue.
Pharmaceutical compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
Pharmaceutical compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration by nasal inhalation, the active ingredients for use according to some embodiments of the invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver
a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
The pharmaceutical composition of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
Pharmaceutical compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (e.g. downregulating agents, ligands or population of exosomes) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., a disease associated with activation of a necroptosis activation pathway, necroptosis or inflammation) or prolong the survival of the subject being treated.
Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be
formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l).
Below is a list of some exemplary animal models that can be used to determine the efficacy of agents that down-regulate ubiquitination of lysine at position 50 of MLKL.
Tumor formation in transgenic mice overexpressing an oncogene - A transgenic mouse model for cancer (e.g., breast cancer) such as the erb model (Shah N., et al., 1999, Cancer Lett. 146: 15-2; Weistein EL, et al., 2000, Mol. Med. 6: 4-16) or MTV/myc model (Stewart TA et al., 1984, Cell, 38: 627-637), the c-myc model (Leder A., et al., 1986, Cell, 45:485-495), v-Ha-ras or c-neu model (Elson A and Leder P, 1995, J. Biol. Chem. 270: 26116-22) can be used to test the ability of agents that down-regulate ubiquitination of lysine at position 50 of MLKL to suppress tumor growth in vivo.
Tumor formation in mice administered with cancerous cell lines - For the formation of solid tumors, athymic mice can be injected with human or animal (e.g., mouse) cancerous cells such as those derived from breast cancer, ovarian cancer, prosate cancer or thyroid cancer, and following the formation of cancerous tumors the mice can be subjected to intra-tumor and/or systemic administration of an agent capable of down-regulating ubiquitination of lysine at position 50 of MLKL.
The following cell lines (provided with their ATCC Accession numbers) can be used for each type of cancer model:
For breast cancer:
Human breast cancer cell lines - MDA-MB-453 (ATCC No. HTB-131), MDA-MB-231 (ATCC No. HTB-26), BT474 (ATCC No. HTB-20), MCF-7 (ATCC No. HTB-22) and MDA- MB-468.
For ovarian cancer:
Human ovarian cancer cell lines - SK0V3 (ATCC No. HTB-77), OVCAR-3 HTB-161), OVCAR-4, OVCAR-5, OVCAR-8 and IGROV1;
For prostate cancer:
Human prostate cancer cell lines - DU- 145 (ATCC No. HTB-81), PC-3 (ATCC No.CRL- 1435);
For thyroid cancer:
Human derived thyroid cancer cell lines - FTC-133, KI, K2, NPA87, K5, WRO82-1, ARO89-1, DRO81-1;
For lung cancer:
Mouse lung carcinoma LL/2 (LLC1) cells (Lewis lung carcinoma) - These cells are derived from a mouse bearing a tumor resulting from an implantation of primary Lewis lung carcinoma. The cells are tumorigenic in C57BL mice, express H-2b antigen and are widely used as a model for metastasis and for studying the mechanisms of cancer chemotherapeutic agents (Bertram JS, et al., 1980, Cancer Lett. 11: 63-73; Sharma S, et al. 1999, J. Immunol. 163: 5020- 5028).
For melanoma:
Mouse B16-F10 cells (Melanoma) - The cells are derived from mouse (C57BL/6J) bearing melanoma (Briles EB, et al., 1978, J. Natl. Cancer Inst. 60: 1217-1222).
Tumor formation in animal models by administration of cancerous cells - Athymic nu/nu mice (e.g., female mice) can be purchased from the Jackson Laboratory (Bar Harbor, ME). Tumors can be formed by subcutaneous (s.c.) injection of cancerous cells (e.g., 2 x 106 cells in 100 pl of PBS per mouse). Tumors are then allowed to grow in vivo for several days (e.g., 6-14 days) until they reach a detectable size of about 0.5 cm in diameter. It will be appreciated that injection of cancerous cells to an animal model can be at the organ from which the cell line is derived (e.g., mammary tissue for breast cancer, ovary for ovarian cancer) or can be injected at an irrelevant tissue such as the rear leg of the mouse.
Modes of administration of MLKL ubiquitination inhibitors to tumor - To test the effect of MLKL ubiquitination inhibitors on inhibition of tumor growth, the inhibitor is administered to the animal model bearing the tumor either locally at the site of tumor or systemically, by intravenous injection of infusion, via, e.g., the tail vein. The time of administration may vary from immediately following injection of the cancerous cell line (e.g., by systemic administration) or at predetermined time periods following the appearance of the solid tumor (e.g., to the site of tumor
formation, every 3 days for 3-10 times as described in Ugen KE et al., Cancer Gene Ther. 2006 Jun 9; [Epub ahead of print]).
Evaluation of solid tumor inhibition - Tumor sizes are measured two to three times a week. Tumor volumes are calculated using the length and width of the tumor (in millimeters). The effect of MLKL ubiquitination inhibitor treatment can be evaluated by comparing the tumor volume using statistical analyses such as Student’s t test. In addition, histological analyses can be performed using markers typical for each type of cancer.
Altogether, once the tumors are formed, the agent capable of down-regulating MLKL ubiquitination at position 40 is administered to the individual in need thereof, e.g., the animal model bearing the tumor, either locally or systemically, and the effect of the agent on tumor growth is detected using methods known in the art.
Models for testing agents that up-regulate ubiquitination of lysine at position 50 of MLKL for treatment of IBD include dextran sulfate sodium-induced colitis, Oxazolone-induced colitis, acetic acid-induced colitis and salmonella-induced colitis. Transgenic and gene knockout animal models of ulcerative colitis include IL-7 Tg mice and TCRa KO mice.
Dosage amount and interval may be adjusted individually to provide the active ingredient at a sufficient amount to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
As used herein the term “about” refers to ± 10 %
The terms "comprises", "comprising", "includes", "including", “having” and their conjugates mean "including but not limited to".
The term “consisting of’ means “including and limited to”.
The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps
and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
As used herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
The subject of the present invention typically refers to a mammalian subject - e.g. a human subject.
The present inventors further propose that uncovering the position on which MLKL is ubiquitilated, paves the way for a novel screening assay which can be used to identify agents that are capable of treating diseases associated with a necroptosis pathway.
Such diseases include, but are not limited to a renal disease, a pulmonary disease, a hepatic disease, cancer, infectious disease, neurodegenerative disease, inflammatory bowel disease, ischemic reperfusion, psoriasis and a cardiovascular disease. Further diseases are described in Choi et al., doi.org/10.1172/jci.insight.128834, the contents of which are incorporated herein by reference.
Thus, according to another aspect of the present invention, there is provided a method of identifying an agent capable of treating a disease associated with activation of a necroptosis pathway comprising:
(a) contacting the agent with MLKL or a polynucleotide encoding same;
(b) analyzing ubiquitination of lysine at position 50 of said MLKL, wherein a change in the amount of ubiquitination at said position is indicative of an agent that is capable of treating the disease associated with a activation of the necroptosis pathway. The method may be carried out in a cell mixture or a cell-free mixture, comprising MLKL and the necessary components for ubiquitination. Ubiquitination may be observed by any means suitable for detection of protein ubiquitination - such as mass spectroscopy and additional methods described in the Examples section herein below. An exemplary method for detecting ubiquitination is disclosed in US Patent Application No. 2019-0185902, the contents of which are incorporated herein by reference.
Depending on whether the agent causes an up or down regulation in the amount of ubiquitination the agent can be proposed as a candidate for treating a particular disease. Preferably, the agent causes at least a 10 %, 20 %, 30 %, 40 %, 50 % or greater increase/decrease in the amount of ubiquitination of MLKL compared to a control assay which is carried out in the absence of the agent.
Additional experiments may be carried out to corroborate that the agent is a suitable agent for treating the disease - both in vitro and in vivo, for example using animal models for the disease.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); “Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.
EXAMPLE 1
MATERIALS AND METHODS
Cell culture: Cells of the human HT-29 colorectal adenocarcinoma line were grown in McCoy’s 5A medium. Normal mouse embryonic fibroblasts (MEFs) and embryonic fibroblasts of MLKL-knockout mice were immortalized by expression of the SV40 large T antigen. MEFs and human embryonic kidney (HEK293T) cells were cultured in Dulbecco’s modified Eagle’s medium. The cell-growth media were supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 pg/ml streptomycin.
Gene knockout and knockdown in vitro in human HT-29 cells: MLKL was knocked out in vitro using the MLKL CRISPR/Cas9 KO plasmid (Santa Cruz, sc-401248) that was transfected with Lipofectamine 3000. FADD was knocked out by lentiviral infection with two gRNA sequences (5’-GTTCCTATGCCTCGGGCGCGT (SEQ ID NO: 1) and 5’- ACGCGCCCGAGGCATAGGAAC (SEQ ID NO: 2)) in the pX459 plasmid (Addgene, 62988). For knockdown of ITCH, SMARTpool ON-TARGETplus human ITCH siRNA(L-007196-00- 0050, Dharmacon) was transiently tranfected into HT-29 cells, and the cells were further incubated for 3 days.
Constitutive and inducible expression of proteins: Unless otherwise indicated, transfected MLKL and its various mutants were fused C-terminally to a double strep tag (WSHPQFEK- GGGSGGGSGGGS-WSHPQFEK - SEQ ID NO: 3). The human MLKL L357A/S358A, L58G/I76G and L162G/165G mutants (and, as a control, the wild-type protein) were expressed constitutively in MLKL knocked-down cells as previously described (Yoon, 2016 #4038).
The GEV16/pF5x UAS system (30) was used to inducibly express, in MLKL knockout cells, the various human and mouse MLKL mutants in which lysine residues were replaced with arginine (and, as controls, the wild-type proteins) and human MLKL fused C-terminally to green fluorescent protein (GFP). In the experiment presented in Figure 3 J, this system was also used for the expression of ITCH and the ITCH C83OA mutant that were fused C-terminally to a myc tag (EQKLISEEDL (SEQ ID NO: 4)). Unless otherwise indicated, induction by treatment with 4HT (1 pM) was carried out for 6 h. In the experiment presented in Figure 3D, the various ITCH- deletion mutants were fused C-terminally to the FLAG-tag (DYKDDDDK - SEQ ID NO: 5). HA- ubiquitin and its K63R mutant, as well as Rab5 and Rab7 fused N-terminally to mCherry, were expressed constitutively by lentiviral infection. Transfections for transient expression of genes were done by Lipofectamine 3000 for HT-29 cells and by JetPEI for HEK293T cells.
Reagents: Bafilomycin Al (11038-500) and pepstatin A (9000469-10) were from Cayman Chemical, and MG132 (M7449), chloroquine (C6628), and 4-hydroxytamoxifen (H6278) were from Sigma- Aldrich. Human EGF from ProSpec was biotinylated using an EZ-Link Sulfo-NHS- biotin kit from Thermo Fisher Scientific (21326). TNF was from YbdY Biotech, and the bivalent IAP (inhibitor of apoptosis protein) antagonist BV6 and the caspase inhibitor z-VAD-fmk were both from WuXi App Tec. Strep-Tactin Sepharose 50% suspension (2-1201-010) and Strep-Tactin elution buffer (2-1042-025 ) were from IBA Lifesciences. Agarose-coupled TUBE1 (UM401) was from LifeSensors. Brij O10 (polyoxyethylene (10) oleyl ether, P6136) was from Sigma-Aldrich. The Lipofectamine 3000 transfection reagent (L3000015) was from ThermoFisher, and the JetPEI transfection reagent (101-10N) was from Polyplus-transfection. LysoTrackerIM Red DND-99 (L7528) was from ThermoFisher. The cDNAs encoding wild-type HA-tagged ubiquitin (17608) were from Addgene.
Antibodies: The following antibodies were applied for Western blot analysis: anti-mouse MLKL (Sabl302339), Anti-HA (H6908), anti p-actin (A5441), anti-Flag M2 (13026) and anti- MVB12B (HPA043683) from Sigma; anti-human MLKL (ab 184718), anti-human phospho- MLKL (abl87091), and anti-Rab7 (ab 137029) from Abeam; anti-TSGlOl (612696), anti-ITCH (611199), anti-EEAl (610456) and anti-phosphotyrosine (61000) from BD Biosciences; anti-LDH (sc-27230), anti-STIM-1 (sc- 166840) and anti-TOM20 (sc- 17764) from Santa Cruz Biotechnology; anti-ubiquitin (VU-1) from LifeSensors; anti-myc tag (05-724) from Millipore; anti-EGFR (6F1) from Enzo Life Sciences; anti-HSP70 (EXOAB-Hsp70A-l) from System Biosciences; anti-Strep tag (34850) from Qiagen; anti-Na+/K+ ATPase (ANP-001) from Alomone Labs, and anti-VPS28 (NBP1-85976) from Novus Biologicals. Horseradish peroxidase- conjugated antibodies from Jackson ImmunoResearch were used for western blot analyses. Normal rabbit IgG control (3900) was from Cell Signaling.
For immunofluorescence analysis Alexa Fluor 647-conjugated anti-mouse IgG (715-605- 150) was used and Cy3-conjugated anti-rabbit IgG (111-165-144) from Jackson ImmunoResearch, anti-Lampl -Alexa Fluor 647 (NBP2-25183AF647, Novus Biologicals) and Alexa Fluor 405- conjugated anti-mouse IgG (abl75660) from Abeam. For staining of infected Listeria anti-Listeria antibody (ab35132) from Abeam was used. Ubiquitin was stained by anti-ubiquitin antibody (FK2, BML-PW88 10-0500) from Enzo Life Sciences. For visualization of early and late endosomes, either Rab5 or Rab7 fused with mCherry was expressed constitutively. In the experiments presented in Figure 6E and F, CellLight Early Endosomes-GFP (C 10586) and CellLight ER-GFP (C10590) (Thermo Fisher) was constitutively expressed in the cells, and these cells were used to
assess co-localization of MLKL with early endosomes and the endoplasmic reticulum, respectively, according to the manufacturer’s protocol.
Immunoprecipitation and Western analyses: Proteins were immunoprecipitated as described (14). To estimate the extent of oligomerization of MLKL, cells were extracted with 1% NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40) including protease and phosphatase inhibitors (1 mM PMSF, 40 mM beta-glycerophosphate, 50 mM NaF and 1 mM sodium vanadate), and this was followed by solubilization in Laemmli SDS PAGE buffer devoid of reducing agent, as described (12). In Western analyses where some nonspecific bands could be seen, specific bands are indicated by arrows. To assess interactions of proteins with MLKL, HT-29 cells constitutively expressing MLKL that was fused C-terminally to the double Strep-tag (31) were used. Interactions of ESCRT proteins with MLKL were assessed following extraction of the cells in a buffer containing 1% Brij, as described (14). Immunoblotting was done as described (9). For identification of the binding site for MLKL in ITCH (Fig.ure 3D), MLKL was eluted by biotin after its precipitation by Strep-Tactin magnetic beads.
Cytological and immunocytological analyses: For immunocytological analyses, cells were fixed with 4% paraformaldehyde for 15 min at room temperature in phosphate buffered saline (PBS), permeabilized with ice-cold methanol for 10 min at -20°C, and blocked with MAXblock Blocking Medium (Active Motif, 15252) overnight at 4°C. The cells were then incubated with the indicated antibodies for 1 h at room temperature, and then with fluorescent dye-conjugated secondary antibodies for 2 h at 4°C in MAXbind Staining Medium (Active Motif, 15253).
Images were acquired with an Olympus IX 81 confocal microscope (Olympus Imaging) using the UPLS APO 60 x /1.35 NA oil objective, and were processed using the FluoView FV 1000 (Olympus Imaging) and ImageJ (NIH) software. Colocalization was determined manually using unsaturated single Z-stack images, by measuring the overlap of signals between channels with constant threshold values. Data are presented as means (%) ± standard deviations (S.D.) in approximately equal numbers of images acquired in at least 3 independent experiments; P values were calculated using a two-tailed Student’s t-test.
Collection of extracellular vesicles: Extracellular vesicles generated by TBZ-treated HT- 29 cells were collected 3 h after TBZ application and were isolated as previously described (14).
Assessment ofEGF uptake and of uptake and phosphorylation of its receptor: Western blot analyses of the uptake of biotinylated EGF and of the uptake and phosphorylation of the EGF receptor were as previously described (14).
Quantification of cell death: Cell death was quantified based on the concentration of lactic dehydrogenase (LDH) in the cell-culture media, using the Cytotoxicity Detection Kit 4744934001 (Sigma-Aldrich).
Assessment of MLKL ubiquitination: Samples of 6 million HT-29 cells and 2 million MEFs, seeded 1 day prior to the experiment, were treated with 1 pM 4HT for 12 h to induce expression of wild-type or mutant MLKL. Ubiquitinated MLKL was isolated from cell extracts using TUBE 1 -agarose (LifeSensors) according to the manufacturer’s protocol, except that the extraction buffer also contained protease and phosphatase inhibitors (1 mM PMSF, 40 mM betaglycerophosphate, 50 mM NaF, and 1 mM sodium vanadate).
For assessment of the incorporation of HA-tagged ubiquitin chains into MLKL, wild-type and mutant HA-tagged ubiquitins were first expressed constitutively by lentiviral infection in cells inducibly expressing MLKL fused to Strep-tag. Following further growth of the cells for 12 h and, when indicated, stimulation by TBZ, the cells were lysed by boiling in a buffer containing 1% sodium dodecyl sulfate (SDS), 20 mM Tris-HCl (pH 7.5), 5 mM EDTA, and 1 mM dithiothreitol (DTT). This was followed by 10-fold dilution of the lysates in a buffer containing 1% NP-40, 20 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM EDTA and the protease and phosphatase inhibitors specified above. MLKL was affinity-purified using Strep-Tactin beads, and conjugation of the tagged ubiquitin chains to it was assessed by western blotting using anti-HA antibody.
Comparison of the effects of various deubiquitinases on the ubiquitin chains conjugated to MLKL: For the in-vitro MLKL ubiquitination assay, wild-type or K50R MLKL, affinity- purified by Strep-Tactin beads following denaturation in SDS as described above, were incubated for 1 h at 37°C with recombinant El (UBE1, E-305; 50 nM), E2 (UBE2L3, E2-640; 200 nM) and E3 (ITCH, E3-260; 1 qM) enzymes, ubiquitin (U-100H, 80 qM), Mg-ATP (B-20, 10 mM) and lOx E3 ligase reaction buffer (B-71).
To assay the deubiquitination in vitro, MLKL, affinity-purified by Strep-Tactin beads or — as controls — synthetic K63-linked and K48-linked tetra-ubiquitin chains (UM-K630 and UM- K480, R&D Systems) were incubated with the indicated recombinant deubiquitinases (USP2(E- 506), 200 nM; Otubainl(E-522B), 1 qM; AMSH(E549), 1 qM; CYLD(E-556), 20 nM), for 1 h at 37°C in a reaction buffer containing 50 mM Tris pH 7.5, 5 mM MgCh, 25 mM KC1 and 1 mM DTT. All enzymes and recombinant proteins were from R&D Systems.
Isolation of subcellular fractions: Subconfluent cultures of HT-29 cells in eight 150-mm plates were incubated with TBZ for 3 h. After the ceils were rinsed twice with PBS they were collected by scraping, and homogenized in a buffer containing 225 mM mannitol, 75 mM sucrose,
0.5 mM EGTA and 30 mM Tris-HCl pH7.4, using a loose-fitting glass/Teflon Potter-Elvehjem homogenizer and a 22-gauge syringe. Fractionation was performed by differential centrifugation, as previously described (32).
Listeria monocytogenes infection and quantification: HT-29 cells and MEFs were seeded 2 days before infection and incubated, prior to infection, for 10 h in BIOGRO-2 serum-free medium (Biological Industries) without antibiotics. Listeria monocytogenes (strain 10403S, kindly provided by Dr. Steffen Jung), was applied in serum-free medium to the HT-29 cells at a multiplicity of infection (MOI) of 20, and to the MEFs at a MOI of 5, and this was followed by centrifugation at 300 x g for 10 min and incubation at 37°C for 1 h to allow invasion of the bacteria. The cells were then rinsed with PBS, incubated with 100 pg/ml gentamycin for 10 min and then with fresh growth medium containing 5 pg/ml of gentamicin. Subsequent treatments of the cells were as described in Figure 8.
To quantify the intracellularly grown bacteria, the infected cells were rinsed twice with PBS and then lysed in 0.2% Triton X-100 in PBS (1 ml per 2.5-cm well). After serial dilutions the lysates were spread on Brain Hear Infusion (BHI) agar plates (BD diagnostic, 211065). Values presented in the figures are means ± S.D. of colony forming units (CFU); P values were calculated using a two-tailed Student’s t-test.
RESULTS
Besides phosphorylating MLKL, treatment of cells by agents that activate the protein kinase RIPK3 also triggers a time-dependent increase in MLKL ubiquitination (Figures 1A and 5A-C). Mutational ablation of the phosphorylation (4) or of the oligomerization of MLKL(72) also prevents its ubiquitination. In contrast, a mutation yielding spontaneous oligomerization of MLKL (L58G/I76G) results in spontaneous ubiquitination, suggesting that this ubiquitination is dictated by a conformational change that occurs in MLKL upon its oligomerization (Figure IB).
Treatment of cells with a proteasomal inhibitor did not result in increase in ubiquitinated MLKL. Nor was such an increase observed in cells treated with bafilomycin Al, which arrests lysosomal degradation (Fig. 1C). Both comparing the effectiveness of incorporation of wildtype and of K63R mutant ubiquitin into the MLKL-conjugated ubiquitin chains (Figure 5D) and assessing the effects of various deubiquitinases on ubiquitinated MLKL (Figure 5E) indicated that the ubiquitin moieties in these chains are interlinked via their K63 residues.
In a mutational study in which different lysine residues in MLKL were replaced with arginine, It was found that mutation of a single residue in human MLKL (K50) and of two adjacent ones in mouse MLKL (K50 and K51) in the loop that connects helices a2 and a3 in the MLKL
4HB domain fully abolished the ubiquitination (Figures 1D-G and 5C). These findings suggested that ubiquitination affects only specific residues in MLKL and does not serve to dictate its degradation.
In comparing the amounts of ubiquitinated MLKL in various subcellular fractions, this protein was found to be specifically associated with the microsomal membranes (Figure 2A).
Consistently, immuno staining of human colon cancer HT-29 cells following activation of MLKL in them revealed colocalization of MLKL with Rab5 and with Rab7 — markers of early and late endosomes, respectively — as well as co-association of ubiquitin and MLKL with these endosomal markers. In contrast, cells in which lysine 50 in MLKL was replaced with arginine (K50R) did not display such associations (Figures 2B-I and 6A-D), nor was association of ubiquitinated MLKL with the endoplasmic reticulum or with the mitochondria observed (Figure 6E, F).
It was previously found that the association of MLKL with endosomal membranes occurs pursuant to its binding to certain components of the ESCRT system and that it eventually results in exclusion of these MLKL molecules in EVs (74). As shown in Figure 2J, the MLKL molecules found in EVs are highly ubiquitinated, to a much greater extent than those found intracellularly. Arrest of MLKL ubiquitination by the K50R mutation greatly decreased the association of MLKL with ESCRT proteins as well as its exclusion within EVs (Figure 2K, L). It thus seems that the association of MLKL with endosomes and its eventual exclusion in EVs are dictated by its ubiquitination.
On examining the list of MLKL-binding proteins that were identified in the exosomes, it was found that these proteins also contain the ubiquitin ligase ITCH (76, 77) (Fig. 3 A). Consistently, it was found that transiently overexpressed ITCH and MLKL effectively bind to each other (Figure 3B) and that oligomerization of MLKL prompts its association with ITCH (Figure 3C). Characteristically of HECT-type E3 ligases, ITCH was found to bind MLKL via its WW motifs (Figure 3D, E). Immunostaining confirmed that following phosphorylation of MLKL, in response to combined treatment with TNF, BV6 and zVAD (TBZ), it associates with ITCH in both early and late endosomes (Figure 3F, G). In an in-vitro test, ITCH catalyzed the ubiquitination of MLKL but not of its K50R mutant (Figure 3H). Overexpression of ITCH consistently enhanced the ubiquitination of MLKL but not of K50R MLKL (Figure 31). It also enhanced the association of MLKL with ESCRT proteins, whereas overexpression of an enzymatically dead ITCH mutant compromised MLKL association with those proteins (Figure 3J). These findings indicate that ITCH contributes to the ubiquitination of MLKL.
The association of MLKL with endosomes has been found to have two functional consequences — facilitation of endosomal trafficking of certain cell-surface receptors, and decrease in cell-death induction, the latter apparently as a result of the release of phosphorylated MLKL in EVs (74). Prevention of this association by mutation of those lysine residues in MLKL that are ubiquitinated was found here to consistently result in a significant decrease in the rate of degradation of cell-bound epidermal growth factor (EGF) and tumor necrosis factor (TNF), as well as of the EGF receptor, in cells in which MLKL phosphorylation was induced (Figure 7A, B), and it increased the effectiveness of necroptosis induction (Figure 7C, D).
MLKL was recently shown to suppress the growth of Listeria monocytogenes 18). Listeria enters cells by co-opting receptor-uptake mechanisms. The extent to which the Listeria cells are then destroyed in the lysosomes, or keep replicating in the cytoplasm or in membrane encased niches, is subject to modulation by antagonistic mechanisms elaborated by this pathogen and its host cells (e.g. (7 -22)). It was therefore decided to examine whether the ubiquitination-dependent association of MLKL with endosomes contributes to its effect on these bacteria.
Both in mouse embryonic fibroblasts (MEFs) (Figure 4A) and in human HT-29 cells (Figure 4B, C), MLKL was found to have an inhibitory effect on Listeria replication, and that this was enhanced by treatment with TBZ. As with the ubiquitination of MLKL, this anti-Listerial effect seemed to be exerted as a result of MLKL oligomerization (Figure 4D). It was observed significantly earlier than any sign of cell death (Figure 4E) and, unlike the cytotoxic effect, was abolished by mutation of the ubiquitination sites in MLKL (Figure 4A-C). It was also eliminated by knockdown of ITCH (Figure 4F). Knockout of MLKL resulted in enhancement of Listerial growth to higher levels than those observed in cells expressing the non-ubiquitinatable MLKL mutant. In cells infected for 24 hours, the relative extent of the inhibitory effect of nonubiquitinated MLKL on Listerial growth, compared to that of ubiquitinated MLKL, was greater than in cells infected for only 5 hours (compare Figure 4C to 4B). Treating the HT-29 cells with chloroquine or with a cathepsin D inhibitor fully blocked the inhibitory effect of TBZ on Listerial growth in MLKL-expressing cells, while having no effect on the extent of inhibition of Listerial growth that resulted from mere expression of MLKL in the cells (Fig. 4G- J).
These findings suggested that MLKL affects Listerial growth both constitutively and in a way that is enhanced upon phosphorylation and ubiquitination of MLKL. They further suggest that the anti-Listerial effect induced upon phosphorylation and ubiquitination of MLKL depends on lysosome functioning, whereas the constitutive anti-Listerial effect of MLKL does not. In exploring the nature of the effect of MLKL on lysosomal function, it was found that stimulation of MLKL
phosphorylation has no effect on the relative amounts of acidified lysosomes (Figures 7E, F). However, immuno staining of the Lzs/erza-infected cells with endosomal markers revealed that stimulation of MLKL ubiquitination dramatically enhances the translocation of Listeria from the early to the late endosomes and from there to the lysosomes, and that this enhancement does not occur in cells expressing the K50R MLKL mutant (Figure 4K, L).
Altogether, these findings suggested that the arrest of Listeria replication by MLKL occurs through at least two distinct functions of this protein: enhancement of lysosomal destruction of the bacteria via the effect of MLKL on the endosomes, and a slower inhibitory effect, independent of lysosomal function, that might correspond to a direct toxic effect of MLKL on the cytoplasmically located bacteria (7S). This sequence of events is consistent with the fact that Listeria enter the cells within phagosomes that either fuse with the endosomes or break open into the cytosol (22).
EXAMPLE 2
Corroboration of the K50 site of MLKL as the substrate for ubiquitination
MLKL, tagged C-terminally with the Strep-tag, was affinity purified using Strep-Tactin beads from 4 x 108 human HT-29 cells that had been treated for 3 hours with TBZ- TNF (1000 units/ml) plus the bivalent IAP antagonist BV6 (1 pM) and the caspase inhibitor z-VAD-fmk (20 pM) or, as control, from the same number of untreated HT-29 cells. The purified proteins were digested by trypsin. Following trypsinization Ubiquitinated peptides were isolated using the PTMScan Ubiquitin Remnant Motif (K-e-GG) Kit (Cell Signaling). The isolated peptides were then analyzed by liquid chromatography tandem mass spectrometry (MS/MS).
RESULTS
The results of the mass spectrometry analysis are provided in Table 4, herein below.
The peptides having the sequence as set forth in SEQ ID NO: 10 (both the oxidized (row 3) and non-oxidized form (row 4) was found to be ubiquitinated in lysine 50. Both show high ubiquitination after TBZ treatment and no ubiquitination prior to the treatment. Oxidation probably occurred during the manipulation of the samples for the mass spec analysis). The peptide listed having the sequence as set forth in SEQ ID NO: 8 was on the border of detection. SEQ ID NO: 9 was ubiquitinated in lysine 331. Unlike lysine 50, lysine 331 is not evolutionary conserved and its ubiquitination was only partially dependent on TBZ treatment.
Confirmation of the identity of the ubiquitinated peptides, by spectral annotation is also seen in Figures 9A-B.
EXAMPLE 3
MLKL ubiquitination also facilitates destruction of some other intracellular bacteria
Similarly to L. monocytogenes, the Gram-negative bacterium Yersinia enterocolitica enters cells by co-opting receptor- uptake mechanisms, and its replication within the infected cells is subject to modulation by antagonistic effects exerted both by the bacteria and by cellular defense mechanisms. On assessing the yields of these bacteria in infected HT-29 and L929 cells it was found that, as with Listeria, in cells that express WT MLKL the yield of Y. enterocolitica was effectively decreased by their treatment with TBZ and TNF, respectively, whereas in HT-29 cells expressing the K50R MLKL mutant and in L929 cells expressing the K50,51R MLKL mutant, these treatments had no effect on their bacterial yields (Figures 10A, B).
The impact of MLKL activation on the infection of these cells by Escherichia coli, a bacterium that mainly grows extracellularly but can also adhere to mammalian cells and be phagocytized by them, was also examined. It was found that the yields of E. coli that could be recovered from HT-29 and L929 cells were decreased by TBZ and TNF treatments, similarly to the effects exerted by those respective treatments on the yields of L. monocytogenes and Y. enterocolitica, and that these effects were also compromised by mutation of lysine 50 in human MLKL or of lysines 50 and 51 in mouse MLKL (Figures 10C, D).
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document(s) of this application is/are hereby incorporated herein by reference in its/their entirety.
Claims
1. A method of treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL), thereby treating the disease caused by the pathogen.
2. An agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) for use in treating a disease caused by a pathogen which utilizes the endosomal pathway to enter a cell of a subject.
3. The method of claim 1 or agent of claim 2, wherein said pathogen is a virus.
4. The method or agent of claim 3, wherein said virus is selected from the group consisting of Influenza A virus, Foot and mouth disease virus, Rhinovirus, Adenovirus, Ebolavirus, Kaposi Sarcoma Virus, Simian virus 40, Papillomavirus, Polio virus, Lymphocytic choriomeningitis virus (LCMV), Rhinovirus and Coronavirus.
5. The method of claim 1 or agent of claim 2, wherein said pathogen is a bacteria.
6. The method or agent of claim 5, wherein said bacteria is Listeria monocytogenes.
7. A method of treating inflammatory bowel disease (IBD) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically up-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the IBD.
8. An agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) for use in treating IBD.
9. The method or agent of any one of claims 1-7, wherein said agent enhances the activity and/or amount of a ubiquitin ligase that is capable of ubiquitinating lysine at position 50 of mixed lineage kinase domain-like protein (MLKL).
59
10. The method or agent of claim 9, wherein said agent is said ubiquitin ligase.
11. The method or agent of claim 9, wherein said agent is a polynucleotide encoding said ubiquitin ligase.
12. The method or agent of claims 10 or 11, wherein said ubiquitin ligase is E3 ubiquitin-protein ligase Itchy homolog (ITCH).
13. The method or agent of any one of claims 1-6, wherein said agent enhances oligomerization of said MLKL.
14. The method or agent of claim 13, wherein said agent activates protein kinase RIPK3.
15. The method or agent of claim 13, wherein said agent is a multivalent agent that binds said MLKL.
16. The method or agent of any one of claims 1-6, further comprising administering to the subject an agent that directly targets the pathogen.
17. A method of treating a cancer sensitive to TRAIL receptor mediated cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the cancer.
18. A method of treating a cancer in a subject in need thereof comprising coadministering to the subject a therapeutically effective amount of an agent that specifically down- regulates ubiquitination of lysine at position 50 of MLKL and TNF alpha, thereby treating the cancer.
19. A method of treating a disease associated with an upregulation of activity of EGF receptor in a subject comprising administering to the subject a therapeutically effective amount of
60 an agent that specifically down-regulates ubiquitination of lysine at position 50 of MLKL, thereby treating the disease.
20. The method of claim 19, wherein the disease is selected from the group consisting of non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer and breast cancer.
21. The method of any one of claims 17, 18 or 19, wherein said agent is a peptide agent that is a substrate for ubiquitination by said E3 ubiquitin-protein ligase.
22. The method of any one of claims 17, 18 or 19, wherein the peptide agent comprises at least 10 amino acids of MLKL.
23. The method of any one of claims 17, 18 or 19, wherein said agent is a polynucleotide agent that is capable of down-regulation the amount of ITCH in cancer cells of the subject.
24. The method of any one of claims 17-22, further comprising administering to the subject an agent that activates the TRAIL apoptotic pathway.
25. The method of claim 24, wherein said agent that activates the TRAIL apoptotic pathway is selected from the group consisting of Mapatumumab, Contatumumab, TAS266, ONC201, Tigatuzumab, Dulanermin and Circularly permuted TRAIL (CPT).
26. The method of claims 17 or 18, wherein said cancer is selected from the group consisting of myeloma, lymphoma, colorectal cancer, NSCLC, liver cancer, triple negative breast cancer, pancreatic cancer, cervical cancer, soft tissue sarcoma, ovarian cancer, glioblastoma.
27. An article of manufacture comprising an agent which upregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) and an antibacterial or antiviral agent.
61
28. The article of manufacture of claim 27, wherein said agent enhances the activity and/or amount of a ubiquitin ligase that is capable of ubiquitinating lysine at position 50 of mixed lineage kinase domain-like protein (MLKL).
29. The article of manufacture of claim 28, wherein said agent is said ubiquitin ligase.
30. The article of manufacture of claim 28, wherein said agent is a polynucleotide encoding said ubiquitin ligase.
31. The article of manufacture of claims 29 or 30, wherein said ubiquitin ligase is E3 ubiquitin-protein ligase Itchy homolog (ITCH).
32. An article of manufacture comprising:
(i) an agent which downregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL); and
(ii) an agent that activates the TRAIL apoptotic pathway and/or TNF alpha.
33. The article of manufacture of claim 32, wherein said agent which downregulates ubiquitination of lysine at position 50 of mixed lineage kinase domain-like protein (MLKL) is coformulated with said agent that activates the TRAIL apoptotic pathway.
34. A method of identifying an agent capable of treating a disease associated with activation of a necroptosis pathway comprising:
(a) contacting the agent with MLKL or a polynucleotide encoding same;
(b) analyzing ubiquitination of lysine at position 50 of said MLKL, wherein a change in the amount of ubiquitination at said position is indicative of an agent that is capable of treating the disease associated with a activation of the necroptosis pathway.
35. The method of claim 34, wherein said disease is a renal disease, a pulmonary disease, a hepatic disease, cancer, infectious disease, neurodegenerative disease, inflammatory bowel disease, ischemic reperfusion, psoriasis and a cardiovascular disease.
62
36. The method of claim 34, wherein when said change is an increase, said disease is a cancer promoted by constitutive signaling of the EGF receptor.
37. The method of claim 35, wherein said cancer is selected from the group consisting of colorectal cancer, non- small cell lung cancer and head and neck cancer.
38. The method of claim 34, wherein when said change is a decrease, said disease is a cancer sensitive to the TRAIL receptor cytotoxic effect.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL279559A IL279559A (en) | 2020-12-17 | 2020-12-17 | Controlling ubiquitination of mlkl for treatment of disease |
IL279559 | 2020-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022130384A1 true WO2022130384A1 (en) | 2022-06-23 |
Family
ID=79687129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2021/051498 WO2022130384A1 (en) | 2020-12-17 | 2021-12-16 | Controlling ubiquitination of mlkl for treatment of disease |
Country Status (2)
Country | Link |
---|---|
IL (1) | IL279559A (en) |
WO (1) | WO2022130384A1 (en) |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3791932A (en) | 1971-02-10 | 1974-02-12 | Akzona Inc | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
US3839153A (en) | 1970-12-28 | 1974-10-01 | Akzona Inc | Process for the detection and determination of specific binding proteins and their corresponding bindable substances |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3850752A (en) | 1970-11-10 | 1974-11-26 | Akzona Inc | Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
US3879262A (en) | 1972-05-11 | 1975-04-22 | Akzona Inc | Detection and determination of haptens |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
WO1994002610A1 (en) | 1992-07-17 | 1994-02-03 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
WO1995003832A1 (en) | 1993-07-30 | 1995-02-09 | Thomas Jefferson University | Intracellular immunization |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
US20050026157A1 (en) | 2002-09-05 | 2005-02-03 | David Baltimore | Use of chimeric nucleases to stimulate gene targeting |
US20060014264A1 (en) | 2004-07-13 | 2006-01-19 | Stowers Institute For Medical Research | Cre/lox system with lox sites having an extended spacer region |
WO2009071334A2 (en) | 2007-12-07 | 2009-06-11 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Transposon-mediated mutagenesis in spermatogonial stem cells |
US8021867B2 (en) | 2005-10-18 | 2011-09-20 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
WO2014085593A1 (en) | 2012-11-27 | 2014-06-05 | Children's Medical Center Corporation | Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction |
US8771945B1 (en) | 2012-12-12 | 2014-07-08 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US20160160189A1 (en) | 2013-05-01 | 2016-06-09 | St. Jude Children's Research Hospital | Truncated Constructs of RIPK3 and Related Uses |
WO2018033929A1 (en) | 2016-08-18 | 2018-02-22 | Yeda Research And Development Co. Ltd. | Diagnostic and therapeutic uses of exosomes |
US20190185902A1 (en) | 2016-08-08 | 2019-06-20 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacterial systems for analyzing ubiquitylated polypeptides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015140313A1 (en) * | 2014-03-20 | 2015-09-24 | Vib Vzw | Necroptosis inducing mlkl fragment and inhibitors thereof |
US20210121522A1 (en) * | 2017-09-07 | 2021-04-29 | Vib Vzw | Mixed-lineage kinase domain-like protein in immunotherapeutic cancer control |
-
2020
- 2020-12-17 IL IL279559A patent/IL279559A/en unknown
-
2021
- 2021-12-16 WO PCT/IL2021/051498 patent/WO2022130384A1/en active Application Filing
Patent Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3850752A (en) | 1970-11-10 | 1974-11-26 | Akzona Inc | Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically |
US3839153A (en) | 1970-12-28 | 1974-10-01 | Akzona Inc | Process for the detection and determination of specific binding proteins and their corresponding bindable substances |
US3791932A (en) | 1971-02-10 | 1974-02-12 | Akzona Inc | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
US3879262A (en) | 1972-05-11 | 1975-04-22 | Akzona Inc | Detection and determination of haptens |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5487992A (en) | 1989-08-22 | 1996-01-30 | University Of Utah Research Foundation | Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
WO1994002610A1 (en) | 1992-07-17 | 1994-02-03 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
WO1995003832A1 (en) | 1993-07-30 | 1995-02-09 | Thomas Jefferson University | Intracellular immunization |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US20050026157A1 (en) | 2002-09-05 | 2005-02-03 | David Baltimore | Use of chimeric nucleases to stimulate gene targeting |
US20060014264A1 (en) | 2004-07-13 | 2006-01-19 | Stowers Institute For Medical Research | Cre/lox system with lox sites having an extended spacer region |
US8119381B2 (en) | 2005-10-18 | 2012-02-21 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
US8148098B2 (en) | 2005-10-18 | 2012-04-03 | Duke University | Methods of cleaving DNA with rationally-designed meganucleases |
US8304222B1 (en) | 2005-10-18 | 2012-11-06 | Duke University | Rationally-designed meganucleases with altered sequence specificity and heterodimer formation |
US8163514B2 (en) | 2005-10-18 | 2012-04-24 | Duke University | Methods of cleaving DNA with rationally-designed meganucleases |
US8124369B2 (en) | 2005-10-18 | 2012-02-28 | Duke University | Method of cleaving DNA with rationally-designed meganucleases |
US8129134B2 (en) | 2005-10-18 | 2012-03-06 | Duke University | Methods of cleaving DNA with rationally-designed meganucleases |
US8133697B2 (en) | 2005-10-18 | 2012-03-13 | Duke University | Methods of cleaving DNA with rationally-designed meganucleases |
US8143015B2 (en) | 2005-10-18 | 2012-03-27 | Duke University | Methods of cleaving DNA with rationally-designed meganucleases |
US8143016B2 (en) | 2005-10-18 | 2012-03-27 | Duke University | Methods of cleaving DNA with rationally-designed meganucleases |
US8021867B2 (en) | 2005-10-18 | 2011-09-20 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
WO2009071334A2 (en) | 2007-12-07 | 2009-06-11 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Transposon-mediated mutagenesis in spermatogonial stem cells |
WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
WO2014085593A1 (en) | 2012-11-27 | 2014-06-05 | Children's Medical Center Corporation | Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction |
US8771945B1 (en) | 2012-12-12 | 2014-07-08 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US20160160189A1 (en) | 2013-05-01 | 2016-06-09 | St. Jude Children's Research Hospital | Truncated Constructs of RIPK3 and Related Uses |
US20190185902A1 (en) | 2016-08-08 | 2019-06-20 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacterial systems for analyzing ubiquitylated polypeptides |
WO2018033929A1 (en) | 2016-08-18 | 2018-02-22 | Yeda Research And Development Co. Ltd. | Diagnostic and therapeutic uses of exosomes |
Non-Patent Citations (60)
Title |
---|
"Advanced in Pharmacology", 1997, ACADEMIC PRESS, article "Gene Therapy", pages: 40 |
"Selected Methods in Cellular Immunology", 1980, FREEMAN AND CO. |
ALEWINE ET AL., THE ONCOLOGIST, vol. 20, 2015, pages 176 - 185 |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", vol. I-III, 1989, JOHN WILEY AND SONS |
BEERLI, R.R. ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 23931 - 23936 |
BERTRAM JS ET AL., CANCER LETT., vol. 11, 1980, pages 63 - 73 |
BIOCCA, S. ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 396 - 399 |
BITTER ET AL., METHODS IN ENZYMOL., vol. 153, 1987, pages 516 - 544 |
BOOTH ET AL., IMMUNOL. LETT., vol. 19, 1988, pages 421 - 463 |
BREAKER, R.R.JOYCE, G., CHEMISTRY AND BIOLOGY, vol. 2, 1995, pages 655 |
BRILES EB ET AL., J. NATL. CANCER INST., vol. 60, 1978, pages 1217 - 1222 |
BRISSON ET AL., NATURE, vol. 310, 1984, pages 511 - 514 |
BROGLI ET AL., SCIENCE, vol. 224, 1984, pages 838 - 843 |
CAPECCHI, SCIENCE, vol. 244, 1989, pages 1288 - 1292 |
CARLSON, J.R., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7427 - 7428 |
CERTO, MT ET AL., NATURE METHODS, vol. 9, 2012, pages 073 - 975 |
CHEN, S-Y. ET AL., HUMAN GENE THERAPY, vol. 5, 1994, pages 595 - 601 |
CHEN, S-Y. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 5932 - 5936 |
CORUZZI ET AL., EMBO J., vol. 3, 1984, pages 1671 - 1680 |
DESHANE ET AL., GENE THER, vol. 1, 1994, pages 332 - 337 |
DONDELINGER YVES ET AL: "Poly-ubiquitination in TNFR1-mediated necroptosis", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 73, no. 11, 11 April 2016 (2016-04-11), pages 2165 - 2176, XP035738829, ISSN: 1420-682X, [retrieved on 20160411], DOI: 10.1007/S00018-016-2191-4 * |
ELSON ALEDER P, J. BIOL. CHEM., vol. 270, 1995, pages 26116 - 22 |
FRESHNEY: "Culture of Animal Cells - A Manual of Basic Technique", vol. I-III, 1994, APPLETON & LANGE |
GARDELLA ET AL., J. BIOL. CHEM., vol. 265, 1990, pages 15854 - 15859 |
GILBOA ET AL., BIOTECHNIQUES, vol. 4, no. 6, 1986, pages 504 - 512 |
GURLEY ET AL., MOL. CELL. BIOL., vol. 6, 1986, pages 559 - 565 |
JINEK ET AL., SCIENCE, vol. 337, 2012, pages 816 - 821 |
KABAT, E. A. ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES |
KHACHIGIAN, LM, CURR OPIN MOL THER, vol. 4, 2002, pages 119 - 21 |
LEDER A. ET AL., CELL, vol. 45, 1986, pages 485 - 495 |
MARASCO ET AL., HUMAN GENE THER, vol. 9, 1998, pages 1627 - 42 |
MENKE D., GENESIS, 2013, pages 51 - 618 |
MHASHILKAR, A.M. ET AL., EMBO J., vol. 14, 1995, pages 1542 - 1551 |
NEGRONI ET AL., BIOMOLECULES, 14 October 2020 (2020-10-14) |
PARK ET AL., CELL DEATH AND DISEASE, vol. 11, 2020, pages 744 |
PERBAL: "A Practical Guide to Molecular Cloning", 1988, JOHN WILEY & SONS |
PERRY W LHUSTAD C MSWING D AO'SULLIVAN T NJENKINS N ACOPELAND N G, NAT GENET., vol. 18, 1998, pages 143 - 6 |
RICHARDSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 3137 - 3141 |
RICHARDSONMARASCO, TIBTECH, vol. 13, 1995, pages 306 - 310 |
SAMBROOK ET AL., MOLECULAR CLONING: A LABORATORY MANUAL, 1989 |
SANTIAGO ET AL., PROC NATL ACAD SCI USA, vol. 105, 2008, pages 5809 - 5814 |
SANTORO, S.W.JOYCE, G.F., PROC. NATL, ACAD. SCI. USA |
SANTORO, S.W.JOYCE, G.F., PROC. NATL, ACAD. SCI. USA, vol. 943, 1997, pages 4262 |
SHA LI ET AL., WORLD J CLIN CASES, vol. 6, no. 14, 26 November 2018 (2018-11-26), pages 745 - 752 |
SHAH N. ET AL., CANCER LETT., vol. 146, 1999, pages 15 - 2 |
SHAHEEN ET AL., J. VIROL., vol. 70, 1996, pages 3392 - 400 |
SHARMA S ET AL., J. IMMUNOL., vol. 163, 1999, pages 5020 - 5028 |
SHINDO ET AL., ISCIENCE, vol. 15, 31 May 2019 (2019-05-31), pages 536 - 551 |
STEWART TA ET AL., CELL, vol. 38, 1984, pages 627 - 637 |
STOLTENBURG RREINEMANN CSTREHLITZ B, BIOMOLECULAR ENGINEERING, vol. 24, no. 4, 2007, pages 381 - 403 |
STUDIER ET AL., METHODS IN ENZYMOL., vol. 185, 1990, pages 60 - 89 |
TAKAMATSU ET AL., EMBO J., vol. 6, 1987, pages 307 - 311 |
UGEN KE ET AL., CANCER GENE THER, 9 June 2006 (2006-06-09) |
WATSON ET AL.: "Genome Analysis: A Laboratory Manual Series", vol. 1-4, 1998, COLD SPRING HARBOR LABORATORY PRESS |
WEISTEIN EJ. ET AL., MOL. MED., vol. 6, 2000, pages 4 - 16 |
WELCH ET AL., CLIN DIAGN VIROL., vol. 10, 1998, pages 163 - 71 |
WELCH ET AL., CURR OPIN BIOTECHNOL., vol. 9, 1998, pages 486 - 96 |
WERGE, T. M. ET AL., FEBS LETTERS, vol. 274, 1990, pages 193 - 198 |
WU CHAOYI ET AL: "Interconnections among major forms of regulated cell death", APOPTOSIS, LONDON, GB, vol. 25, no. 9-10, 5 September 2020 (2020-09-05), pages 616 - 624, XP037258659, ISSN: 1360-8185, [retrieved on 20200905], DOI: 10.1007/S10495-020-01632-2 * |
YUAN ET AL., CANCER METASTASIS REV, vol. 37, no. 4, December 2018 (2018-12-01), pages 733 - 748 |
Also Published As
Publication number | Publication date |
---|---|
IL279559A (en) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI716367B (en) | Massively parallel combinatorial genetics for crispr | |
JP2020188757A (en) | Methods and compositions for rna-guided treatment of hiv infection | |
JP2023078373A (en) | Methods and compositions for editing RNA | |
CN107406854A (en) | RNA-guided eradication of human JC virus and other polyomaviruses | |
CN113939591A (en) | Methods and compositions for editing RNA | |
Pefanis et al. | RNA exosome regulates AID DNA mutator activity in the B cell genome | |
WO2016038550A1 (en) | Inhibition of prmt5 to treat mtap-deficiency-related diseases | |
US20200370040A1 (en) | Treatment for parkinsonian patients with mutations in the lrrk2 gene | |
KR20200136978A (en) | Use of exosomes for targeted delivery of therapeutic agents | |
US20220235380A1 (en) | Immune cells having co-expressed shrnas and logic gate systems | |
WO2013020366A1 (en) | The use of ache as nuclease | |
Fang et al. | Expression of PTEN‐long mediated by CRISPR/Cas9 can repress U87 cell proliferation | |
Cherubini et al. | The FANC pathway is activated by adenovirus infection and promotes viral replication-dependent recombination | |
KR20190040824A (en) | Fusion protein for CRISP/Cas system and complex comprising the same and uses thereof | |
US20220133701A1 (en) | Methods of treating pain | |
WO2022130384A1 (en) | Controlling ubiquitination of mlkl for treatment of disease | |
WO2022020192A1 (en) | Compositions and methods for targeting tumor associated transcription factors | |
Zelceski et al. | MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells | |
WO2020165570A1 (en) | Methods relating to disrupting the binding of af9 partner proteins to af9 and/or enl | |
US20240108734A1 (en) | Methods for treating and ameliorating cancer | |
Lauria | Determining the role of replication stress and Proliferating Cell Nuclear Antigen SUMOylation in its telomere localization | |
Pulice et al. | Dosage amplification dictates oncogenic regulation by the NKX2-1 lineage factor in lung adenocarcinoma | |
CN110156877B (en) | Polypeptide analogue UBE2Z for inhibiting tumor 1-330aa Coding nucleic acid, primer pair, expression vector and application thereof | |
CN109718385B (en) | Function and application of Klotho-beta | |
Chanda | Characterizing natural compounds for anticancer activity and validating RNA binding proteins as therapeutic cancer targets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21844413 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21844413 Country of ref document: EP Kind code of ref document: A1 |